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Preface 
This thesis is comprised of a literature review (Chapter 1), a methods chapter (Chapter 2), four 
results chapters (Chapter 3-6) and a general discussion (Chapter 7). 
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Abstract 
One of the required virulence determinants for Shigella flexneri pathogenesis is the 
lipopolysaccharide and in particular the 0-antigen component. There are 15 known S. flexneri 
serotypes, which differ in their virulence, prevalence, distribution and the nature of their 0-
antigens. 0-antigen modification occurs via glucosylation, which is a process that is brought 
about by the addition of glucosyl groups to one or more of the 0-antigen sugars. The three 
bacteriophage genes gtrA, gtrB and gfr(typeJ are responsible for 0-antigen glucosylation in 
' 
Shigella flexneri. Both gtrA and gtrB have been demonstrated to be highly conserved and 
interchangeable among serotypes while gtr (type) was found to be specific to each serotype, leading 
to the hypothesis that the Gtr(type) proteins are responsible for attaching glucosyl groups !O the 0-
antigen in a site- and serotype- specific manner. Based on the confirmed topologies of Gtrl, Gtrll 
and GtrV, such ipteraction and attachment of the glucosyl groups to the 0-antigen has been 
postulated to occur in the periplasm. 
,~. 
. . 
In this study, the t_opology of GtrIV, a S. flexneri glucosyltransferase responsible for 
. 
converting serotype Y to serotype 4a, was experimentally determined by creating different 
fusions between ·GtrIV and a dual-reporter protein, PhoA/LacZ. This study shows that GtrIV 
. 
consists of 8 trq.nsmembrane helices, 2 large periplasmic loops, 2 small cytoplasmic N- and C-
, ' 
terminal ends and a re-entrant loop that occurs between transmembrane helices III and IV. 
Though this topology differs from that of Gtrl, Gtrll, GtrV and GtrX, it is similar to that of Gtrlc. 
. . . 
V 
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Based on the newly elucidated topology of GtrIV, the roles of the N-tenninal and C-
, terminal periplasmic loops of GtrIV (loop No. 2 and loop No. 6) were investigated by carrying 
out a series of loop deletions. By sequentially deleting loop segments in loop No. 6, the presence 
of a potential catalytic site located between resides D260 to W269 was hypothesised. This study 
also investigated the roles of conserved or specific functions of the two periplasmic loops of 
GtrIV by creating loop swap chimeras between GtrIV and its closest structural homologue, 
Gtrlc. The resulting hybrids lost their native function and were unable to substitute function to 
the other protein thus, signifying the importance of both loops in Gtr IV function. 
A total of 20 negatively charged amino acids that occur throughout GtrIV were mutated 
--
to alanine to investigate their role in GtrIV function. Three of these acidic residues located in the 
periplasmic loop No. 6, D261, E262 and D267, when mutated in tandem, were found to abolish 
function of GtrIV. They are thought to be involved in the interaction with the donor and acceptor 
substrates that help confer serotype specificity in O-antigen glucosylation. 
" 
This study also looked at 28 wildtype strains isolated from Japan, Bangladesh and 
. 
Vietnam that were originally typed as serotype 4a, 4b or just 4 and were subjected to a series of 
slide agglutination experiments to confirm their serotype. A number of strains had atypical 
. 
agglutination patterns, highlighting the possibility that they are potentially new serotypes or 
' 
subserotypes. The GtrIV sequences obtained from these strains revealed the presence of point 
mutations within several strains, although we were not able to identify mutations that were 
detrimental to the function of GtrIV. Southern blots carried out using DIG-labelled gtrIV 
Vl 
.. 
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revealed that two different serotype 4a strains, with the possibility of one of them being 
originally a 4b strain, have been circulating within these populations. Taken together, this study 
has provided valuable insight into the possibly unique mode of action of GtrIV and has provided 
grounds for further investigation into the evolution of one of the most important human 
pathogens. 
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CHAPTER 1 
1.1 Shigellosis 
Shigella is the major causative agent of bacillary dysentery (shigellosis), which is 
characterised by fever, abdominal ~ramps and bloody mucopurulent stools (Kotloff et al., 1999). 
Shigella belongs to the Gram-negative bacterial family Enterobacteriaceae, which contains 
facultatively anaerobic straight rods with simple nutritional requirements, and includes other 
important pathogenic genera such as Escherichia and Salmonella (Sansonetti, 2001; Ni yogi, 
2005; Zhu et al., 2009). If they were classified today, the Shigella species and E. coli would 
comprise one species, since they are very closely related genetically (Jin et al., 2002; Wei et al., 
2003; Christopher et al., 2010). There are four major serogroups in this genus namely, Shigella 
flexneri, Shigella sonnei, Shigella boydii and Shigella dysenteriae (H~le, 1991; Phalipon & 
Sansonetti, 2007; Bamoy et al., 2010). These serogroups differ greatly in their O-antigen 
. structures, their prevalence, their diversity and the severity of the infection caused (Yang et al., 
2005). 
A review of literature between 1966 and 1997 estimated that the annual number of 
,-., 
Shigella cases was 163 .2 million in developing· countries, with 1.1 million deaths (Kotloff et al., 
1999). In industrialized countries, the number of cases was much less, with only 1.5 million 
cases of Shigella cases annually (Kotloff et al., 1999). It was also estimated that 69% of all 
. . 
Shigella cases and 61 % of all deaths due to the disease occurred in children under the age of five 
• I 
(Farshad et al., 2006). A more recent study carried out by Ram et al. (?008) found that the actual 
incidence of shigellosis cannot yet be measured due to the lack of epidemiological studies in 
low-human development index (HDI) countries such as those in sub-Saharan Afr1.ca. Due to the 
1 
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limited access to clean water supplies and sanitation facilities, low-HDI countries are expected to 
have a higher incidence of shigellosis in comparison to those countries . that have been 
documented in the studies (Ram et al., 2008). Shigella infections are the second most common 
cause of traveller's diarrhoea (Svennerholm and Steele, 2004). 
The different serogroups of Shigella vary greatly in their prevalence. Previous 
epidemiological studies indicate that the distribution of the different serogroups is heavily 
_dependent on socioeconomic factors (Opintan & Newman, 2007). It was further found that S. 
flexneri was the main serogroup responsible for causing shigellosis in developing countries,., with 
a median percentage isolate of 60% (Kotloff et al., 1999). S. sonnei had the second highest 
median percentage isolate of 15%, followed by S. dysenteriae and S. boydii, with each having a 
-
6% median isolate percentage (Kotloff et al., 1999; Ram et al., 2008). In industrialized countries, 
' the median percentage of isolated serogroups differed greatly. S. sonnei had the highest 
percentage (77%)', followed by S. flexneri (16%), S. boydii (2%) and S. dysenteriae (1 %) 
(Kotloff et al., 1999; Ram et al., 2008). 
r, 
The clinical signs cause~ by Shigella can range from mild diarrhoea to severe dysentery. 
Dysentery is diarrhoea 1.n which blood and ~ucus ar~ present in the stools. Some other common 
symptoms includ·e fever, nausea, vomiting, intestinal cramps, abdomin~l pain and seizures 
(Niyogi, 2005; Sansonetti, 2001). Inflammation in the colon and epithelial destruction gives rise 
to th1s clinical manifestation in shigellosis (Taylor et al., 1986; Jennison et al., 2006). In rare 
cases, the Shigella bacteria can invade the blood, lungs or brain leading to serious and often fatal 
complications such as haemolytic uremic syndrome, Gram-negative septicaemia, acute 
2 
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hypoglycaemia, megacolon, or seizures (Bennish, 1991; Sansonetti, 2001; Daneman & Rescigno, 
2009; Christopher et al., 2010; Butler, 2012). Furthermore, salt and water fluctuations due to 
diarrhoea and dysentery can lead to kidney malfunction and failure (Christopher et al., 2010). In 
very severe cases, shigellosis can even lead to death. This especially occurs in young children, 
infants below five years of age and other immunodeficient individuals and is commonly 
accompanied by fever, abdominal pain and anorexia (Bennish, 1991; Ferreccio et al., 1991; 
Kosek et al., 2010; Wong et al., 2010). 
Shigellosis is transmitted mainly via the faecal-oral route. The consumption of 
contaminated water or food is the most common means of disease acquisition. The transmissi.on 
of the disease is also enhanced by poor hygiene, malnutrition and the lack of medical treatment 
(Al Jarousha et al., 2010; Vu Nguyen et al., 2006). Shigellosis is highly contagious, as it has a 
low infective dose, whereby only 10-100 bacterial cells are needed to establish the infection 
(DuPont et al., 19-~9; Phalipon & Sansonetti, 2007; Sousa et al., 2010). As a result of the highly 
infectious nature of Shigella, the disease can also be spread by person-to-person contact. This 
mode of transmi~sion is most frequently encountered in day-care centres for children and other 
" 
institutions (in both developing and industrialised nations) where personal hygiene standards are 
low (Pickering et al., 1981; Mahoney et al., 1993). 
1.2 Pathogenesis of Shigella flexneri 
• An: understanding of the pathogenesis of Shigella is vita~ for developing vaccme 
candidates. Elucidation of the pathogenesis of Shigella has been complicated by the absence of a 
good animal model. Only higher primates develop a similar illness to humans, and practical 
3 
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considerations limit their use. The mouse pulmonary model (Mallet et al., 1993), guinea pig eye 
and colitis models (Sereny, 1957; Shim et al., 2007; Kweon M. N., 2008), and rabbit intestinal 
loop model (Wassef et al., 1989) have been used to study some aspects of Shigella pathogenesis, 
but caution must be applied when extrapolating these findings to humans. 
Through the up regulation of acid resistance genes, Shigella survive their passage through 
the acidic environment of the stomach (Small et al., 1994; Espina et al. , 2006). The pathogen 
the]). employs three methods to cross the colonic epithelial layer in order to gain access to the 
basolateral sides of the mucosal cells for invasion. 
Firstly, tight junction proteins can be manipulated to allow the pathogens to reach the 
basal side of the epithelia layer (Sakaguchi et al., 2002; Jennison & Verma, 2004, Kaminski & 
Oaks, 2009). S. flexneri also exploits the highly endocytic M cells (microfold cells) of the 
mucosal-associatetl lymphoid tissue, which mediate the translocation of lumenal antigen and 
microorganism~ across the epithelial barrier to the inductive sites of mucosal immunity (Jepson 
and Clark, 1998;_ Ogawa & Sasakawa, 2006; Kaminski & Oaks, 2009). The bacteria are able to 
r. 
survive the killing mechanisms of the macrophages by an lpaB-mediated (protein effector) lysis 
of the phagocytic vacuole ~nd initiates macrophage apoptosis that causes the release of cytokines 
interleukin-I~ (IL-1~) and interleukin-18 (IL-18) (Barzu et al., 1996; Che1:1 et al., 1996; Neutra 
MR, 1999; Espina et al., 2006; Ogawa & Sasakawa, 2006; Ashida et al., 2011). These cytokines 
cause the charactertistic intestinal inflammation of shigellosis (Ashida et al., 2011). Shigella is 
then able to invade .the epithelial cell from the basolateral side, triggering a strong inflammatory 
response that leads to the secretion of the chemokine interleuine-8 (IL-8) that helps recruit 
4 
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polymorphonuclear (PMN) cells to the site of infection by transmigrating through the epithelial 
lining to reach luminal bacteria (Girardin et al., 2003; Singer & Sansonetti, 2004; Schroeder and 
Hilbi, 2008; Ashida et al., 2011 ). This disruption of the epithelium allows further shigellae to 
cross the colonic epithelial layer (Perdomo et al., 1994; Beatty and Sansonetti, 1997). The three 
mechanisms by which Shigella can cross the colonic epithelial layer are illustrated in Figure 1.1. 
To counteract the host's defences, Shigella express a needle-like type III secretion system 
(T3SS) that consists of cytoplasmic, transmembrane, and extracellular domains (Deane et al., 
2006) (Figure 1.2). Physical contact with host cells initiates secretion of effector proteins and 
leads to formation of a pore in the host-cell membrane (West et al., 2005; Kenjale et al., 20.05; 
Deane et al., 2006; Matoo et al., 2007; Dickenson et al., 2011; Rahman & McFadden, 2011). 
--
Through this pore, the translocated proteins are able to enter the host cell cytoplasm wliere they 
subvert normal cell functions and induce major cytoskeletal re-arrangements to aid uptake of the 
bacterium. (Michinaga & Chichiro, 2006; Schroeder & Hilbi, 2008; Mounier et al., 2009; 
Dickenson et al., 2011). 
Upon uptake, the bacterium is surrounded by the membrane vacuole of infected epithelial 
. . 
cells. After the vacuole -membrane and escaping into the cytoplasm, Shigella are able multiply 
.. 
and spread to adj'acent cells (Kaminski & Oaks, 2009; Marteyn et al., 20~0). Movement within 
the host cell is achieved by inducing local actih polymerization at one pole of the bacterium. 
(Mantis et al., 1996; Faherty & Maurelli, 2009).' This enables cell-to-cell spread without 
exposure to immune cells in the extracellular environment. Contact of Shigella with the 
membrane of the adjacent epithelial cell causes a protrusion to be formed and the bacterium is 
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endocytosed by the neighbouring cell (Rathman et al., 2000). The bacteria subsequently end up 
in a vacuole with_two membranes, both of which are lysed by the proteins IpaB and IpaC (Espina 
et al., 2006; Faherty & Maurelli, 2009). The major steps involved in Shigella invasion, 
replication and spread are summarised in Figure 1.3. It is thought that the host's inflammatory 
response is responsible for the killing of epithelial cells as there would be little advantage for 
Shigella in destroying an environment that provides protection from immune cells and 
favourable conditions for replication (Mantis et al., 1996; Faherty & Maurelli, 2009). 
1.2.1 Factors .that determine Shigella virulence 
The bacterial DNA of Shigella encodes a number of plasmid and chro~osomal proteins 
· such as the invasion plasmid antigens (Ipa), surface presentation antigens (Spa), membrane 
excretion proteins (Mxi), and virulence proteins (Vir). Th~se proteins are epcoded by genes that 
are scattered throughout the 221-kb virulence pl~smid and are subsequently secreted through the 
T3SS for post-invasion virulence (Buchrieser et al., 2000; Faherty & Maurelli, 2009) (Figure 
1.4). A 31kb locus in this plasmid contains genes for entry (San~onetti P, 2001; Schroeder & 
Hilbi, 2008; Faherty & Mau~elli, 2009). Thi_s 31kb region consists of two main loci: the mxi-spa 
locus and ipa locus (Figure 1.5). There are about 20 genes associated with the mxi-spa-ipa locus 
. • . r 
encoding the T3SS. Temperature regulation of the genes on the virulence plasmid allows the 
. 
needle complex to be synthesized and assembled at 37°C (Deane et al., 2006; Matoo et al., 2007; 
Faherty & Maurelli; 2009). The virulence protein VirF induces tp.e expression of the VirB 
. 
.protein. The VirB protein then activates the ipa, mxi, and spa promoters leading to expression of . . 
. 
. ' 
the spa and mxi operons. This results. in the synthesis and assembly of a protein co~plex called 
the Mxi-Spa translocon (Sansonetti P, 2001; Schroeder & Hilbi, 2008). At the basal state, the 
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Figure 1.4: Circular map of the large virulence plasmid (,--,221kb) of Shigellaflexneri 5a. With respect to 
the outermost ring, all genes coloured in red are identical or essentially identical to known virulence-
associated proteins. The 31kb mxi-spa-ipa locus is indicated with the help of the bold red bracket. Image 
taken from Venkatesan et al., (2001) 
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T3SS is inactive and presents at its tip two type III substrates, IpaB and IpaD, which form a so-
called ''tip complex'' (Veenendaal et al., 2007). The tip complex proteins regulate the activity of 
the T3 SS and could participate in the recognition of host cell receptors, such as b 1-integrins or 
the hyaluronan receptor CD44 (Parsot et al., 1995; Watarai et al., 1997; Lafont et al., 2002; 
Veenendaal et al., 2007). When the bacterium makes contact with the epithelial cell membrane, 
the translocon becomes activated and secretes the pre-synthesized Ipa proteins. IpaB, IpaC and 
IpaD associate to form a complex which interacts with the host epithelial cell membrane to 
induce a cascade of cellular signals which will lead to the internalization of the bacterium via an 
endosome. The Ipa proteins are also required for escape from the endosome (Nhieu et al., 1997; 
Jennison & Verma, 2004; Gala' n & Wolf-Watz, 2006; Ogawa et al., 2008). Other genes within 
this locus include spa40, which encodes for one of the inner membrane components, Spa40. This 
protein belongs to a family of proteins that regulate the switching of substrate specificity of the 
T3SS (Deane et al., 2008). Spal5 (encoded by spa] 5) has been described as a T3SS chaperone 
based on the requirement of Spal 5 for secretion of several proteins (Parsot et al., 2005). 
However, recent studies have revealed that Spal 5 contributes to the intracellular survival of 
Shigella by blocking apoptosis in the infected host cell (Faherty & Maurelli, 2009). 
Shigella pathogenicity islands (SHI) have also been identified in the chromosome 
(Ingersoll et al., 2002; Schmidt & Hensel, 2004). The presence and genomic localization of SHI 
varies between Shigella strains and may contribute to the variation of virulence phenotypes 
(Peng et al., 2006). · Although these islands contain a host of genes, specific virulence functions 
have only been identified for some of these genes. Table 1.1 lists these various SHI virulence 
, factors that have been identified to date. The acquisition of SHI-O was a very important event in 
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the evolution and diversification of Shigella (Schroeder & Hilbi, 2008). This island contains the 
genes that are responsible for carrying out O-antigen modification and as a result, accounts for 
the wide variety of Shigella serotypes (Nie et al., 2006). A PAI, designated the Shigella 
resistance locus (SRL), is the most recent acquisition of genes and has contributed to the 
organism's resistance to antibiotics such as ampicillin, chloramphenicol, tetracycline and 
streptomycin (Turner et al., 2001; Turner et al., 2003). 
1.3 Prevention and Treatment of shigellosis 
The best means of preventing shigellosis is the usage of clean water and sanitary 
facilities. However in developing countries the use of such ideals is far from reaching. Thus 
other means for preventing and treating the disease are required. 
Treatment of acute or self-limiting shigellosis involves oral re-hydration to restore lost 
levels of water in the stool. In more severe cases, antibiotic therapy is required. Using antibiotics 
in the treatment of shigellosis can shorten the period of faecal excretion of Shigella, thereby 
reducing the possibility of secondary spread of the infection and litniting the course of illness. 
Antibiotic therapy often involves the use of ampicillin, trimethoprim-sulfamethoxazole and 
tetracycline (Ashkenazi et al., 2003; Christopher et al., 20 l 0). However, Shigella strains are 
becoming more resistant to these antibiotics through the uptake of plasmids containing antibiotic 
resistant genes, thus requiring the development of new antibiotics (Barman et al., 2010). This, 
coupled with the high cost of antibiotic treatments, has led to WHO giving priority to the 
development of an effective vaccine against shigellosis (Kotloff et al., 1999) 
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After an initial Shigella infection, a 70-80% protection against reinfection from the same 
serotype is induced (Kotloff et al., 1999). Therefore, vaccination is a viable option for the control 
of shigellosis. Although the mechanisms of protection against Shigella have not been elucidated, 
mucosal immune defenses are sought, as they block pathogens in the intestinal lumen, preventing 
their attachment and infe,ction of epithelial cells. Therefore, the optimal Shigella vaccine must be 
able to activate long-lasting mucosal immunity, be cheap to produce, cause minimal side effects 
and be simple to administer (Lindberg & Pal, 1993; Salam, 1998). Most of the vaccines currently 
available have low immunogenic responses or are not well tolerated (Kaminski & Oaks, 2009). 
A common problem faced during the development of vaccines against shigellosis is that 
immunity is serotype specific. As there are multiple serotypes present in a single region, a 
vaccine produced against a single serotype would not be beneficial. Thus, research into 
development of a multi-valent vaccine which favours long-lived, broad immunity is needed 
(Kaminski & Oaks, 2009). 
Many different vaccine strategies such as subunit vaccines, killed oral vaccines, non-
invasive live vaccines, invasive live vaccines, and Shigella-E. coli hybrid vaccines have been 
adopted and tested in animals and humans (Kweon M. N., 2008; Kaminski & Oaks, 2009; 
Martinez-Becerra et al., 2012). However, the achievement of a balance between immunogenicity 
and safety has been problematic. Oral immunization may achieve intestinal immunity but due to 
delivery restrictions, it is often difficult to consistently accomplish especially for inactivated or 
subunit vaccines (Kaminski & Oaks 2009; Tribble et al., 2010). An alternative route of delivery, 
touted to trigger t4e mucosal immune response is through intranasal immunization (Tribble et 
al., 201 O; Riddle et al., 2011 ). 
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1.3.1 Promising vaccine candidates 
In recent years, there have been some promising vaccine candidates. Protein antigens, 
such as the Ipa protein effectors of the type three-secretion system, remain attractive vaccine 
candidates due to their active role in pathogen-directed cellular invasion, as well as the highly 
conserved sequences among these essential virulence factors (Kweon M. N., 2008; Kaminski & 
Oaks, 2009; Tribble et al., 2010; Riddle et al., 2011). By exploiting the capacity of the Shigella 
Ipa proteins to interact with the host cell receptors and induce an endocytic event, researchers at 
the Walter Reed Army Institute of Research (Washington DC, USA) have developed an invasin 
complex (Invaplex 50) vaccine (Tribble et al., 201 O; Riddle et al., 2011; Martinez-Becerra et al., 
2012). The Invaplex product, isolated from wild-type S. flexneri 2a, contains a native, 
biologically active complex of LPS, IpaB, IpaC and IpaD that targets M cells, resulting in the 
uptake and delivery of key Shigella antigens to underlying antigen presenting cells (APCs) 
(Kaminski et al., 2009; Tribble et al., 2010; Riddle et al., 2011). The presence of LPS and the 
conserved Ipa proteins stimulates a more comprehensive immune response similar to that 
witnessed after natural infection compared to vaccines that deliver LPS alone (Kaminski et al., 
2009; Riddle et al., 2011; Martinez-Becerra et al., 2012). The Shigella Invaplex 50 vaccine, 
currently under clinical investigation, was seen to stimulate robust intestinal and pulmonary 
responses upon intranasal immunization. Encouragingly, an initial phase 1 dose-escalation study 
evaluating the safety and immunogenicity of the S. flexneri Invaplex 50 vaccine showed that it 
was well tolerated and resulted in antigen-specific humoral and mucosal immune responses in 
adults (Riddle et al,, 2011). 
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In another study conducted by Martinez-Becerra et al. (2012), they examined the 
immunogenicity and protective efficacy of IpaB and IpaD, alone or combined, co-administered 
with a double mutant heat-labile toxin ( dmL T) from E. coli as a mucosal adjuvant in a mouse 
model of intranasal immunization and pulmonary challenge. The authors demonstrated that both 
proteins were able to induce high levels of serum and mucosal antibodies, along with elevated 
frequencies of antibody secreting cells in mucosal and systemic tissues. It was observed that very 
high levels of protection (80 to 100%) were achieved against a homologous and a heterologous 
strain, using a lethal pulmonary challenge model. Unlike the Invaplex 50, this vaccine does not 
contain LPS. It also only contains known quantities of highly purified IpaB, along with IpaD 
(Martinez-Becerra et al., 2012). An advantage to this vaccine candidate is the fact that a protein-
based, LPS-free vaccine would be safer and amenable for use in infants, young children and 
immune-compromised individuals (Martinez-Becerra et al., 2012). As such, the study concluded 
that subunit-based IpaB/D vaccine could be an effective broadly protective vaccine for the 
prevention of shigellosis (Martinez-Becerra et al., 2012) 
1.4 Evolution of Shigella 
Over the last 15 years, studies employing a variety of technical approaches have shown 
that Shigella belong to the species E. coli, thus debunking the long held dogma that Shigella 
formed a separate genus (Pupo et al., 1997; Fukushima et al., 2002). In the past decade, new 
sequence information has revealed that the sequence divergence between S. flexneri and E. coli 
K-12 is about 1.5% compared to 15% diversity between E. coli and its close relative, pathogenic 
Salmonella enterica (Lan & Reeves, 2002; Lan et al., 2004). Using eight housekeeping gene 
sequences from the Shigella chromosomes, Pupo et al. (2000) proposed that the current Shigella 
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clones were independently evolved from multiple E. coli ancestors 35,000- 270,000 years ago. 
Subsequent genome sequencing projects have strongly supported the multiorigin and convergent 
evolution hypothesis (Jin et al., 2002; Wei et al., 2003; Yang et al., 2005). Bacterial evolution is 
a dynamic process whereby horizontal gene transfer between microorganisms of distant relation 
allows them to acquire genes that lead to the gain of advantageous phenotypic traits (Ochman et 
al., 2000). The transfer and chromosomal incorporation of pathogenicity islands (PAI) are 
important steps for the rapid evolution of pathogenic Shigella bacteria from their non-pathogenic 
E. coli progenitors. Through the acquisition of a large virulence plasmid and chromosomal 
pathogenicity islands mentioned in the above section, Shigella spp. have gained genes that have 
enabled them to invade the epithelial cells of the host and to multiply and thrive intracellularly. 
Both the Shigella chromosome and the virulence plasmid contain numerous insertion sequences 
(IS) and markers of genomic rearrangements (Buchreiser et al., 2000; Jin et al., 2002). The 
distribution of IS types and the phylogenetic grouping of chromosome- and plasmid-encoded 
genes indicate that the Shigella chromosome and the virulence plasmid ~oevolved (Escobar-
Paramo et al., 2003; Yang et al., 2007). As such, these findings suggest that the acquisition and 
transfer of plasmids between the strains were early steps in the diversification from E. coli 
ancestors. 
While gairung genes that increase virulence and assist in the bacteria's intracellular 
survival has contributed significantly to the evolution of Shigella, it is also shaped by loss of 
gene function due to' deletion or gene inactivation. Compared to E. coli K-12, an average of 726 
genes are missing, and over 200 pseudogenes are found within Shigella, indicating that genes 
~ithin Shigella have been deleted, reduced or inactivated (Yang et al., 2005; Peng et al., 2006). 
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Genome reduction due to the loss of functional genes is driven mainly by the bacteria adapting to 
its pathogenic intracellular lifestyle (Ochman et al., 2000; Maurelli A. T ., 2007). Examples of 
genes that have been inactivated include omp T, which encodes for the outer membrane protease 
OmpT. Studies have shown that it interfered with the polar localisation of the actin nucleator 
protein IcsA (VirG) which in tum, inhibited the spread and virulence of Shigella (Peng et al., 
2006). It is present in various non-pathogenic E. coli strains but deleted in all Shigella strains 
(Peng et al., 2006). Genome analyses also confirmed that cadA, encodes a lysine decarboxylase, 
though present in ancestral E. coli strains, was deleted in most of the Shigella due the protein's 
indirect inhibitory effect on the activity of Shigella enterotoxins (Day et al., 2001; Peng et al., 
2005). In addition to loss of genes, a very prominent trait that lost by Shigella is the ability to 
synthesise functional flagella. Tominaga et al. (1994) identified flagellar genes in Shigellq that 
were expressed in E.coli K-12. Evidence has also been shown of flagella and motility in Shigella 
species under modified laboratory conditions (Giron, J. A, 1995). Flagella and other surface 
structures like fimbriae, which are also degenerated in Shigella, have bee!l found to be potent 
activators of the host immune system (Sakellaris et al., 2000; Ramos et al., 2004).). Therefore, 
the loss of these surface structures might may minimize the exposure to the host defence system 
and allow the bacterium to invade the epithelial cells more efficiently. Figure 1.6 documents the 
events that are considered to be most important for the evolution of pathogenic Shigella from 
non-pathogenic E. coli. 
A peek into · the evolution of Shigella could be provided by studying enteroinvasive 
Escherichia coli (EIEC). EIEC is a pathogenic form of E. coli that can cause dysentery. 
llowever, unlike non-pathogenic E. coli, it is difficult to make a distinction between EIEC and 
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Shigella as both EIEC and Shigella bear almost identical phenotypic likeness from spending 
much of their lifetime within eukaryotic cells (Lan et al., 2004). Therefore, both organisms have 
a different nutrient supply from most E. coli strains and harbor a common 221-kb virulence 
plasmid (Lan et al., 2004). However, EIEC and Shigella lack several catabolic pathways widely 
present in E. coli have (Lan et al., 2004). Mucate and acetate are an example of two biochemical 
properties that differentiate E. coli and Shigella. EIEC may be positive for one or both of the 
properties, while, with rare exceptions, Shigella strains are negative for both and more than 90% 
of typical E. coli strains are positive for both (Doyle & Padhye 1989; Bopp et al., 2003; Lan et 
al, 2004). It is clear that EIEC and Shigella form a pathovar of E. coli. As such, Lan et al., 
(2004) have speculated that the reason EIEC retained some E. coli properties that have been lost 
in multiple lineages of Shigella could be due the EIEC strains being an intermediate stage and as 
such, may be a precursor of "full-blown" Shigella strains. 
1.5 Serotype diversity of Shigella flexneri 
To date, there are 15 known S. flexneri serotypes, which differ in their virulence, 
prevalence, and distribution. The S. flexneri serotypes differ in their O-antigens. These are 
components of lipopolysaccharide that extend from the bacterial surface. 
1.5.1 Lipopolysaccharide (LPS) structure 
The bacterial LPS is a major constituent of outer-membrane structure that occupies most 
of the cell wall of Gram-negative bacteria and is vital to their virulence ( Guan et al., 1999; Nagy 
& Pal, 2008). It accounts for approximately 10-15% of the total molecules in the outer 
membrane occupying approximately 7 5% of the bacterial surface area (Lerouge & 
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Vanderleyden, 2002). Most Gram-negative bacteria express a common LPS backbone, which 
consists of; a lipid A, core polysaccharide and O-antigen (Allison & Verma, 2000) (Figure 1. 7). 
The lipid A, which is anchored in the outer membrane, is highly conserved in members of the 
Enterobacteriaceae family and is responsible for maintaining the integrity of the outer 
membrane LPS structure (Lerouge & Vanderleyden, 2002; Acheson & Luccioli, 2004). The core 
polysaccharide links lipid A to the O-antigen and is composed of a short chain of sugars. The 
core polysaccharide has slightly more variation between members of the Enterobacteriaceae 
family, but it is still limited in structural diversity (Lerouge & Vanderleyden, 2002; Nagy & Pal, 
2008). The O-antigen on the other hand ( outermost structure of LPS) is highly variable and gives 
rise to different S. flexneri serotypes. It extends outward from the core polysaccharide and can 
consist of up to 40 repeating subunits comprising of three to five sugars. Serotype diversity is 
brought about by the differences in the sugar residues, their relative position and linkage. 
1.5.2 Properties and synthesis of the Shigella flexneri O-antigen 
The O-antigen is highly immunogenic and can elicit a strong immune response due to the 
fact that it is the only part of the bacterial LPS that is exposed to the environment (Opal, 2007; 
Carter et al., 2007; Phalipon & Sansonetti, 2007; Nagy & Pal, 2008). The length of the O-antigen 
varies and has been found to change depending on the growth phase of the bacteria (Carter et al., 
2007). Studies have shown that the length of the LPS is fundamental to the adherence and 
internalisation of S. flexneri into polarized epithelial cells (Carter et al., 2007). The O-antigen has 
also been found to be critical to the survival of Gram-negative bacteria as it prevents penetration 
from the complement membrane attack complex (MAC) of the innate immune response, thus 
-- preventing the clearance of the bacteria by the complement system of the innate immune 
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Figure 1.7: The basic bacterial lipopolysa~charide (LPS) structure consisting of a lipid A, core-
polysaccharide and O-antigen. The lipid A anchors the core-polysaccharide and Q-antigen to the outer 
cellular membrane. The O-antigen is different for· each S. flexneri serotype. The basic Y serotype O-
antigen is shown here (GlcNac, N-acetylglucosamine; Rha, rhamnose). 
CHAPTER 1 
response (Erridge et al., 2002). It has been proposed that modifications to the O-antigen via 
glucosylaton would induce it to change from a linear to helical conformation with the glucosyl 
residue exposed on the exterior of the helix. This would dramatically shorten the O-antigen, 
halving the distance it extends beyond the outer membrane (West et al., 2005) and may affect the 
accessibility of the type III secretion system that is required for bacterial invasion (West et al., 
2005). Though the serotypes differ in their virulence, it is not yet known to what extent the O-
antigen structure contributes to this. 
There are three distinct processes for the synthesis and translocation of O-antigens, 
namely, the Wzx/Wzy dependent process, the ATP-binding cassette (ABC) transporter 
dependent process and the synthase dependent process (Samuel & Reeves, 2003; Liu et al., 
2008). Most E. coli and all the Shigella forms use the Wzx/Wzy process (Figure 1.8). The initial 
step in the Wzy-dependant pathway model involves synthesis of the repeating polysaccharide 
units on the lipid carrier molecule undecaprenyl phosphate (UndP) on the-cytoplasmic leaflet of 
the inner membrane (IM). Following this, the O-antigen flippase, Wzx, translocates the UndP-
linked sugar repeats from the cytoplasmic leaflet to _the periplasmic leaflet (Liu et al., 1996; 
Burrows & Lam, 1999). Here, the repeating units are sequentially added to the reducing terminus 
of a growing glycan chain by the O-antigen polymerase Wzy (de Kievit et al., 1995; Woodward 
et al., 2010). The length of the growing chain is governed by the chain length regulator Wzz 
(Woodward et al., 2010). The assembly process is then completed when the extended O-antigen 
chain is ligated to the lipid A-core polysaccharide complex by the O-antigen ligase WaaL 
(Abeyrathne & Lam, 2007) which the O unit is synthe~ized by transfer of a sugar phosphate and 
- then sequential transfer of other sugars from the respective sugar nucleotides to the carrier lipid. 
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Figure 1.8: Wzy-dependent assembly pathway. 1) Synthsis of O-antigen polysaccharide repeat unit on 
UndP by glycosyltransferases. 2) The flippase, Wzx, translocates the UndP-linked O-antigen from the 
innner leaflet to the outer leaflet. 3) UndP-linked O-antigen binds to recruitment arm of O-antigen 
polymerase Wzy. 4) Single UndP-linked O-antigen repeat transferred from recruitment arm of to the base 
of the retention arm of Wzy. This leads to the polymerization of the glycan chain at the reducing terminus. 
5) Wzz regulates the length of the O-antigen chain. 6) Polymerised O-antigen-is ligated to the lipd A-core 
polysaccharide complex. This gives rise to a heteromeric LPS. Adapted from Cuthbertson et al., (2010) 
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1.5.3 O-antigen structure of the known Shigella flexneri serotypes 
The 15 known serotypes of S. flexneri differ in the nature of their O-antigens. The O-
antigen backbone consists of repeating units of the tetrasaccharide N-acetylglucosamine-
rhamnose-rhamnose-rhamnose (Simmons and Romanowska, 1987). This basic backbone is 
present for all serotypes except serotype 6. Bacteria with this basic O-antigen repeat unit have 
been typed as serotype Y. The addition of glucosyl and/or O-acetyl groups to different sugars in 
the tetrasaccharide unit by one of several linkages gives rise to the other serotypes (Figure 1.9). 
Glucosylation can occur in any one of the four residues that are present in the tetrasaccharide 
unit. However, O-acetylation occurs only on the rhamnose (Rha) III residue, resulting in the 
presence of the group 6 epitope (Jennison et al., 2006). 
Serotypes 1 a, 2a, 4a, Sa and X differ from serotype Y by the addition of a single glucosyl 
group. Serotypes 2b and Sb have two glucosyl groups added on different acceptor sugar residues. 
Serotype 3b has a single O-acetyl group added. Serotypes 1 b, 3a and 4b ·have both an O-acetyl 
and a glucosyl group added. Serotype 1 c is unique as it has two glucosyl groups added 
sequentially with a direct glucosyl to glucosyl linkage (Ramiscal et al., 20 l 0). Each serotype has 
one type-specific, and one or more group-specific, antigenic determinants (Jennison et al., 2006). 
The type antigen denotes a sugar residue with a specific linkage to the basic O-antigen chain 
(serotypes Y and X do not have type antigens), while the group antigen refers to an additional 
sugar or a particular immunogenic chemical conformation. This scheme for classifying 
0 
serological specificity was invented before the chemical structure of the O-antigen was 
determined, and was based -on the use of rabbit antisera _(Kenne et al., 1978). 
17 
Serotype Y 
(-:3,4) 
Serotype la 
(1:4) a 4 
Serotype 2a 
(11:3,4) 
Serotype 3a 
(111:6,7,8) 
Serotype Sa 
(V:3,4) 
3P 1,2a . Rhal 1,2a RhaII 
Serotype 
(-:7,8) 
Serotype le 
' ' .. I~ n 
-
Serotype lb 
(1:6) 
Serotype 2b 
(11:7,8) 
Serotype 3b 
(111:6,3,4) 
Serotype 4b 
(IV :6) a 6 • 2 • 
Serotype Sb 
(V:7,8) 
• Glucosyl group 
■ O-acetyl group 
Figure 1.9: The different serotypes of S. flexneri and their respective O-antigens. The basic O-antigen 
(Serotype Y) is a tetrasaccharide consisting of repeating N-acetylglucosamine-rhamnose (I)-rhamnose 
(II)-rhamnose (III) units. The large variety of serotypes is dependent on the attachment of glucosyl groups 
(glucosylation) and/or O-acetyl groups (acetylation) in a site and linkage specific manner to different 
sugar molecules in the O-antigen. Serotype 4a has a gluco·syl group attached to the N-acetylglucosamine 
via an al-6 linkage. Adapted from Allison & Verma (2000) 
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1.5.4 Modification of the O-antigen 
Sero type conversion in S. flexneri is mediated by O-antigen modification factors encoded 
by temperate bacteriophages. It is not unusual for bacteriophages that utilise O-antigens as 
receptors for adsorption and infection to contain O-antigen modification genes (Makela and 
Stocker, 1969). These bacteriophages may possess glucosyltransferase genes, acetyltransferase 
genes, or novel O-antigen polymerase systems to modify the O-antigen of the bacterial host 
(Wright, 1971; Sasaki et al., 1974; Verma et al., 1991). The bacteriophages most likely modify 
the O-antigen of their bacterial host to exclude the entry of homologous bacteriophages and/or to 
contribute to their host bacterium's evasion of the immune response (Guan et al., 1999). 
1.5.4.1 Serotype converting bacteriophages 
Bacteriophages are viruses that infect bacteria, and can be important determinants of 
bacterial pathogenesis and evolution. In the 125 completed bacterial genpme sequences, at least 
300 intact or defective prophages (integrated bacteriophage genomes) -have been identified 
(Casjens et al., 2004). Six different serotype-converting phages or prophages, Sfl, SfII, Sf6, 
SfIV, SfV and SfX, have been identified and characterized which can convert serotype Y to 
serotype la, 2a, 3b, 4a, 5a and X, respectively (Clark et al., 1991; Mavris et al., 1997; Guan et 
al., 1999; Allison et al., 2002; Casjens et. al., 2004; Sun et al., 2011). Except for Sf6 which 
carries a single gene, oac, for acetylation of the O-antigen, the other phages carry three genes, 
gtrA, gtrB, and gtr(typeJ for O-antigen modification (Verma et al., 1991). The morphologies of 
these bacteriophages are diverse, yet their integration, excision and glucosylation modules are 
conserved (Allison and Verma, 2000). Sf6 does not haye a glucosylation module but encodes O-
'a acetyltransferase, and modifies the O-antigen of its host by the addition of the O-acetyl groups 
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(Verma et al., 1991 ). The glucosylation modules in serotypes 1 a and 4a are found in non-
inducible bacteriophage remnants (Adhikari et al., 1999; Adams et al., 2001). 
The bacteriophages responsible for serotype conversion in S. flexneri establish a stable 
relationship (lysogeny) with the host bacterium, and are therefore temperate bacteriophages. 
Site-specific recombination between the bacteriophage and the S. jlexneri genome occurs at short 
homologous DNA sequences in the bacteriophage and bacterial genomes called attachment sites 
(attP and attB, respectively). The process is in accordance with the Campbell model first 
described for bacteriophage A (Campbell, 1986). 
1.5.4.2 O-antigen glucosylation 
Most of the S. jlexneri serotypes arise from the addition of a glucosyl residue to a specific 
sugar of the O-antigen repeat unit via one of several linkages. The three genes involved in O-
antigen glucosylation are gtrA, gtrB, and gtr(type) • These genes are located downstream of the attP 
site in the bacteriophage genome (Allison and Verma, 2000). While gtrA and gtrB are highly 
conserved and interchangeable among serotypes (Huan et al., 1997; Mavris et al., 1997; Guan et 
al., 1999), gtr (type) is serotype-specific and is unique to each serotype. The organisation of the 
glucosylation gene clusters that have been identified up till now is illustrated in Figure 1.10. 
gtr A is highly conserved among the serotypes and encodes a 120-amino-acid protein with 
four transmembrane helices (Korres et al., 2005). Guan et al. (1999) proposed that GtrA is 
involved in flipping lipid-linked glucose across the plas~a membrane for it to be available to the 
-- Gtr( type) for the attachment of the glucose to the correct rhamnose unit conferring serotype 
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Figure 1.10: Organisation of S. flexneri O-antigen modification genes. The glucosylation cassette 
comprises of three genes: gtrA, gtrB and gtr(type). gtrA and gtrB are conserved among serotypes while 
gtr(type) is unique and serotype specific. Bacteriophage Sf6 uses only a single gene. This gene, oac, is 
responsible for acetylation of O-antigens. No bacteriophage for S. flexneri le and S. flexneri 4a has yet 
been isolated. The O-antigen modification mediated by each cluster of genes is shown on the right. 
Adapted from H. Korres (PhD Thesis, 2006) and V. Tran (Honours Thesis, 2010) 
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specificity. However, no direct evidence has yet been put forward to support this. The GtrB 
proteins, encoded by gtrB, vary in size from 305 to 309 amino acids. As with GtrA, GtrB is 
highly conserved between the S. flexneri serotypes. Hydropathy data suggests that GtrB has two 
transmembrane domains with a large hydrophilic N-terminus and a short C-terminal tail (Korres 
et al., 2005). GtrB catalyses the transfer of glucose from UDP-Glucose to bactoprenol phosphate 
to form UndP-~-glucose in the cytoplasm (Guan et al., 1999). This structure is then flipped by 
GtrA into the periplasm before the glucosyl residue is attached by the Gtr(type) to the growing O-
antigen unit (Korres et al., 2005). GtrB homologues are found in a number of organisms, 
including E. coli and Salmonella (Mavris et al., 1997). 
The gtr(typeJ is the third gene in the three-gene glucosylation cluster involved in serotype 
conversion. It encodes for a serotype-specific glucosyltransferase (Gtr) which is thought to be 
responsible for the actual attachment of glucosyl residues onto the appropriate sugar residue of 
the O-antigen repeat unit (Guan et al., 1999). Till now, the various Gtr(type) proteins that have 
been identified vary in size from 416 to 526 residues and have 9-11 putative transmembrane 
regions. The secondary structure of the different Gtr(type) proteins is similar to flipases, O-antigen 
polymerases and O-antigen ligases (Whitfield, 1995) As such, it has been proposed that, apart 
from attaching a glucosyl residue to the appropriate sugar residue of the O-antigen, Gtr( type) 
may also play a role in recycling the lipid carrier after addition of the glucosyl group to the O-
antigen (Guan et al., 1999). Figure 1.11 summarises the proposed mechanism for O-antigen 
, 
glucosylation. 
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Figure 1.11: The hypothetical model of the glucosylation of the O-antigen. GtrB transfers a glucosyl 
group from UDP-glucose to the membrane linked-lipid UndP. The G.trA protein itself or in conjunction 
with the Gtr(type), flips the lipid associated glucose into the periplasm. The Gtr(type) protein then specifically 
transfers the glucosyl residue to a particular site on the O-antigen chain and returns the bactoprenol to the 
cytoplasmic side of the membrane. GlcNAc, N-acetylglucosamine; Rha, Rhamnose; UDP, uridine 
diphosphate; UndP, undecaprenyl phosphate. Adapted from Guan et al., (1999) and Brockhausen et al., 
(2008) 
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1.5.4.3 O-acetylation of the O-antigen 
O-acetylation of the O-antigen is carried out by the enzyme, O-acetyltransferase (Oac ). 
The gene encoding for the enzyme differs from the gtr cassette in that it lies in an independent 
open reading frame (Ramiscal et al. , 2010). Oac is able to convert S. flexneri serotype Y, la, 4a 
to 3b, 1 b, 4b, respectively, by adding an acetyl group to the sugar residues of the O-antigen 
(Allison & Verma, 2000). Unfortunately, it is still not known where O-acetylation of the O-
antigen takes place within the cell. 
1. 5. 5 Emergence of new serotypes 
In recent times, it was reported new S. flexneri serotypes such as serotype 1 c and SFxv 
had emerged. Serotype le was first identified in Bangladesh in 1989 (Carlin N. I. et al,. 1989) 
and was later found to be prevalent in Bangladesh, Egypt, Indonesia, and Pakistan (El-Gendy et 
al., 1999; Talukder et al. , 2002; von Seidlein et al., 2006). At present, it is the most prevalent 
serotype in Vietnam (Stagg et al., 2008). SFxv first appeared in Herran province in 2001 and 
spread to several other provinces, including Shanxi, Gansu, Anhui, and Shanghai and has 
become one of the predominant serotypes in these Chinese provinces (Ye et al., 201 0; Sun et al, 
2011; Qiu et al., 2011 ). Less than a year ago, Qiu et al., (2011) described the first isolation of a 
new S. flexneri serotype, designated 4s, in Beijing, China. With the emergence of untypeable or 
novel serotypes of S. flexneri from natural infections, Sun et al., (2011) sought to investigate the 
roles played by serotype-converting phages in the emergence of new serotypes and also the 
potential of emergence of novel serotypes through this mechanism in nature. In doing so, they 
successfully engineered a new S. flexneri serotype that \3/as termed serotype id by infecting an S. 
flexneri serotype Y strain (native LPS) sequentially with 2 serotype-converting bacteriophages, 
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SfX first and then Sfl. This lab-generated strain displayed slide agglutination characteristics of 
both serotype X and serotype 1 a. 
1.5.6 Distribution o/Shigella flexneri serotypes 
Through the use of serotyping techniques, aetiological studies found that S. flexneri 
serotype 2a was the most predominant serotype in both developing and developed countries 
(Kotloff et al., 1999; Ram et al., 2008). It was further found that serotype 1 a, 1 b, 1 c, 2a, 3 a, 4a 
and 6 are commonly isolated in South and East Asian countries (Kotloff et al., 1999; Ram et al., 
2008; Stagg et al., 2008). This pattern changes with area as well as time, with new serotypes and 
untypeable strains rising frequently. Ahmed et al, (2006) reported that one of the newly 
identified serotypes, S. flexneri l c, has emerged as a dominant S. flexneri serotype in Egypt. A 
study by Stagg et al., (2008) showed S. flexneri serotype 1 c to be the most prevalent serotype 
within the Son Tay Province, Vietnam. The authors went on to suggest that there is a large 
variation of S. flexneri serotypes within different regions of Vietnam {Stagg et al., 2008). 
Alarmingly, reports of new serotypes 4s and SFxv have surfaced within several provinces in 
China. (Ye et al., 2010; Sun et al, 2011; Qiu et al., 2011) 
1.6 Structural and functional studies of O-antigen modifying 
enzymes 
A major drawback with current live-attenuated vaccines is that they are serotype specific. 
Therefore, to creat~ a multi-valent vaccine for shigellosis, the mechanisms behind how Gtrs and 
Oac modify the O-antigen need to be determmed. By identifying the structures of the enzymes, a 
better understanding of how the enzymes interact with one another is provided. Work on 
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glycosyltransferases (GTs) in the past has helped shed light on these integral membrane proteins 
that recognise identical donor or acceptor substrates. Firstly, it was discovered that few regions 
of sequence homology exist. It was also shown that enzymes that are structurally related often 
catalyse the same or a similar reaction (Breton and Imberty, 1999). Although sequence-based 
classification places GTs in many families, the 3-D structures of glycosyltransferases have 
revealed two major structural folds that can be grouped into 2 super families GT-A and GT-B 
(Breton and Imberty, 1999; Lairson et al., 2008). S. flexneri glucosyltransferases bear similarity 
to, but are not part of the GT-A superfamily although they contain a DxD motif similar to that 
witnessed in the GT-A superfamily (Breton and Imberty, 1999; Lairson et al., 2008). Therefore, 
by gathering as much structural and functional information as we can about Gtrs, it will enable 
us to make comparisons with the large library of GTs in order to elucidate their mode of action 
and determine their catalytic domains. 
Lehane et al. (2005) revealed that GtrII has a cytoplasmic N-terminus, nme 
transmembrane helices, a re-entrant loop and a large periplasmic C-terminal region (Lehane et 
al., 2005). The enzyme's hydropathy profile was found to be similar to Gtrl, indicating that there 
is some structural homology between the two Gtr(type) proteins (Lehane et al., 2005). Four critical 
residues were identified in GtrII (D40, F414) C435 and L478) (Lehane et al., 2005). C435 forms 
a disulfide bond with C437 that was postulated to be required for the positioning of other critical 
residues (Lehane et al., 2005). D40 was hypothesised to be critical as, many Gtrs use either 
glutamic or aspartic acid residues to help deprotonate the hydroxyl group of the acceptor sugar 
(Lehane et al., 2005). In the same vein, GtrV was e~perimentally found to have a structure 
--consisting of a cytoplasmic N-terminus, nine transmembrane helices, a re-entrant loop and a 
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large periplasmic C-terminal region. The same study also found that GtrV had strong sequence 
similarity to GtrX, and that there were three motifs (two in loop No. 2 and one in loop No. 1), 
which contain acidic residues critical to GtrV function (Korres & Verma, 2006). Gtrlc is the 
largest member of the Gtr family and is 526 amino acids in size. Gtrlc consists of ten 
transmembrane helices, cytoplasmic N- and C-termini, two large periplasmic loops and a double 
intramembrane dipping loop (Ramiscal et al., 2010). Even though the topology of Gtrlc is unique 
comparative to other members of the Gtr family, this protein shares some structural homology 
with the predicted GtrIV model as both proteins have cytoplasmic N- and C-termini along with 
two large periplasmic loops. Figure 1.12 illustrates compares the known topologies of all the 
Gtrs to date. 
Studies on Oac showed that the enzyme is an integral membrane protein consisting of ten 
transmembrane helices, a cytoplasmic N-terminus and a periplasmic C-terminus (Thanweer et 
al., 2008). Two domains (one in loop No. 3 and the other in loop No. 4) were found to be critical, 
as deletion studies resulted in a loss of function (Thanweer et al., 2008). Through site-directed 
mutagenesis, the study discovered three critical residues (R73 and R75-R76) in loop No. 3 that 
are critical to the enzymes function. However, the role of these residues has yet to be determined 
(Thanweer et al., 2008). 
The construction of chimeric proteins is a way in which investigations can be carried out 
into Chimeric experiments have been conducted on members of the Gtr family to determine if 
any regions can·y out conserved functions between the Gtr proteins. The second purpose was to 
-discover whether a chimera protein with the capability to convert two or more serotypes could be 
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Figure 1.12: Topological comparison of all the Gtrs from the S. flexneri family. A conserved reentrant 
loop is present in Gtrl, Gtrll, GtrV and GtrX. Also Loop No. 2 is conserved indicating a conserved mode 
of action. Extended periplsmic loops are also evident in Gtrl and Gtrll in the C-terminal end. Adapted 
from V. Tran (Honours thesis, 2010) 
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created. Previously in our lab, given the structural homology between GtrV and GtrX, chimeric 
protein experiments were conducted between the two proteins (Korres & Verma, 2006). It was 
found that when loop No. 2 of GtrX was swapped into GtrV, the resulting chimera still retained 
its function. This led the authors to hypothesize that the N-terminal periplasmic regions of the 
Gtrs had a conserved function. 
1.7 Main objectives 
In order to develop a vaccine strain expressing multiple serotypes a number of process 
have to be understood. One of these processes is the glucosylation of the O-antigen conferring 
serotype specificity. As seen in the introduction, the mechanism involves three 
glucosyltransferases GtrA, GtrB and Gtr(type)· The broad aim of this project was to gain insight 
into the structures and mechanisms of action of the S. flexneri glucosyltransferase IV (GtrIV), 
which is encoded by the cryptic bacteriophage SflV. This may contribute to the ultimate goal of 
developing a polyvalent vaccine strain expressing multiple Gtrs. GtrIV adds a glucosyl residue to 
N-acetylglucosamine of the O-antigen repeat unit via an al,6 linkage, thus converting 
serotype Y to the virulent serotype 4a. The main aims of this project are as follows: 
1. Determine the topology of GtrIV 
The topological information gathered from this objective will be useful for the identification 
of putative catalytic domains and residues ·critical for GtrIV function that may reside within 
these domains. 
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2. Investigate the functions of the large periplasmic loops of GtrIV 
By determining whether the periplasmic loops of GtrIV are required for catalytic activity or 
to maintain structural stability of the protein, it will help narrow down segments within the 
loops that may contain potential catalytic sites. This will be achieved through sequential 
loop deletion experiments. Through the creation of chimeric proteins between GtrIV and its 
closest structural homologue Gtrlc, regions that confer their serotype specificity can be 
identified. The localisation of specific functional domains within GtrIV would accelerate the 
identification of critical residues. 
3. Locate critical residues in GtrIV 
In conjunction with topological information and the localisation of distinct domains, the 
identification of critical residues would enable the development of a model mechanism of 
action of GtrIV, which may be unique as compared to the other Gtrs. 
4. Gain insight into genetic diversity of wildtype serotype 4a strains 
By carrying out sequence analysis and Southern blots on the various wildtype serotype 4a 
strains isolated from Japan, Bangladesh and Vietnam, we will be able to determine if there is 
any genetic variation between the strains of each region. This can help give an insight into 
the evolution of the serotype 4a strains and may help uncover the presence of the cryptic 
bacteriophage SflV. 
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All centrifugation steps were performed at 16,000 x g unless otherwise stated. For 
reagents that needed to be made sterile, they were either autoclaved at 121 °C for 15 minutes or 
filter sterilized through 0.2 µm filter (Minisart). 
2.1 Bacterial Strains and Growth Conditions 
All bacterial cultures were grown aerobically at 37°C on either Luria-Bertani (LB) agar 
plates (Appendix A) or in LB medium (Appendix A). Cultures were incubated with shaking 
(150-200 rpm). Antibiotics such as chloramphenicol (Cm), kanamycin (Kan) and ampicillin 
(Amp) were added to media when required. The final concentrations of these antibiotics were 25 
µg/mL, 50 µg/mL, and 100 µg/mL, respectively. Bacterial plates were stored for up to 3 weeks 
at 4°C in the cold room. For long term storage, bacterial strains were preserved in 1 mL of 
glycerol:LB (1: 1 v/v). The glycerol stocks were then stored at -80°C. 
/ 
-The E. coli strains used in this study are derivatives of E. coli K-12. JM109 cells were 
used for topology studies while XLl-Blue cells for routine cloning procedures. The E. coli _and S. 
flexneri strains used in this study are listed in Tables 2.1 and 2.2, respectively. 
2.2 DNA Preparation 
2.2.1 Plasmids 
The plasmids used and constructed in this study are shown in Table· 2.3. All the plasmids 
-~onstructed were derived from the cloning vector pBC SK (Stratagene) and is shown in Figure 
2. _1. 
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fl ( +) origin 135-441 
~-galactosidaso et-fra.gmont 460-816 
multiple cloning site 653-7 60 
lac promoter 81 7-938 
pUC origin 1158-1825 
chloramphonicol rosistanco ORF 2125-278 l 
ch loramphenicol ·n\ 
pBC SK(+/-) Multiple Cloning Site Region (sequence shown 598-826) 
pBC SK+ 
3.4 kb 
Apo I Hine U 
Ecc()i09 I Ace I BssH II T7 Promoter a-, Kpn I Dt~ 11 Xho l Sol I I \ I I I I TTGTAMACGACGGCCAGTGAGCGCGCGTAATACGACTCACTATAGGGCGAATTGGGTACCGGGCCCCCCCTCGAGGTCGAC ... 
M 13 - 20 primer bindi ng sil·e T7 primer brnding ;ite KS ptim er b-in c!ing siiL . 
ilsol06 r Nol l Cl~ I Hind m EcoR V EcoR I P,t I Sma I BamH I Spe I Xba I j E
1
os I BrtX I Sa <: fl Sac I I I I I I I I I I I I I 
... GGTATCGATAAGCTTGATATCGAATTCCTGCAGCCCGGGGGATCCACTAGTTCTAGAGCGGCCGCCACCGCGGTGGAGCTC . .. ► 
... K::i prim;r binding s.ite SK pri m~r binding sit~ 
~ T3 Promoter BssH II ◄ll-gal Cl-fmqmenl II . l 
.. . CAGCTTTTGTTCCCTTTAGTGAGGGTTAATTGCGCGCTTGGCGTAATCATGGTCATAGCTGTTTCC 
T3 p rim o:r bir,din9 sit~ 1\ •1 l j , R~,.-e rse. ?rimer binding ~ite 
Figure 2.1: Map of cloning vector pBC SK+ ( adapted from Stratagene) 
,,.,,.- Kp n I 
,/ 
MCS 
- Sac I 
· P lac 
Table 2.1: E. coli strains used and created in this study. 
XLl-Blue MRF' 
B1758 
B1904 
B1905 
B1906 
B1907 
B1908 
B1909 
B1910 
B1911 
B1912 
B1913 
B1914 
B1919 
B1920 
B1921 
B1922 
B1923 
B1924 
B1925 
B1926 
B1933 
B1934 
B1935 
B1936 
B1937 
B2182 
B2338 
B2339 
B2340 
B2341 
B2342 
B2343 
B2344 
B2345 
B2346 
B2347 
B2348 
B2349 
B2350 
B2351 
B2352 
B2353 
,. ;~ ;~§ftltt~~n~nofype'~~;-;..:;:,·.: ,~,.;,.,•·:··•::~·,. ·3:'::i1~;'.~~;?~::~:liitt~C~1f ~:~\\~~,. ·"'X:~;j1:·);~····· ·.··~•~:····''~;~-····, _:••·~~ 
recAl supE44 endAl hsdRl 7 gyrA96 relAl Yanisch-Perron et al. 
thi 11(/ac-proAB) [F' traD36 proAB laclq (1985) 
lacZl1Ml5] 
supE44 hsdRl 7 recAl endAl gyrA96 thi-l Jerpseth et al. (1992) 
relAl lac [F' proAB laclqZl1Ml5 Tnl0 
(Te{)] 
JM109 carrying pNV1473 
JMl 09 carrying pNVl 562 
JM109 carrying pNV1563 
JM109 carrying pNV1564 
JM109 carrying pNV1565 
JMl 09 carrying pNVl 566 
JM109 carrying pNV1567 
JM109 carrying pNV1568 
JM109 carrying pNV1569 
JM109 carrying pNV1570 
JM109 carrying pNV1571 
JM109 carrying pNV1572 
JM109 carrying pNV1577 
JM109 carrying pNV1578 
JM109 carrying pNV1579 
JM109 carrying pNV1580 
JMl 09 carrying pNVl 581 
JM109 carrying pNV1582 
JM109 carrying pNV1583 
JM109 carrying pNV1584 
JM109 carrying pNV1591 
JM109 carrying pNV1592 
JMl 09 carrying pNVl 593 
JM109 carrying pNV1594 
JMl 09 carrying pNVl 595 
JMl 09 carrying pNVl 792 
JM109 carrying pNV1920 
JM109 carrying pNV1917 
JM109 carrying pNV1921 
JM109 carrying pNV1924 
JM109 carrying pNV1926 
JM109 carrying pNV1922 
JM109 carrying pNV1927 
JM109 carrying pNV1925 
JM109 carrying pNV1923 
XLl-Blue MRF' carrying pNV1918 
XLl-Blue MRF' carrying pNV1919 
XLl-Blue MRF' carrying pNV1929 
XLl-Blue MRF' carrying pNV1928 
XLl-Blue MRF ' carrying pNV1931 
XLl-Blue MRF' carrying pNV1930 
XLl-Blue MRF' carrying pNV1932 
Nair et al., (2011) 
Nair et al., (2011) 
Nair et al., (2011) 
Nair et al., (2011) 
Nair et al., (2011) 
Nair et al., (2011) 
Nair et al., (2011) 
Nair et al., (2011) 
Nair et al., (2011) 
Nair et al., (2011) 
Nair et al., (2011) 
Nair et al., ( 2011) 
Nair et al., (2011) 
Nair et al., (2011) 
Nair et al., (2011) 
Nair et al., (2011) 
Nair et al., (2011) 
Nair et al., (2011) 
Nair et al., (2011) 
Nair et al., ( 2011) 
Nair-et al., (2011) 
Nair et al., (2011) 
Nair et al., (2011) 
Nair et al., (2011) 
Nair et al., (2011) 
Ramiscal et al., (2010) 
This study 
This study 
This study 
This study 
This study 
This study 
This study 
This study 
This study 
This study 
This study 
This study 
This study 
This study 
This study 
This study 
.i/ 
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B2354 
B2355 
B2356 
B2357 
B2358 
B2359 
B2360 
B2443 
B2444 
B2445 
B2446 
B2447 
B2448 
B2449 
B2450 
B2451 
B2452 
B2453 
B2454 
B2455 
B2456 
B2457 
B2458 
B2459 
B2460 
B2461 
B2462 
B2463 
B2464 
B2465 
XLl-Blue MRF' carrying pNV1933 
XLl-Blue MRF' carrying pNV1934 
XLl-Blue MRF' carrying pNV1935 
XLl-Blue MRF' carrying pNV1936 
XLl-Blue MRF' carrying pNV1937 
XLl-Blue MRF' carrying pNV1938 
XLl-Blue MRF' carrying pNV1939 
XLl-Blue MRF' carrying pNV1998 
XLl-Blue MRF' carrying pNV1999 
XLl-Blue MRF' carrying pNV2000 
XLl-Blue MRF' carrying pNV2001 
XLl-Blue MRF' carrying pNV2002 
XLl-Blue MRF' carrying pNV2003 
XLl-Blue MRF' carrying pNV2004 
XLl-Blue MRF' carrying pNV2005 
XLl-Blue MRF' carrying pNV2006 
XLl-Blue MRF' carrying pNV2007 
XLl-Blue MRF' carrying pNV2008 
XLl-Blue MRF' carrying pNV2009 
XLl-Blue MRF' carrying pNV2010 
XLl-Blue MRF' carrying pNV2011 
XLl-Blue MRF' carrying pNV2012 
XLl-Blue MRF' carrying pNV2013 
XLl-Blue MRF' carrying pNV2014 
XLl-Blue MRF' carrying pNV2015 
XLl-Blue MRF' carrying pNV2016 
XLl-Blue MRF' carrying pNV2017 
XLl-Blue MRF' carrying pNV2018 
XLl-Blue MRF' carrying pNV2019 
XLl-Blue MRF' carrying pNV2020 
This study 
This study 
This study 
This study 
This study 
This study 
This study 
This study 
This study 
This study 
This study 
This study 
This study 
This study 
This study 
This study 
This study 
This study 
This study 
This study 
This study 
This study 
This study 
This study 
This study 
This study 
This study 
This study 
This-study 
This study 
"' 
Table 2.2: S. flexneri strains used and created in this study. 
S1ttI~af , .. ~2'~;•;,p1e's!ii!1tigii~Wr •~e~ ~fYP~·-··_.· · '.'·· .. ? -·~7r·•······· .. ~~~·';,~~~~~:~~;·~~E~:;~·sgil:il~~:,.:,,;~~'"?''~•-•·•• 
SFL1253 Wildtype S. flexneri serotype 4a NCTC 8296 
SFL1255 Wildtype S.flexneri serotype 4b NCTC 8336 
SFL1294 Wildtype S. flexneri serotype 4a C. Sasakawa, Japan 
SFL1295 Wildtype S. flexneri serotype 4a C. Sasakawa, Japan 
SFL1304 Wildtype S. flexneri serotype 4a C. Sasakawa, Japan 
SFL1305 Wildtype S. flexneri serotype 4b C. Sasakawa, Japan 
SFL1314 Wildtype S. flexneri serotype 4a C. Sasakawa, Japan 
SFL1328 Wildtype S.flexneri serotype 4a C. Sasakawa, Japan 
SFL1416 Wildtype S. flexneri serotype la NCTC 
SFLI 522 Wildtype S. flexneri serotype 4a ICDDR, Bangladesh 
SFLI 523 Wildtype S. flexneri serotype 4a ICDDR, Bangladesh 
SFLI 524 Wildtype S. flexneri serotype 4a ICDDR, Bangladesh 
SFLI 525 Wildtype S. flexneri serotype 4a ICDDR, Bangladesh 
SFLI 526 Wildtype S. flexneri serotype 4a ICDDR, Bangladesh 
SFL1616 SFL124 with gtrA and gtrB from SfV in Lehane et al., (2005) 
SFLI 714 
SFLI 758 
SFLI 767 
SFLI 768 
SFL1769 
SFL2069 
SFL2175 
SFL2176 
SFL2178 
SFL2179 
SFL2180 
SFL2183 
SFL2187 
SFL2193 
SFL2234 
SFL2241 
SFL2265 
SFL2271 
SFL2324 
SFL2325 
SFL2326 
SFL2327 
SFL2328 
SFL2329 
SFL2330 
SFL2331 
SFL2332 
SFL2333 
SFL2334 
SFL2335 
SFL2336 
pACYC177. 
Wildtype S. flexneri serotype 4a 
Wildtype S. flexneri serotype 4 
Wildtype S. flexneri serotype 4 
Wildtype S. flexneri serotype 4 
Wildtype S. flexneri serotype 4 
Wildtype serotype la host to pNVl 792 
Wildtype S. flexneri serotype 4a 
Wildtype S. flexneri serotype 4a 
Wildtype S. flexneri serotype 4a 
Wildtype S. flexneri serotype 4a 
Wildtype S. flexneri serotype 4a 
Wildtype S. flexneri serotype 4 
Wildtype S. flexneri serotype 4a 
Wildtype S. flexneri serotype 4a 
Wildtype S. flexneri serotype 4 
W ildtype S. flexneri serotype 4 
Wildtype S. flexneri serotype 4a 
Wildtype S. flexneri serotype 4a 
SFL1616 carrying pNV1917 
SFL1616 carrying pNV1918 
SFL1616 carrying pNV1919 
SFL1616 carrying pNV1929 
SFL1616 carrying pNV1928 
SFL1616 carrying pNV1931 
SFL1616 carrying pNV1930 
SFL1616 carrying pNV1932 
SFL1616 carrying pNV1933 
SFL1616 carrying pNV1934 
SFL1616 carrying pNV1935 
SFL1616 carrying pNV1936 
SFL1616 carrying pNV1937 
P. D. Cam, Vietnam 
P. D. Cam, Vietnam 
P. D. Cam, Vietnam 
P. D. Cam, Vietnam 
P. D. Cam, Vietnam 
Ramiscal et al., (2011) 
P. D. Cam, Vietnam 
P. D. Cam, Vietnam 
P. D. Cam, Vietnam 
P. D. Garn, Vietnam 
P. D. Cam, Vietnam 
P. D. Cam, Vietnam 
P. D. Cam, Vietnam 
P. D. Cam, Vietnam 
P. D. Cam, Vietnam 
P. D. Cam, Vietnam 
P. D. Cam, Vietnam 
P. D. Cam, Vietnam 
This study 
This study 
This study 
This study 
This study 
This study 
This study 
This study 
This study 
This study 
This study 
This study 
This study 
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SFL2337 SFL1616 carrying pNV1938 
SFL2338 SFL1616 carrying pNV1939 
SFL2339 SFL1416 carrying pNV1936 
SFL2340 SFL1416 carrying pNV1937 
SFL2341 SFL1416 carrying pNV1938 
SFL2342 SFL1416 carrying pNV1939 
SFL2388 SFL1616 carrying pNV1998 
SFL2389 SFL1616 carrying pNV1999 
SFL2390 SFL1616 carrying pNV2000 
SFL2391 SFL1616 carrying pNV2001 
SFL2392 SFL1616 carrying pNV2002 
SFL2393 SFL1616 carrying pNV2003 
SFL2394 SFL1616 carrying pNV2004 
SFL2395 SFL1616 carrying pNV2005 
SFL2396 SFL1616 carrying pNV2006 
SFL2397 SFL1616 carrying pNV2007 
SFL2398 SFL1616 carrying pNV2008 
SFL2399 SFL1616 carrying pNV2009 
SFL2400 SFL 1616 carrying pNV2010 
SFL2401 SFL1616 carrying pNV2011 
SFL2402 SFL1616 carrying pNV2012 
SFL2403 SFL1616 carrying pNV2013 
SFL2404 SFL1616 carrying pNV2014 
SFL2405 SFL1616 carrying pNV2015 
SFL2406 SFL1616 carrying pNV2016 
SFL2407 SFL1616 carrying pNV2017 
SFL2408 SFL1616 carrying pNV2018 
SFL2409 SFL 1616 carrying pNV2019 
SFL2410 SFL1616 carr)jng pNV2020 
ICDDR- International Centre for Diarrhoeal Disease Research 
I . 
This study 
This study 
This study 
This study 
This study 
This study 
This study 
This study 
This study 
This study 
This study 
This study 
This study 
This study 
This study 
This study 
This study 
This study 
This study 
This study 
This study 
This study 
This study 
This study 
This study 
This study 
This study 
This study 
This study 
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Table 2.3: Plasmids used and constructed in this study. 
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pNV1792 
pNV1914 
pNV1917 
pNV1918 
pNV1919 
pNV1920 
pNV1921 
pNV1922 
pNV1923 
pNV1924 
pNV1925 
pNV1926 
pNV1927 
pNV1928 
pNV1929 
pNV1930 
pNV1931 
pNV1932 
pNV1933 
pNV1934 
pNV1935 
pNV1936 
pNV1937 
pNV1938 
pNV1939 
pNV1973 
3.4 kb cloning vector (Fig. 2.1) 
Product of ligation between gtrIV and majority of pNVl 090 
( excluding gtr V) (NheI/ Xbal) 
pNVl 734 having gtrlc downstream terminus fused to phoA/lacZ 
pNV1473 withphoA/lacZ excised out 
pNVl 4 73 with phoA/LacZ fused to C-terminus of gtrIV 
pNV1917 with GtrIV loop No. 2 deletion. Contains Smal site at 
point of deletion 
pNV1917 with GtrIV loop No. 3 deletion. Contains Smal site at 
point of deletion 
pNV1473 in-frame PCR-based fusion with PhoA/LacZ at residue 
N255 
pNV1473 in-frame PCR-based fusion with PhoA/LacZ at residue 
V102 
pNV1473 in-frame PCR-based fusion with PhoA/LacZ at residue 
V155 
pNV1473 in-frame PCR-based fusion with PhoA/LacZ at residue 
D169 
pNV1914 with PhoA/LacZ sandwich fusion at residue R93 
pNV1914 with PhoA/LacZ sandwich fusion at residue Kl 17 
pNV1914 with PhoA/LacZ sandwich fusion at residue A181 
pNV1914 with PhoA/LacZ sandwich fusion at residue R375 
pNV1917 with GtrIV loop No. 6 deletion. Contains Smal site at 
point of deletion 
pNV1917 with GtrIV loop No. 6 partial deletion 1. Contains Smal 
site at point of deletion 
pNV1917 with GtrIV loop No. 6 partial deletion 2. Contains Smal 
site at point of deletion 
pNV1917 with GtrIV loop No. 6 partial deletion 3. Contains Smal 
site at point of deletion 
pNV1917 with GtrIV deletion of residues N251-N255. Contains 
Smal site at point of deletion 
pNV1917 with GtrIV deletion of residues P256-V260. Contains 
Smal site at point of deletion 
pNV1917 with GtrIV deletion of residues D261~G265. Contains 
Smal site at point of deletion 
pNV1917 with GtrIV deletion of residues V266-W269. Contains 
Smal site at point of deletion 
Gtrlc-GtrIV Loop No. 2-Gtrlc chimera. Bgffi and Mlul sites at 
points of fusion 
GtrIV-Gtrlc Loop No. 2-GtrIV chimera. Bgffi and Mlul sites at 
points of fusion 
Gtrlc-GtrIV Loop No. 6-Gtrlc chimera. Bgffi and Mlul sites at 
points of fusion 
GtrIV-Gtrlc Loop No. 10-GtrIV chimera. Bgffi and Mlul sites at 
points of fusion 
pNV1914 with PhoA/LacZ sandwich fusion at residue K162 
Strata gene 
Nair et al. , 
(2011) 
Ramiscal et al. , 
(2010) 
This study 
This study 
This study 
This study 
This study 
This study 
This study 
This study 
This study 
This study 
This study 
This study 
This study 
This study 
This study 
This study 
This study 
This study 
This study 
This study 
This study 
This study 
This study 
This study 
This study 
pNV2001 
pNV2002 
pNV2003 
pNV2004 
pNV2005 
pNV2006 
pNV2007 
pNV2008 
pNV2009 
pNV2010 
pNV2011 
pNV2012 
pNV2013 
pNV2014 
pNV2015 
pNV2016 
pNV2017 
pNV2018 
pNV2019 
pNV2020 
,:...,.;,_,.. 
This study 
pNV1917 after site-directed mutagenesis to DE261 mutated to AA This study 
in GtrIV 
pNV1917 after site-directed mutagenesis to ED326 mutated to AA This study 
in GtrIV 
pNV1917 after site-directed mutagenesis to ED283 mutated to AA This study 
in GtrIV 
pNV1917 after site-directed mutagenesis to D267 mutated to A in This study 
GtrIV 
pNVl 917 after site-directed mutagenesis to E254 mutated to A in This study 
GtrIV 
pNV1917 after site-directed mutagenesis to E58 mutated to A in This study 
GtrIV 
pNV1917 after site-directed mutagenesis to E333 mutated to A in This study 
GtrIV 
pNV 191 7 after site-directed mutagenesis to E294 mutated to A in This study 
GtrIV 
pNV1917 after site-directed mutagenesis to D274 mutated to A This study 
in GtrIV 
pNV1917 after site-directed mutagenesis to D49 mutated to A in This study 
GtrIV 
pNV2005 after site-directed mutagenesis to D267 mutated to A This study 
in GtrIV 
pNV2001 after site-directed mutagenesis to E254 mutated to A in This study 
GtrIV 
pNV2001 after site-directed mutagenesis to D267 mutated to A This study 
in GtrIV 
pNV1917 after site-directed mutagenesis to W269 mutated to A This study 
in GtrIV 
pNV1917 after site-directed mutagenesis to 1264 mutated to A in This study 
GtrIV 
pNV1917 after site-directed mutagenesis to V266 mutated to A This study in GtrIV 
pNV1917 after site-directed mutagenesis to G265 mutated to A This study 
in GtrIV 
pNV2013 after site-directed mutagenesis to A262 mutated to E in This study 
GtrIV 
pNV2013 after site-directed mu ta genesis to A26 l mutated to D This study in GtrIV 
pNV1917 after site-directed mutagenesis to C263 mutated to A This study in GtrIV 
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2.2.2 Isolation of plasmid DNA 
When plasmid DNA was required for either sequencing or cloning, extraction of 
plasmids was carried out using Axygen Axyprep Plasn1id Miniprep Kit. A 1.5 mL aliquot of a 5 
mL overnight culture was transferred to a 1.5 mL Eppendorf tube and centrifuged for 2 min, 
before removing the supernatant. The resulting pellet was resupended in 250 µL of Buffer S 1. 
250 µL of Buffer S2 was added to the tube and inverted 4-6 times. 3 50 µL of Buffer S3 was then 
added and the tube was inverted for 6-8 times before being centrifuged for 10 min. The 
supernatant was transferred to a Miniprep column assembly and centrifuged for 1 min. The flow-
through solution was discarded, and the column was washed with 500 µL of Buffer Wl, 
followed by two washes with 700 µL of Buffer W2. After discarding the flow-through solution, 
the MiniPrep column assembly was then centrifuged for 1 minute to remove any excess flow-
through solution. The AxyPrep column was then ·placed in a sterile 1.5 mL Eppendorf tube and 
60 µL of eluent was added to the centre of the column. The column was allowed to stand for 1 
minute before being centrifuged for 1 minute to elute the plasmid DNA. _ 
When plasmid DNA needed to be isolated from many cultures for screening purposes, 
the alkaline lysis method adapted by Sambrook & Russell (2001) from Birnboim & Doly (1979). 
Bacteria were pelleted as described above. Once the supernatant medium was discarded, the 
pellet was resuspended in 100 µL of ice-cold Alkaline Lysis Solution I (Appendix A). 200 µL of 
freshly made Alkaline Lysis Solution II (Appendix A) was then added and the tube was inverted 
5-10 times and placed on ice. 150 µL of ice-cold Alkaline Lysis Solution III (Appendix A) was 
then added and the tube was inverted immediately but gently 5-10 times and left on ice for 
5 min. The tube was then centrifuged for 5 minutes and the supernatant solution was transferred 
into a clean microcentrifuge tube. 
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CHAPTER 2 
The plasmid DNA was then precipitated by adding 2 volumes of absolute ethanol. The 
tube was inverted and allowed to stand for 2 min. Following a 5 minutes centrifugation, the 
supernatant was discarded and 300 µL of 70% ethanol was added. The tube was vortexed and 
centrifuged for 2 min. The supernatant was discarded and the plasmid DNA was dried under 
vacuum (Savant SpeedVac SC 100 and high drying rate) for 10 min. The plasmid DNA was 
resuspended in sterile MilliQ water (typically 50 µL). 
2.2.3 Genomic DNA extraction 
Genomic DNA was purified from the S. flexneri wildtype 4 strains using the Illustra™ 
Bacteria GenomicPrep Mini Spin Kit (GE). 1 mL of overnight culture was centrifuged for 30 
seconds at 16,000 x g. After discarding the supernatant, 40 ~LL of Lysis buffer type 2, 10 µL of 
proteinase Kand 10 µL of Lysis buffer type 3 was added and the tube incubated at 55°C for 7 
minutes. After which, the tube was vortexed, centrifuged at 1,000 x g for 5 seconds and 
incubated for another 8 minutes at 55°C. RNase A was then added and the Eppendorf tube was 
-incubated at room temperature for 15 minutes. 500 µL of Lysis buffer type 4 was added followed 
by another 10 minute incubation at room temperature. After a 5 second centrifugation step at 
1,000 x g, the supernatant was transferred to a Bacteria Mini Column that was placed inside a 
collection tube and centrifuged for 1 minute at 11,000 x g. The resulting flowthrough was 
discarded and 500 µL of Lysis buffer type 4 was added. Following another 1 minute 
centrifugation step at 11,000 x g, the flowthrough was discarded and Wash buffer type 6 was 
added. The tube was then centrifuged for 3 minutes at 16,000 x g. The Bacteria Mini Column 
was the transferred to a new DNase-free eppendorf tube. 200 µL of pre-heated Elution buffer 
type 5 was added and the tube was incubated for 1 minute at room temperature. After a 1 minute 
spin at 11,000 x g, the flow through was retained, the genomic DNA was then stored at 4 °C. 
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2.3 DNA Cloning 
2.3.1 Restriction enzyme (RE) digestion 
Single digest reactions involving only one restriction enzyme were typically performed in 
20 µL volumes. This final volume would reach up to 60 µL when the digestion of a large 
quantity of DNA was required. The reaction mixture consisted of plasmid DNA, 1 Ox RE buffer 
added accordingly to give a final concentration of lx and 0.5-2 U of restriction enzyme. Sterile 
MilliQ water was added to the reaction mixture to reach the final volume required. The mixture 
was vortexed and incubated at 37°C for 1-3 h. 
Double digests involving two restriction enzymes were performed simultaneously when 
the buffering conditions required by both enzymes were compatible. The reaction mixture and 
conditions used were the same as those for single digest reactions. In some cases, the 
concentration of buffer varied depending on the requirements of the enzymes and the reactions 
were typically performed in 30 µL volumes. 
Most of the restriction enzymes were heat inactivated as specified by Fermentas or New 
England Biolabs (NEB). In cases where the entire reaction was to be immediately loaded onto an 
agarose gel, heat inactivation was not carried out. 
2.3.2 DNA amplific~tion 
Amplification of specific genes was performed via Polymerase Chain Reaction (PCR). 
Before carrying out a PCR reaction, primers ·were designed following a number of specifications. 
Custom designed primers were ordered from Sigma-Proligo and diluted in nuclease free water to 
reach a final concentration of 50 µM. The PCR primers for this study are listed in Table 2.4. The 
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Table 2.4: Primers used in this study 
gtrIVNheIFnew 
gtrIVXbaIRnew 
VJ 02HpaIRev 
Lp5Ql46Rev 
VJ 55HpaIRev 
,. J 
, • DJ 69HpaIRev 
Lpl 0D407Rev 
GtrIVCtermHpaIR 
TCAGCTA GCCTCGGTGGTGTGCAGCTC 
TCATCTAGACCCCCCAGGATAACTGTGGG 
GTTCTGGAAAACCGGGCTGCTCAG 
TCAGTTAACCACGATTTTGGAAAGAGATGAC 
CTGATAAAATGCTGTGAATTG 
TCAGTTAACCGGAAGTAAAGTGATTACTATTTG 
TCAGTTAACATCAAACCTTGATATTTCTTTTTTAAG 
GTCTAAATCTCTATATCCTTC 
V ?::C:: 
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GtrIVR93NruIF CA CATTTGATCTTTCGCGATGGTCATCTCTTTCC 
Gtr IVR9 3NruIR GGAAAGAGATGACCATCGCGAAAGATCAAATGTG 
GtrIVKJ l 7NruIF GTAGAAATAAACAATCGCGAATATTCTTATCTTTTATTTC 
GtrIVKJ l 7NruIR GAAATAAAAGATAAGAATATTCGCGATTGTTTATTTCTAC 
, GtrIVIJ 36NruIF GCTATTTACTCCTTCGCGACTTTCACAATC 
, 1 1 GtrIVIJ 36NruIR GAATTGTGAAAGTCGCGAAGGAGTAAATAGC 
111n GtrIVAJ 81NruIF GCGCAGCGCTAATCGCGACATCAAAATCTC 
GtrIVAJ 81NruIR GAGATTTTGATGTCGCGATTAGCGCTGCGC 
1 11GtrIVR375NruIF CACTGATTTTTATTCGCGAAAAATATTCTGTTG 
,GtrIVR375NruIR CAACAGAATATTTTTCGCGAATAAAAATCAGTG I·. L _____ _ 
I, ]11VLp2De!SmaIF TCACCCGGGTATAAAAGCTCATTCAGTTATATTC 
I IVLp2DelSmaIR TCACCCGGGATTATTCATCATCCATATGTC 
iLp8DelSmaIF TCACCCGGGCAAAAAATAAAA GACTCGC 
l~p8DelSmaIR TCACCCGGGATTGCTTTTATTGTATAGC 
,p8P _Dell SmaR TCACCCGGGAGGAACATGGAAGGTTGCTTTAG 
,·Y(Lp8P _Del2SmaIF TCACCCGGGCTTTTGATGCTAAAGCAACC 
~p8P __ Del2SmaIR TCACCCGGGTTTATTTCCCCATGCATCAAC 
ILp8P _Del3SmaIF TCACCCGGGTTTGATTTAGATAAGGGAGC 
.. JlVLp6P.Del3FD 1 F TCACCCGGGGCTTTTATTGTATAGCAAAGTC 
1{VLp6P.Del3FD2F TCACCCGGGGACGAATGCATTGGTGTTGATG 
, 
11
'{vLp6P.Del3FD2R TCACCCGGGATTTTCTTTTCCATTGCTTTTATTG I 
'" iJVLp6P.Del3FD3F TCACCCGGGGTTGATGCATGGGGAAATAAATTTG 
iTVLp6P.Del3FD3R TCACCCGGGCACGGCCCACGATGGATTTTC 
·TLp6P.Del3FD4R TCACCCGGGACCAATGCATTCGTCCACGGC · 
,. 
0 
-
Upstream of 
gtrIV gene 
Downstream of 
gtrIV gene 
Beginning of 
phoA/lacZ 
In gtrIV gene 
In gtrIV gene 
In gtrIV gene 
In gtrIV gene 
In gtrIV gene 
In gtrIV gene 
In gtrIV gene 
In gtrIV gene 
In gtrIV gene 
In gtrIV gene 
In gtrIV gene 
In gtrIV gene 
In gtrIV gene 
In gtrIV gene 
In gtrIV gene 
in gtrl v gene 
In gtrIV gene 
In gtrIV gene 
In gtrIV gene 
In gtrIV gene 
In gtrIV gene 
In gtrIV gene 
In gtrIV gene 
In gtrIV gene 
In gtrIV gene 
In gtrIV gene 
In gtrIV gene 
In gtrIV gene 
In gtrIV gene 
Nhel 
Xbal 
Hpal 
Hpal 
Hpal 
Nrul 
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Smal 
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Smal 
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Smal 
Smal 
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Smal 
Smal 
Smal 
Table 2.4: Primers used in this study 
gtrIVNheIFnew TCAGCTA GCCTCGGTGGTGTGCAGCTC Upstream of gtrIV gene Nhel 
. gtrIVXbaIRnew TCATCTAGACCCCCCAGGATAACTGTGGG Downstream of gtrIV gene Xbal 
Beginning of 
GTTCTGGAAAACCGGGCTGCTCAG phoA/lacZ 
coding sequence 
:*<•*~~~, lf-;~,~ . ,_··, ··.· --~ ·_ .. '-~ 
VJ 02HpaIRev · TCAGTTAACCACGATTTTGGAAAGAGATGAC In gtrIV gene Hpal 
Lp5QJ46Rev CTGATAAAATGCTGTGAATTG In gtrIV gene 
VJ 55HpaIRev TCAGTTAACCGGAAGTAAAGTGATTACTATTTG In gtrIV gene Hpal 
DJ 69HpaIRev TCAGTTAACATCAAACCTTGATATTTCTTTTTTAAG In gtrIV gene Hpal 
LpJ 0D407Rev GTCTAAATCTCTATATCCTTC In gtrIV gene 
TCAGTTAACCTTATAAATTCCTGATGCTACC In gtrIV gene 
0:sc~-~----~~-~ ~-;_ ..... -. . ; . • ... ~. . ::.t, ... ~ •, ,. \. . '1'. '· • . . . . • •. . "' -, - • . ~ ' c, ' . . • . ., . • •• • ' CACATTTGATCTTTCGCGATGGTCATCTCTTTCC In gtrIV gene Nrul 
Gtr IVR9 3NruIR GGAAAGAGATGACCATCGCGAAAGATCAAATGTG In gtrIV gene Nrul Ir GtrIVKJJ7NruIF GTAGAAATAAACAATCGCGAATATTCTTATCTTTTATTTC In gtrIV gene Nrul 
-
1
11! GtrIVKJ J 7NruIR GAAATAAAAGATAAGAATATTCGCGATTGTTTATTTCTAC In gtrIV gene Nrul 
GtrIVIJ 36NruIF GCTATTTACTCCTTCGCGACTTTCACAATC In gtrIV gene Nrul 
· GtrIVIJ36NruIR GAATTGTGAAAGTCGCGAAGGAGTAAATAGC In gtrIV gene Nrul 
GtrIVAJ 8JNruIF GCGCAGCGCTAATCGCGACATCAAAATCTC In gtrIV gene Nrul 
GtrIVAJ 8JNruIR GAGATTTTGATGTCGCGATTAGCGCTGCGC In gtrIV gene Nrul 
GtrIVR3 7 5NruIF CACTGATTTTTATTCGCGAAAAATATTCTGTTG In gtrIV gene Nrul 
·' ;i GtrIVR3 7 5NruIR CAACAGAATATTTTTCGCGAATAAAAATCAGTG In gtrIV gene Nrul 
IVLp2DelSmaIF TCACCCGGGTATAAAAGCTCATTCAGTTATATTC In gtrIV gene Smal 
IVLp2DelSmaIR TCACCCGGGATTATTCATCATCCATATGTC In gtrIV gene Smal 
Lp8DelSmaIF TCACCCGGGCAAAAAATAAAAGACTCGC In gtrIV gene Smal 
Lp8DelSmaIR TCACCCGGGATTGCTTTTATTGTATAGC In gtrIV gene Smal 
Lp8P _Dell SmaR TCACCCGGGAGGAACATGGAAGGTTGCTTTAG In gtrIV gene Smal 
Lp8P _ Del2SmaIF TCACCCGGGCTTTTGATGCTAAAGCAACC In gtrIV gene Smal 
. Lp8P _ Del2SmaIR TCACCCGGGTTTATTTCCCCATGCATCAAC In gtrIV gene Smal 
Lp8P _Del3SmaIF TCACCCGGGTTTGATTTAGATAAGGGAGC In gtrIV gene Smal -
IVLp6P.Del3FD J F TCACCCGGGGCTTTTATTGTATAGCAAAGTC In gtrIV gene Smal 
IVLp6P.Del3FD2F TCACCCGGGGACGAATGCATTGGTGTTGATG In gtrIV gene Smal 
IVLp6P.Del3FD2R TCACCCGGGATTTTCTTTTCCATTGCTTTTATTG In gtrIV gene Smal 
IVLp6P.Del3FD3F TCACCCGGGGTTGATGCATGGGGAAATAAATTTG In gtrIV gene Smal 
•r IVLp6P.Del3FD3R TCACCCGGGCACGGCCCACGATGGATTTTC In gtrIV gene Smal 
IVLp6P.Del3FD4R TCACCCGGGACCAATGCATTCGTCCACGGC · In gtrIV gene Smal 
- --...-.--.:. - '<:I 
TCAAGATCTAATGGCGACTTCGATAGGGC Jn gtrl V gene Bglll 
GtrIVLp2MluIR TCAACGCGTATACTCATAGTTCACAATTGAAC In gtrIV gene Mlul 
GtrIVMluIF TCAACGCGTTCATTGAGTTATATTCTTTATTTATACG In gtrIV gene Mlul 
1tl GtrIVBglIIR TCAAGATCTCATCCATATGTAAATTGACTCC In gtrIV gene Bglll 
- GtricLp2BglIIF TCAAGATCTCACCATGGAAGCTGGTCAGG In gtric gene Bglll 
GtricLp2MluIR TCAACGCGTATTGAAATCGTGACTTATATAAAATATAG In gtric gene Mlul l GtrJcBodyM/uJF TCAACGCGTGTTACCGTTAAGTTATTAGCG In gtric gene Mlul 
TCAAGATCTAAAGACTGGCATCCACGATA In gtric gene 1 · . Gtric VectorBglIIR Bgill 
[ GtrIVLp8NruIF TCATCGCGAAAAATAACAGCTATCACTCC In gtrIV gene Nrul 
GtrIVLp8NruIR TCATCGCGATTTTTTGAACTTCATTCAAAAAAAC In gtrIV gene Nrul 
Gtr IVBodySmaIF TCACCCGGGGACTCTGCTCTATCAACTGTG In gtrIV gene Smal 
GtrIVBodySmaIR TCACCCGGGGCTTGGCGAGAAAAATGAAAATG In gtrIV gene Smal 
Gtr I cLp 1 OSmaIF TCACCCGGGGTACCTAAAAAAAGTAGCCAC In gtric gene Smal 
GtricLpl OSmaIR TCACCCGGGCCTGTTTGAACCTATAAGTTG In gtric gene Smal 
Gtr I cBodySmaIF TCACCCGGGAGTAATCGCACTTGTCATCAAAC In gtric gene Smal 
Gtr IcBodySmaIR 
D31ForA GATGAATAATGGCGCATTCGATAGGGCCATAAC In gtrIV gene 
-
, .• D31RevA GTTATGGCCCTATCGAATGCGCCATTATTCATC In gtrIV gene 
1•11 . D33ForwardA GAATAATGGCGACTTCGCAAGGGCCATAACACC In gtrIV gene 
111 -D33ReverseA GGTGTTATGGCCCTTGCGAAGTCGCCATTATTC In gtrIV gene 
1n D31D33ForAA GATGAATAATGGCGCATTCGCAAGGGCCATAAC In gtrIV gene 
D31D33RevAA GTTATGGCCCTTCGGAATGCGCCATTATTCATC In gtrIV gene 
D49AFor CAGTTCTCACATGCTGGCACATTACTTTATAC In gtrIV gene 
D49ARev GTATAAAGTAATGTGCCAGCATGTGAGAACTG In gtrIV gene 
ll 'E58AFor CTTTATACCCTGAAGGCAAATTTCAGTTCAATT In gtrIV gene 
AATTGAACTGAAATTTGCCTTCAGGGTATAAAG In gtrIV gene 1 - E58ARev 
I 
E67AFor TCAATTGTGAACTATGCGTATAAAAGCTCATTC In gtrIV gene 
E67ARev GAATGAGCTTTTATACGCATAGTTCACAATTGA In gtrIV gene 
E254AFor AAAAGCAATGGAAAAGCAAATCCATCGTGGGCC In gtrIV gene 
-E254ARev GGCCCACGATGGATTTGCTTTTCCATTGCTTTT In gtrIV gene 
DE261AAFor CATCGTGGGCCGTGGCCGCATGCATTGGTGTTG In gtrIV gene 
. DE261AARev CAACACCAATGCATGCGGCCACGGCCCACGATG In gtrIV gene 
, GtrIVA261DFor AATCCATCGTGGGCCGTGGACGCATGCATTGGTGTT In gtrIV gene 
IW GtrIVA261DRev AACACCAATGCATGCGTCCACGGCCCA CGATGGATT In gtrIV gene 
111 GtrIVA262EFor TCGTGGGCCGTGGCTGAATGCATTGGTGTTGCT In gtrIV gene 
GtrIVA262ERev AGCAACACCAATGCATTCAGCCACGGCCCACGA In gtrIV gene 
1u C263AFor TGGGCCGTGGACGAAGCCATTGGTGTTGATGCA In gtrIVgene 
1.t C2 63ARev TGCATCAACA .CCAATGGCTTCGTCCACGGCCCA In gtrIV gene 
I264AFor GCCGTGGACGAATGCGCTGGTGTTGATGCATGG In gtrIV gene 
~ 
I264ARev CCATGCATCAACACCAGCGCATTCGTCCACGGC In gtrIV gene 
G265AFor GTGGA CGAA TGCATTGCTGTTGATCGATCCGGA In gtrIV gene 
G265ARev TCCCCATGCATCAACAGCAATGCATTCGTCCAC In gtrIV gene 
I266AFor GACGAATGCATTGGTGCTGATGCATGGGGAAAT In gtrIV gene 
I266ARev ATTTCCCCATGCATCAGCACCAATGCATTCGTC In gtrIV gene 
D267AFor GAATGCATTGGTGTTGCTGCATGGGGAAATAAA In gtrIV gene 
i r D267ARev TTTATTTCCCCATGCAGCAACACCAATGCATTC In gtrIV gene 
W269AFor ATTGGTGTTGATGCAGCGGGAAATAAATTTGAT In gtrIV gene 
W269ARev ATCAAATTTATTTCCCGCTGCATCAACACCAAT In gtrIV gene 
D276ForwardA GGAAATAAATTTGATTTAGCTAAGGGAGCTGTTACC In gtrIV gene 
D276ReverseA GGTAACAGCTCCCTTAGCTAAATCAAATTTATTTCC In gtrIV gene 
ED283AAFor GCTGTTACCACAGCAGCTGCTGGAGCCTGC In gtrIV gene 
ED283AARev GCAGGCTCCA GCA GCTGCTGTGGTAA CAGC In gtrIV gene 
E294AFor TTCGCAAAAAATAAA GCAAGGGGATTGAAGGAT In gtrIV gene 
E294ARev ATCCTTCAATCCCCTTGCTTTATTTTTTGCGAA In gtrIV gene 
D317For CTCCTTCTTCCTTTTGCTTCTGGA GTTCGAA CC In gtrIV gene 
D317Rev GGTTCGAACTCCAGAAGCAAAAGGAAGAAGGAG In gtrIV gene 
ED326AAFor GAACCCAATTAACTGCAGCTTACTTCCATGTC In gtrIV gene 
ED326AARev GACATGGAAGTAAGCTGCAGTTAATTGGGTTC In gtrIV gene 
-E334AFor CTTCCATGTCTTCAAGCCAAATAAGCTAATAATAAG In gtrIV gene 
CTTATTATTAGCTTATTTGGCTTGAAGACATGGAAG In gtrIV gene 
AGTGTTTTTTTGAATGCAGTTCAAAAAATAAAA In gtrIV gene 
TTTTATTTTTTGAA GA GCATTCAAAAAAA CA CT 
173 bp into 
PhoSeqNewR GCACCTTCGGCATAATTACGTGC phoA/lacZ 
coding sequence 
Ml3R GGAAACAGCTATGACCATG pBS ~s m_ultiple 
cloning szte 
Primers have been grouped into categories that correspond to their main use. Some primers were used in multiple 
studies. Restriction enzyme sites on the primers are underlined. For primers used in mutagenesis, the bases that have 
been changed are in bold italics. 
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design of the oligionucleotide sequence for a pair of forward and reverse primers was based on a 
matching melting temperature (Tm), which was calculated using the formula below: 
Tm (°C) = (2 x number of A+ T bases)+ (4 x number of G + C bases) 
A typical PCR reaction (3x) consisted of a mastermix of 103 .5 µL of sterile MilliQ water, 
3 µL of each 2.5 µM primer stock (final concentration: 0.05 µM), 3 µL of 10 mM 
deoxynucleotide triphosphate ( dNTP) mix (final concentration: 0.2 mM), and 15 ~LL of 1 Ox Pfu 
ultraII polymerase buffer (Stratagene; to give Ix) are added together into an l .5mL 
microcentrifuge tube. From this mastermix, 42-48 µL was aliquoted out into a PCR tube. 2-8 µL 
of DNA template ( diluted 1/20) was added to give a final mastermix volume of 50 µL. Finally, 
0.2 µL of Pfu ultraII poymerase (Stratagene) was added to each PCR tube. Table 2.5 lists the 
different protocols used for the respective PCR reactions. A T3 thermal cycler (Biometra) was 
used. The primer annealing temperature was typically 3-5°C below the melting temperature (Tm) 
of the primer ( excluding non-complementary overhangs). The extension step used was 1 minute 
per kb of DNA. For the amplification of entire plasmids, the primer annealing and extension 
temperatures were 55°C and 68°C, respectively, with 25 cycles amplification. Upon completion 
of the PCR, the holding temperature was 4 °C. 
2.3 .2.1 Colony PCR 
Colony PCR was used to amplify gtrIV from the wildtype serotype 4 strains. The 
protocol was adapted from Schuch and Maurelli (1997). Colonies were smeared into 1.5 mL 
microcentrifuge tubes, resuspended in 25 µL of 0.5 M NaOH and let at RT for 30 min. 25 µL of 
1 M Tris (pH 8) and 450 ~LL of sterile MilliQ water were then added to each microcentrifuge 
tube. The PCR. mastermix had the same composition as described above with Pfu ultraII 
31 
Table 2.5: Typical PCR conditions used in this study. 
Initial 
95°C, 2 min 
lx 
9s 0 c, 30 s 
lx 
__ : - - ':::i 
95°c, 30 s 
30x 
9s 0 c, 30 s 
25x 
3 °C below lowest 
primer Tm, 30 s 
30x 
55°C, 1 min 
25x 
72°C, 1 min per kb 
30x 
68°C, 1 min per kb 
25x 
72°C, 7 min 
lx 
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polymerase. The total volume depended on the number of reactions. The reaction mixes 
consisted of 45 µL PCR mastermix and 5 µL of lysed colony to make a total volume of 50 ~LL. 
2.3.3 Removal of template DNA through Dpnl treatment 
To remove methylated template DNA from PCR products, 10 U of Dpnl (NEB) was 
added directly to a completed PCR reaction. The tube was incubated at 3 7°C for 1-2 h. In some 
cases, the digest was left overnight in the 3 7°C waterbath. 
2.3.4 DNA Quantification 
The concentration and purity of DNA was estimated using the Nanodrop ND-1000 
Spectrophotometer by N anodrop Technologies. A 2 µL aliquot of each sample was used for 
analysis. 
2.3.5 DNA Ligations 
Both the vector and insert DNA were digested with two restriction enzymes. This forms 
cohesive overhangs. A vector to insert ratio of 3: 1 was used to help the insert ligate to the vector. 
Typically, ligation reactions were made up to 20 µL consisting of 6 µL digested vector, 1-2 µL 
insert DNA, sterile MilliQ water, lx ligase buffer (Promega) and 1.2 U of T4 DNA ligase 
(Promega). Sticky end ligation reactions were incubated overnight at 4 °C while blunt-end 
ligation reactions were incubated overnight at l 5°C. All ligations were stored at -20°C. For 
transformation into rubidium chloride competent cells, the entire ligation mix was used. For 
transformation into electrocompetent cells, smaller volumes (1-3 µL) were used. 
32 
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2.3.6 DNA sequencing 
For sequencing, DNA was prepared using the Axygen Axyprep Plasmid Miniprep Kit 
(section 2.2.2). The extracted DNA was then quantified by using the NanoDrop ND-1000 
spectrophotometer (section 2.3.4). Approximately 150-200 ng of DNA, 1 ~LL of Terminator 
Ready Reaction Premix, 3 .5 ~LL of 5x dilution buffer, 1.5 µL of 2.5 µM primer and sterile MilliQ 
water up to 20 ~LL were mixed together into a PCR tube. The Terminator Ready Reaction Premix 
and 5x dilution buffer were obtained from the Biomolecular Resources Facility (BRF), John 
Curtin School of Medical Research, Australian National University. The tube was vortexed, 
pulse centrifuged and then subjected to 25 cycles of the following conditions in the GenAmp 
thermal cycler: 96°C 10 s, 50°C 5 s, 60°C 4 min. The reaction was held at 4 °C. 
The 20 ~LL reaction was transferred into a microcentrifuge tube and the following were 
added: 2 ~LL of 3 M sodium acetate, 2 µL of 125 mM EDTA, and 50 µL of 100% ethanol. The 
mixture was vortexed and centrifuged for 30 1nin. The DNA pellet was washed with 250 µL of 
70% ethanol followed by a 2 minutes centrifugation. This was repeated 2 times. After the three 
washes, the pellet was then dried under vacuum for 5 minutes (Savant SpeedVac SC 100; high 
drying rate). After the tube was dry, it was stored away from light at 4°C until it was delivered to 
the BRF to be sequenced with ABI 3730 capillary sequence analyser (PE Applied Biosystems). 
The resulting sequencing data was analysed using a bioinformatics program, pDraw32 
(AcaClone Software, http://www.acaclone.com) and ClustalW (European Bioinformatics 
Institute, Larkin et al., 2007). 
2.4 Agarose Gel Electrophoresis 
Agarose gel electrophoresis was carried out using 0.7% agarose gels that contained 
ethidium bromide (10 µg/mL) in 0.5x Tris-Borate-EDTA (TBE) buffer (Appendix A). The 
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running buffer, which consisted of 0.5x TBE buffer, was poured into the gel tank before the 
samples were loaded. Approximately 0.2 volumes of blue loading dye (Appendix A) was added 
to each sample prior to loading. The voltage was usually set between 70-90 V and the gel was 
run until the blue loading dye moved to the end of the gel. The size marker used was EcoRI-
digested SPP-1 bacteriophage DNA (GeneWorks) and is shown in Figure 2.2. In order to 
visualise the DNA bands, the gel was viewed under ultraviolet light by utilising a CCD camera 
and NIH image software (Mitsubishi). 
2.4.1 Purification of DNA from agarose gels 
By using a sterile scalpel, the DNA bands were excised from the agarose gel. The gel 
slice was then placed into 1.5 mL microcentrifuge tubes and weighed. The DNA was extracted 
using the Wizard SV Gel and PCR Clean-up System (Promega). 10 µL of Membrane Binding 
Solution was added to per 10 mg of gel slice. The tubes were then vortexed and incubated in a 
65°C waterbath for 15 minutes. An SV column was then added to a collection tube and the 
dissolved gel mixture was then transferred to this assembly and left at room temperature for 1 
minute. The tubes were then centrifuged for 1 minute. The flowthrough was discarded and the 
SV column was reinserted into the collection tube. 700 µL of Membrane Wash Solution was 
added to the column assembly and centrifuged for 1 minute. The resulting flowthrough was 
discarded. This washing step was repeated again with 500 µL of Membrane Wash Solution, 
followed by a 5 minute centrifugation. The collection tube was emptied and the column 
assembly was re-centrifuged for 1 minute with the microcentrifuge lid open to allow evaporation 
of any residual ethanol. The minicolumn was then transferred to a clean 1.5 mL microcentrifuge 
tube. 40µL of Nuclease-Free water was added to the column. Following a 1 minute incubation at 
room temperature, the tubes were centrifuged for 1 minute. The minicolumn was discarded and 
the DNA was stored at -20°C. 
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Figure 2.2: The EcoRI digest of the Bacillus subtilis SPP-1 bacteriophage genome. The 
digest was run in parallel with the DNA samples as a DNA size marker (adapted from 
Gene Works). 
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2.5 Bacterial Transformation 
2.5.1 Preparation of electrocompetent cells 
The protocol for the preparation of electrocompetent cells is from Dower et al. (1988). 
All non-centrifugal steps to prepare the electrocompetent cells were carried out in a cold room at 
4°C. XLl-Blue and JM109 were grown overnight in 20 mL of LB broth. SFL1616 was grown 
overnight in 20 mL of LB broth supplemented with Cm and Kan. The 20 mL overnight cultures 
were then diluted (1/100) into 1 L of LB broth that was pre-warmed at 37°C. The diluted cultures 
were then incubated at 37°C while being vigorously shaken at 230 rpm. The cultures were 
continuously incubated for 2-4 hours until the cultures reached log phase, which was measured 
by a Cary50 Bio Spectrophotometer (Varian) when the culture had an A600 of 0.6-0.8. The 1 L 
cultures were then chilled on ice for 30 minutes before they were aliquoted into duplicate 500 
mL centrifuge bottles (Sorvall) that were pre-chilled at 4°C. The bacteria were then formed into a 
pellet by centrifugation at 3,000 x g at 4°C for 10 minutes (SLA-3000; Sorvall RC-SC Plus 
Superspeed Centrifuge). After centrifugation, the supernatant was discarded and the bacterial 
pellet was washed by resuspending it in 200 mL of ice-cold MilliQ water followed by 
centrifugation as before. The washing step was repeated twice more. The pellets were twice 
resuspended in 50 mL of ice-cold 10% glycerol (v/v) and centrifuged as before for the final time. 
The supernatant was discarded leaving behind a residual glycerol solution of about 1 mL for the 
bacterial pellet to be re-suspended in. 50 µL aliquots were transferred into sterile 1.5 mL 
Eppendorf tubes that were pre-chilled at 4°C. The bacterial aliquots were then stored at -80°C 
until they were required for transformation. 
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2. 5.2 Trans/ ormation into electrocompetent cells 
Electrocompetent cells were taken from the -80°C freezer and thawed on ice. About 1-3 
µL of DNA was mixed with the cell suspension. The suspension was transferred into a chilled 
Bio-Rad electroporation cuvette and tapped to the bottom prior to electroporation. Using a 
BioRad Genepulser, a pulse of 2.5 kV was supplied. 1 mL of LB broth was then added to the 
cells in order to recover them. After mixing with the pipette, the mixture was transferred into a 
microcentrifuge tube. The cells were incubated at 3 7°C with shaking for 1 h. The tube was 
centrifuged for 1 minute and most of the supernatant solution was discarded, leaving behind 
about 100 ~LL of supernatant solution. The cells were resuspended in the remaining supernatant 
and spread onto an LB agar plate containing the appropriate antibiotic. 
2.5.3 Determination of transforn1ation efficiency 
By determining the number of colonies obtained by transformation of a known 
concentration of pBC SK, the efficiency of competent cells was calculated. 1/10, 1/100, 1/1000 
and 1/10,000 dilutions were performed to obtain a plate with an appropriate number of colonies. 
The efficiency was calculated using the following formula: 
Number of transformed cells (N) = Number of colonies x Dilution factor 
N/µg DNA (efficiency)= N/amount of DNA transformed (~tg) 
2.5.4 Selecting Transformed Colonies 
Transformed bacteria were selected for their ability to grow on antibiotic-containing LB 
agar plates. The plasmids· used in this study contained ampicillin, chloramphenicol or kanamycin 
resistance genes .. The concentrations used for selection were stated in section 2.1. 
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2.6 Bioinformatics 
Six topology prediction programs that were available on the Internet were used to 
examine the GtrIV protein sequence for the presence of hydrophobic regions. They were 
HMMTOP (www.enzim.hu/hmmtop/; Tusnady & Simon, 1998), SOSUI 
(http://sosui.proteome.bio.tuat.ac.jp/sosuiframeO.html; Hirokawa et al., 1998), TMpred 
(www.isrec.isbsib.ch/software/TMPRED _form.html; Hofmann & Stoffel, 1993), DAS 
(www.sbc.su.se/,....,miklos/DAS/; Cserzo et al., 1997), TopPred (www.sbc.su.se/,....,erikw/toppred2/; 
von Heijne, 1992) and finally, TMHMM (www.cbs.dtu.dk/services/TMHMM1 .0/; Sonnhammer 
et al., 1998). In addition, to compare the sequence and amino acid homology between GtrIV and 
the other wildtype sequences, the web-based program ClustalW (European Bioinformatics 
Institute, Larkin et al., 2007) was used. 
2.7 Alkaline Phosphatase and f3-Galactosidase Assays 
Alkaline phosphatase (AP) and P-galactosidase (BG) assays were carried out to quantify 
the AP and BG activities, respectively. The AP assay was first described by Manoil et al. (1990) 
while the BG assay was first described by Miller (1992). Both assays were performed in parallel. 
Two experiments were done simultaneously for each strain, with duplicates for each experiment. 
A negative control (B 1752 carrying pNV1473), was included in each assay. This was done so 
that the background activities could be subtracted from the experimental activity values. 
2. 7.1 Alkaline phosphatase assay 
0.5 mL aliquots of overnight cultures (5 mL) were added to each of two 9.5 mL aliquots 
of LB broth (1/20 dilution) supplemented with the appropriate antibiotic. The cells were 
incubated at 37°C with shaking until they reached log phase. This took approximately 2-3 h. The 
optimal OD6oo was 0.6. 1 mM IPTG was used to induce the samples. The induced samples were 
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incubated at 37°C with shaking for 1 h. A 1 mL aliquot of each culture was then centrifuged for 
3 min. Cold 10 mM Tris (pH 8)/10 mM MgSO4 was used to wash the pellets. The pellets were 
then resuspended in 1 mL of cold IM Tris (pH 8). Upon resuspension, 0.1 mL aliquots of cells 
were diluted in 0.9 mL of cold 1 M Tris (pH 8). At this point, the OD6oo was measured. The 
remaining steps were performed in duplicate. 0.1 mL of washed cells were added to 0.9 mL of 1 
M Tris (pH 8)/0.1 mM ZnCh. The cells were then permeabilised by adding 50 µL of 0.1 % SDS 
and 50 µL of chloroform. After vortexing the tubes, they were incubated at 37°C for 5 minutes 
and then placed on ice for another 5 min. 
To begin the assay, 0.1 mL of 0.4% p-nitrophenyl phosphate dissolved in IM Tris (pH 8) 
was added to each tube. The tubes were inverted and placed in a 37°C water bath. The time was 
recorded immediately after the tubes were placed into the water bath. The reaction was stopped 
when it had turned pale yellow in colour. This was done by adding 0.12 mL of 1:5 0.5 M EDTA 
(pH 8): 1 M KH2PO4 and placing the tubes on ice. The time was noted at this point. For reactions 
in which no yellow colour developed, they were stopped after 2 hours. The OD420 and OD550 
were measured. These two wavelengths were chosen because the OD420 measures a combination 
of absorbance by o-nitrophenol and light scattering by cell debris. On the other hand, the OD5so 
corrects for light scattering. An assay mixture without cells was used as a blank. The AP activity 
was calculated in units activity as follows: 
Units activity= [OD42o - (1.75 x OD55o_,.L..1)]..._l_;_OO_;_O-'-------
Time (min) x OD600 x volume of cells (mL) 
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2. 7.2 P-galactosidase assay 
Cells were diluted, grown and induced with IPTG as described for the AP assay. After 
the induction step, 2 mL of cells were pelleted by centrifuging for 3 min, and the supernatant 
solution was discarded. 2 mL of cold Z buffer (Appendix A) was used to resuspend the cell 
pellet. The OD600 was measured using Z buffer as a blank. Subsequent steps were performed in 
duplicate. Cells were diluted 1/2 by adding 0.5 mL of cells to 0.5 mL of Z buffer to give a final 
volume of 1 mL. At this point, 100 ~LL of chloroform and 50 µL of 0.1 % SDS were added. After 
vortexing, the tubes were incubated for 5 minutes at 28°C. 0.2 mL of substrate, o-nitrophenyl-~-
D-galactoside (ONPG; 4 mg/mL dissolved in phosphate buffer (Appendix A)) was added to each 
tube to start the reaction. The time of addition was recorded and the tubes were vortexed and 
incubated at 28°C. When a yellow colour had developed, the reactions were stopped . by the 
addition of 0.5 mL of 1 M Na2CO3. At this point the time was recorded again. As with the AP 
assay, reactions that did not develop any colour were stopped after 2 h. The tubes were vortexed 
and 1 mL was transferred to a microcentrifuge tube and centrifuged for 5 minutes to remove 
debris and chloroform. The supernatant solution was then transferred to new tubes. The OD420 
and ODsso were 1neasured for each sample. The san1e formula used to determine units of AP 
activity was used to determine the units of BG activity. 
2. 7.3 Calcuating the Normalised Activity Ratios (NAR) 
After ol;,taining the AP and BG activities for each fusion in the dataset, the normalised 
activity ratios were calculated as follows: 
NAR = (AP/highest AP)+ (BG/highest BG) 
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2.8 Site-Directed Mutagenesis 
Site-directed mutagenesis was performed as described in the protocol by Stratagene 
(QuikChange Site-Directed Mutagenesis Kit) (Figure 2.3). The following parameters were used 
when designing mutagenic primers: 
1. Primers were designed to be about 25-35 bases long 
2. The desired mutations were in the middle of the primer 
3. C or G bases were on the 3' and 5 'ends of the primers 
4. Both forward and reverse primers that carry the same mutation were designed to anneal 
to the same sequence but on opposite strands. 
Upon arrival of mutagenic primers, PCR amplification was carried out (section 2.3.2). A 
small aliquot (5 µLout of a 50 µL reaction) of the PCR product was then run on an agarose gel 
(section 2.4) to check if amplification had worked. The PCR product was then treated with Dpnl 
(section 2.3.3) and transformed into electrocompetent XLI-Blue cells using the protocol 
described in section 2.5.2. Transformant colonies were patched onto a masterplate and about 3-4 
colonies were inoculated overnight so that the plasmid DNA could be isolated (section 2.2.2) and 
sequenced (section 2.3.6) to check the desired mutation. 
2.9 Slide agglutination assays 
The function of Gtr proteins was tested by transformation into· a serotype Y S. flexneri 
strain containing gtrA and gtrB (SFL1616). Serotype conversion indicated a functional Gtr 
protein. Therefore, 3-4 colonies were streaked onto LB agar plates containing the appropriate 
antibiotics. Once grown, these lawns were used in slide agglutination tests. Cells were mixed 
directly into a drop of S. flexneri specific antisera on a glass slide. The slide was then rocked 
gently back and forth and the mixture was observed for agglutination. Agglutinations that 
40 
- ·~~·--- • -- 'i) 
Step 1 
Plasmid Prepoi--0:t ion 
Step 2 
Tem p erature Cyding 
Step 3 
Digestion 
Step 4 
Tra nsfio rmatf on 
• 
~__.--
,/ _,/----~ \ (' {Q \ I 
\ . I\ ~~ .· J 
~
.) 
• /,--~ 
M1..;togieo ic 
pr1m~r:5. 
t ~, ')• \ ~ /) 
~
'-.__# '"ll Ml,)lo l;;i:dl p lo srnid /,, l' . . .. _-1 
,,.,,y. cont,ains rnc.K= 
-~- c iircufor :s tra nds) 
• fry, 
\ ' ,/4✓' ) \ '-C,,,-41 ~----~✓ 
Gene in plasm id with 
to rget site {® J for m utati o 1i 
Denc;tu re the p lasm id and a rnnso. l tne 
o ligom.J d eotide pri rn ern. (#} con ta i t1 lng 
tne desire•d muta tion {x) 
Uslng I he n o n s!rand -d ispla!Cing 
a cti o n, of PfuTurho DNA polymeras.e ,, 
exten d ond inco,rp,ornte the 
mul·ogen Ec: primers resul tin g 
in nick ed ci rculo ir ~1ronds 
D ige·s.t the· methy latedi , n o n,muta t ed 
porento l DNA tem p late w itn Dpn I 
Trcmsfo m 1 the circular, nicke-d dsDNA 
into XL 1 -Blue supercompetent c d ls 
After konsformotion,. t lhe XL 1-B iue 
supercompetent ce lls repa ir the 
nfcks i n t he muta ted p,losm vd 
LEGEND 
- Porenia l DNA p lasm id 
C.,.f}' 1\.·\utageni:: p rimer 
;\1\1) l·o ted ON.A. plo-~n1id 
Figure 2.3: A summary of the steps involved in site-directed mutagenesis. Image taken 
from Stratagene manual. 
~ 
CHAPTER 2 
occurred within one minute were considered positive. For a negative control, cells were mixed in 
phosphate buffered saline (PBS) instead of S. flexneri specific antisera. 
2.10 Membrane protein preparation 
The membrane protein isolation method is a modified version of that described by 
Morona et al. (1995). XLl-Blue cells were grown in LB to mid-log (OD6oo of 0.6) and pelleted 
using a Sorvall SLAl 500 rotor (3,000 x g, 10 min, 4°C) and resuspended in 1 mL of 20% (w/v) 
sucrose, 30 mM Tris-HCl pH 8.1, transferred to SS-34 tubes and chilled on ice. 0.1 mL of 1 
mg/mL lysozyme in 0.lM EDTA pH 7.3 was added to the cells for 30 minutes on ice. The cells 
were collected again as described above using a Sorvall SS-34 rotor and the pellet frozen for 30 
minutes at -80°C. The pellet was thawed and resuspended vigorously in 6 mL 3 mM EDTA, pH 
7.3. The cells were completely lysed by passing them twice through a French Press at 15,000 psi. 
Unlysed cells and inclusion bodies were removed by slow centrifugation as described above 
(7,000 rpm, l0min, 4°C). Membrane proteins were sedimented by high speed centrifugation 
using a 50Ti or 80Ti rotor spun at 35, 000 rpm for 90 minutes at 4°C. The pellet was then 
resuspended in 200 µL sterile Milli Q H2O. 
2.10.1 Protein quantification by BCA assay 
To calculate the protein concentration in the membrane protein preparation, a BCA 
protein assay (Thermo Scientific) was carried out. A 2.0 mg/mL stock of BSA was prepared. 
Nine diluted standards of BSA with the following concentrations were made using this stock 
solution (2.0 mg/mL, 1.5 mg/mL, 1.0 mg/mL, 0.75 mg/mL, 0.5 mg/mL, 0.25 mg/mL, 0.125 
mg/mL, 0.025 mg/mL and 0 mg/mL). The BCA working reagent (WR) was also prepared by 
mixing 50 parts of Reagent A with 1 part of Reagent B. The total volume of WR required was 
calculated by the_ following formula: 
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Total Volume of WR required= (No. of Standards+ No. of Unknowns) x (No. of Replicates) x 
(Volume of WR per Sample) 
After the nine BSA standards and WR had been prepared, 25 µL of each standard and 
protein sample was loaded into a 96-well microplate. 200 µL of the WR was then added to each 
of the wells. The microplate was gently shaken and covered before being incubated at 3 7°C for 
30 min. The plate was left to cool at room temperature before the absorbance levels of the 
standards and samples were measured on a plate reader at a wavelength of 562 nm (Gen5-Biotek 
Instruments). To determine the protein concentration of each unknown sample, a standard curve 
of Blank-corrected 562 nm measurement for each BCA standard versus mg/mL was created and 
used to determine the protein concentration of the unknown samples. 
2.11 Bacterial lipopolysaccharide (LPS) preparation 
This method was adapted from Hitchcock & Brown (1983) with several modifications. 
Overnight cultures were diluted 1/100 in LB containing the appropriate antibiotics and incubated 
for 2 - 3 hours at 37°C until OD600 of 0.6 was reached. 1.5 ml of culture was then spun down and 
the pellet was resuspended in 80µ1 sample loading buffer ( 4°/o SDS, 160mM Tris-HCl, 20% 
glycerol, 10% ~-mercaptoethanol). Proteinase K was then added to each sample at a 
concentration of 50 mg/mL and the samples were incubated overnight at 56°C and stored at -
20°C. Before samples are run on 12% SDS Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
gel, 0.5 µl ~-mercaptoethanol was added to the samples and boiled for 10 min. 
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2.12 Sodium dodecyl sulfate Polyacrylamide Gel Electrophoresis (SDS-
P AGE) 
SDS page electrophoresis was carried out using a 4% stacking and 12% resolving SDS 
gel (Appendix A). SDS gels were set in 1 x SDS-PAGE buffer (Appendix A) before either LPS 
or membrane fraction samples were loaded on the gel. A Pierce Blue Prestained Protein 
Molecular Weight Marker (Thermo Scientific) or PageRuler™ Prestained Protein Ladder 
(Fermentas) was loaded in parallel with the samples as a protein size marker (Figure 2.4.). The 
gels were run by electrophoresis at 60-S0V until the blue loading dye had run off the gel. 
For SDS gel electrophoresis of membrane protein fractions, equal protein concentrations 
of each sample ( estimated by a protein BCA assay) were aliquoted into sterile 1.5 mL Eppendorf 
tubes. 6x SDS blue loading dye was then added to each tube to obtain a final concentration of 1 x 
SDS blue loading dye before the samples were loaded on the SDS gel. 
Before SDS gel electrophoresis could be carried out on the bacterial LPS, 10 µL of each 
LPS preparation was aliquoted into a sterile 1.5 mL Eppendorf tube. 0.5 µL of 2-
mercaptoethanol was added to each sample and the samples were boiled at 100°C for 5 min. The 
condensation was spun down by centrifugation for 5 seconds and each sample was loaded into 
the SDS gel. 
2.13 Coomassie Staining of Membrane Protein Preparation 
Following SDS gel electrophoresis of membrane protein samples (Section 2.12), the gel 
was then stained with 200 mL of Coomassie brilliant blue solution (Appendix A) overnight. The 
.. 
gel was destained with 100 mL of destaining solution for 15 minutes (Appendix A). The 
43 
-..---: ~ 
a) I I t t»J. I I b) ~ L ....110 _ 
... 130 ,.... Protein MW 
... 10D f1illil!J 
-. Myosin 215K illlf\TO r J.1°!',,.-.'.,.::C •• , 
~ J . ~ . I I ....,. Phosphorylase B 120K 
""'40 -i ~ ·E I 
_. BSA 84K 
-- ""2'- > f"'"T •· 1 
- · Ovalbumin 60K 
- '"1S 1,~,, 
- CamonicAnhydrase 392K 
... 10 --..._ ~ 
...,. Trypsin Inhibitor 28K 
~u . ,-
-4-mli Tris..glycme ~PAGE I ,....,... Lysozyme 18-3K 
Figure 2.4: a) The PageRuler™ Prestained Protein Ladder is a 3-color ladder with 10 
proteins covering a molecular weight range from 10 to 170 kDa (Fermentas). b) The 
appearance and molecular weight (MW) of constituent proteins in the Blue Prestained 
Protein Molecular Weight Marker Mix (Thermo Scientific). 
--~ -~~ . --·· ~ 
CHAPTER 2 
destaining step was repeated twice. The gel was then sealed in a plastic sleeve containing 2 mL 
of 10% glycerol (v/v). 
2.14 Silver staining of Bacterial LPS 
10 ~LL of each LPS preparation was aliquoted into a sterile 1.5 mL Eppendorf tube. 0.5 
µL of 2-Mercaptoethanol was added to each sample and the samples were boiled at 100°C for 5 
min. The samples were spun down by centrifugation for 5 seconds before each sample was 
loaded into the SDS gel (Section 2.12). After SDS gel electrophoresis, the SDS gel was fixed 
overnight with 100 mL of fixing solution (Appendix A). The following day, the fixing solution 
was discarded and the gel was washed twice with 7 .5% acetic acid (v/v) for 30 minutes each 
time. The gel was then soaked in oxidising solution (Appendix A) for 5 min. The oxidising 
solution was then discarded and the gel was washed with 100 mL MilliQ water for 30 min. The 
washing step was repeated thrice. The gel was then soaked in silver stain solution (Appendix A) 
for 10 minutes. The silver stain solution was discarded and the gel was washed three times with 
100 mL of MilliQ water for 5 minutes each. After the washes, the gel was soaked in developer 
solution (Appendix A) for 5-10 minutes until the desired band intensity was obtained. To stop 
development, the gel was blocked using 1 % acetic acid for 15 minutes. The gel had a final wash . 
of 100 mL of MilliQ water before being stored in a plastic sleeve containing 2 mL of 10% 
glycerol (v/v). · 
2.15 Western Immunoblotting 
Prior to carrying out the Western blotting, membrane protein and LPS samples were run 
on SDS page gels until the dye front ran out of the gel. 15 minutes prior to the transfer, one sheet 
of PVDF membrane (Millipore) was soaked in methanol and two sheets of Whatman paper and 
two support pads were soaked in transfer buffer (Appendix A). The transfer sandwich apparatus 
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was assembled in the following order; black face of the sandwich holder at the bottom, support 
pad, Whatman paper, SDS gel, PVDF membrane, Whatman paper, support pad, white face of the 
sandwich holder at the top. The sandwich apparatus was then closed and placed in the BioRad 
Mini Trans-Blot Transfer cell apparatus. The tank was then filled with Ix transfer buffer and the 
samples were transferred at a maximum current of 250mA at 4°C for 2 hours with gentle stirring. 
After the transfer, the membrane was blocked overnight with 50 mL of blocking solution 
containing 5% skim milk powder in PBS (Appendix A). After being blocked overnight, the 
membrane was washed three times with 50 mL of Ix PBS + 0.05% Tween20 for 15 minutes 
each time (Appendix A). The membrane was then transferred to a plastic sleeve and 5 mL of the 
appropriate primary antibody diluted in 1 % skim milk and 0 .1 % Tween20 was added to the 
plastic sleeve. The plastic sleeve was sealed and vigorously shaken at 4°C for 2 hours. After the 
2 hours, the membrane washed three times with 50 mL 1 x PBS + 0.05% Tween20 for 10 
minutes each time (Appendix A). The membrane was then transferred to a plastic sleeve and 5 
mL of the appropriate secondary antibody mix diluted in 1 % skim milk and 0.1 % Tween20 was 
added. The sleeve was sealed and vigorously shaken at 4°C for 1 hour. Following this, the 
membrane was washed twice with Ix PBS + 0.05% Tween 20 and twice with Ix PBS for 10 
minutes each. Finally, the membrane was then covered with 4 mL of SuperSignal West Pico 
Stable Peroxide. Solution and SuperSignal West Pico KLuminol/Enhancer Soltuion (Thermo 
Scientific) in a ratio of 1: 1. The tray was covered with foil and the membrane was left at room 
temperature for 5 minutes. The reactions were detected either by X-ray film (GE Healthcare) or 
viewed under the Fusion Chemiluminescence Camera (Fisher Biotech). 
Primary antibodies used were either Mouse anti-alkaline phosphatase (Chemicon) diluted 
1: 1000 for membrane protein preparations, Type IV antisera (Denka Seiken) (specific to 
serotype 4a) diluted 1: 100 or serotype. le-specific MASFic (monoclonal antibody Shigella 
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flexneri le) monoclonal antibody (Reagensia) diluted 1 :500 for bacterial LPS extractions. The 
secondary antibodies used were Goat anti-mouse IgG horse radish peroxidase (HRP)-conjugated 
(Sigma) diluted 1 :8000 for membrane protein preparations while Goat anti-rabbit HRP-
conjugated lg (Sigma) diluted 1: 1000 and anti-mouse IgM peroxidise conjugate (Sigma) diluted 
1 :5000 were used for profiling bacterial LPS extraction. 
2.16 Southern Hybridization 
2.16.1 Transferring of DNA .from gel to membrane 
Genomic DNA digests were run on 0. 7% agarose gel until the blue loading dye was run 
off the gel. Following this, the gel was photographed under ultraviolet light by utilising a CCD 
camera and NIH image software. The wells on the gel were cut off and the gel was soaked in 
0.25M HCl (Appendix A) for 15 minutes at room temperature with gentle shaking. The gel was 
then rinsed with MilliQ water before being soaked in denaturing solution (Appendix A) for 30 
minutes at room temperature with gentle shaking. The gel was rinsed again with MilliQ water. 
Following this, the gel was soaked with neutralising solution (Appendix A) for 15 minutes at 
room temperature with gentle shaking. After another rinse in MilliQ water, the gel placed in the 
transfer apparatus. Care was taken to ensure that the Hybond N+nucleic acid transfer membrane 
from GE was cut such that it was only slightly larger than the gel. 
The following day, the gel was removed from the apparatus with the transfer membrane 
attached to it. The positions of the gel wells were marked on the membrane. Then, the membrane 
was washed 5x SSC for 5 minutes before being placed on top of aluminium foil and baked in 
vacuum oven at 80°C for ·2 hours. After baking, the membrane was sandwiched between hybond 
cover papers and, stored in the fridge until it was used. 
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2.16.2 Labelling of probe with Digoxigenin (DIG) 
The probe was labelled by adding l00ng of DNA (3.8 kb gtrIV cassette fragment) to 16 
µL of MilliQ water in a 1.5 mL Eppendorf tube. This mixture was boiled for 10 minutes to 
denature the DNA and then placed on ice for 1 minute. 4 µL of DIG-High Prime (Roche) was 
then added to the tube and left overnight (up to 20 hours) at 37°C. The next day, 1 µl of 0.5M 
EDT A (pH 8) was added to the tube to stop the labelling reaction. The tube was then incubated 
for 10 minutes at 65°C. The desired amount of probe was added to the hybridization buffer (20-
50 ml) to commence the Southern hybridization process. 
2.16. 3 Hybridization of n1embranes 
An appropriate volume of DIG Easy Hybrid (10 mL per membrane) was pre-heated to 
the hybridization temperature of 65°C. The membranes were then placed in hybridization tubes 
with the preheated DIG Easy Hybrid for 30 minutes - 2 hours in a Hybridization oven at 65°C. 
Meanwhile, the DIG-labelled probe was boiled to denature any remaining double strands. After 
hybridization, the freshly denatured probe was added and left overnight. The next day, the 
membrane was washed for 5 minutes with 50 mL of DIG Washing Buffer. The membrane was 
then treated with 100 mL of DIG lx blocking buffer. Following this, the membrane was 
incubated with 10 mL a-DIG-Antibody-solution (Roche) for 30 minutes. Two 15 minute washes 
with 100 mL DIG Washing Buffer then ensued. After the washes, the membrane was 
equilibrated in 20 mL of DIG Detection Buffer. The membrane was incubated 5 minutes at 15-
250C with 10 mL of CSPD-Solution. Using a pair of tweezers, the membrane was placed (DNA 
side up) in an x-ray cassette or hybridization bag. After incubating for 10 minutes, the membrane 
was viewed under the Fusion Chemiluminescence Camera (Fisher Biotech). 
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3.1 Introduction 
Determining the topologies of the Gtrs, or their dispositions relative to the plasma 
membrane, may provide insights into their mechanisms of action. A topology model allows 
predictions to be made about which protein regions interact by helping to exclude the possibility of 
certain interactions between regions on opposite sides of the membrane. It also helps reduce the time 
required to identify protein regions involved in particular functions. As O-antigen glucosylation is 
thought to take place in the periplasm (Guan et al., 1999), one or more periplasmic region(s) of 
considerable size must be present for the attachment of a glucosyl residue to the O-antigen. 
Therefore, topological information can reduce the time required to identify protein regions involved 
in particular functions. By identifying such regions, it can provide a basis for their characterisation 
and localisation of the active site. In addition, topological information en':1.bles us to make direct 
comparisons to other well characterised proteins for structural homology, which may give greater 
insights into their function. 
A dual reporter system consisting of alkaline phosphatase (phoA) which is in-frame with the 
~-galactosidase a-fragment (lacZa) developed by Alexeyev and Winkler (1999) was used to help 
determine the topology of GtrIV. Alkaline phosphatase (AP) is an E. coli enzyme that catalyses the 
hydrolysis of a variety of phosphomonoesters in the periplasm. It is only active when located in the 
periplasm. This is based on the assumption that in the periplasm, the mature part of PhoA is oxidised 
such that the cysteine residues are able to form disulfide bridges which enables PhoA to fold 
correctly (Alexeyev and Winkler, 1999). The process of folding and the assembly of PhoA occurs 
only after export to the periplasm. In this case, since its signal sequence has been removed, 
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localisation depends on the protein region to which it is fused (Sugiyama et al, 1991; Alexeyev and 
Winkler, 1999). 
In contrast to AP, ~-galactosidase (BG) is only active in the cytoplasm. BG is encoded by the 
E. coli lac operon and splits lactose into glucose and galactose. Its activity is only restricted to the 
cytoplasm as the a-fragment must interact with the cytoplasmically located co-fragment to cause a-
complementation (Alexeyev and Winkler, 1999) Thus fusions to periplasmic sites will be inactive 
whereas fusions to cytoplasmic domains will be active. 
The enzymatic activity of AP can be detected by using 5-bromo-4-chloro-3-indolyl 
phosphate (Xphos). This substrat~ is cleaved by AP to produce a blue colouration. On the other 
-hand, the enzymatic activity of BG can be detected by 6-chloro-3-indolyl-~-D-galactoside (Red-Gal) 
which is cleaved by BG to produce a red colouration. The use of dual indicator (DI) plates 
containing the substrates of AP and BG discriminates between non-informative (for example out-of-
frame) fusions that are colourless ( described as white), red cytoplasmic fusions and blue or even 
purple periplasmic fusions. For both enzymes, there are more quantitative assays based on different 
absorbance properties of p-nitrophenyl phosphate upon hydrolysis by AP and the cleavage of o-
nitrophenyl-~-D-galactoside by BG that have been described (Manoil et al., 1990). These assays 
were done simultaneously to quantitatively determine the enzymatic activity that takes place at each 
fusion as reported by Alexeyev & Winkler (2002) who stated that by using the PhoA/LacZ dual 
reporters, BG and AP activities can be measured at the same point simultaneously without resorting 
to genetic recombination to switch fusions. The normalized activity ratios (NAR) can correct for 
variable expression. Thus, determination of protein synthesis rates is not necessary. 
• , 
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3.2 Previous work on GtrIV 
In the past, two approaches were carried out to experimentally determine the topology of 
GtrIV (Anesh Nair, Honours Thesis 2006). The first approach was by using exonuclease III (Exo 
III) deletion from the end of the gtrIV gene followed by in-frame fusion with phoA/lacZ. This 
method developed by Sugiyama et al. (1991), enables a rapid creation of random fusions that span 
the entire length of gtrIV successfully. Another method was also carried out involving a PCR-based 
approach to create C-terminal deletion fusions at predetermined points. 
A predicted topology model for GtrIV was first created based on the results given by the 
various computer prediction programs. The strategies used to identify transmembrane helices and 
the predictions made by each program are presented in Table 3.1. The DAS and TMHMM 
predictions are also shown in Figure 3 .1. Based on the results of the computer predictions, a 
consensus model was constructed. In this model, GtrIV was depicted to have ten transmembrane 
helices, a cytoplasmic N-terminus, a small cytoplasmic C-terminal end, and two large periplasmic 
loops between helices I and II, and VII and VIII (Figure 3 .2). 
To confirm this model, Exo III deletion and PCR-based fusions were then carried out to 
create gtrIV-phoA/lacZ truncations within the gtrIV pNV1473 was the template used (Figure 3.3). It 
was engineered such that gtrIV is in tandem with 'the dual reporter. This construct also contained a 
restriction site that leaves a 5' overhang susceptible to Exo III digestion closest to the end of gtrIV 
and a restriction site that generates an Exo-resistant 3' overhang just upstream of phoA/lacZ to 
protect the reporter. The random C-terminal fusions brought about by Exo III deletion resulted in 14 
blue fusions that were confirmed by the AP and BG assays to be in the periplasm due to their NAR 
values. All these fusions occur in the periplasmic loops No 2 and No 8. As such, these results 
so 
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Table 3.1: Results from the computer programs used to predict GtrIV topology and the basis for 
each prediction. 
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Figure 3.1: Representative computer-based topology predictions of GtrIV. (a) TMHMM (9 
helices). The red peaks indicate transmembrane regions, the blue lines indicate cytoplasmic 
regions and the pink lines indicate periplasmic regions. (b) DAS (9 helices). The peaks 
correspond to predicted transmembrane helices. 
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showed that there were no fusions in the two loops that conflicted with the consensus model of 
GtrIV. Only one in-frame red fusion was obtained by Exo III deletion. A series of PCR-based 
fusions were then carried out to further confirm the consensus model. However, this approach led to 
the creation of a blue fusion, D 146, which conflicted with the model, as it indicated that D 146 is 
located in the periplasm instead of the cytoplasm. To this accord, a second model was put forward 
(Figure 3.4). In this model, in order to satisfy all fusions, the presence of a hypothetical re-entrant 
loop between transmembrane helices IV and V was proposed. As the presence of a re-entrant loop 
was hypothesised based on just one fusion, it could not be relied on completely and further fusions 
had to be created to confirm its presence. All fusions that were created in Figure 3 .4 were done 
during my honours year. From this point onwards, all the subsequent fusions were created as part of 
my PhD project. Once all the fusions were obtained (including the ones from this PhD project), the 
AP and BG assays (described later in this chapter) were carried out on tbem. Thus the AP and BG 
assays were repeated on the fusions created during honours such that all the fusions could be taken 
as one dataset. The results of the enzyme assays carried out in honours are not used in this thesis. 
3.3 Creation of gtrIV-phoA/lacZ-gtrIV sandwich fusions 
So far, fusions around the region where the proposed re-entrant loop is located have been 
elusive as none were obtained using Exo in deletion. To circumvent this, two approaches were 
adopted. These two methods were the use of sandwich fusions and the PCf-based fusion technique. 
The construction of sandwich fusions within GtrIV can indicate a more accurate representation of 
topology since the whole protein is present with the dual reporter sandwiched in the middle. A basic 
overview of how sandwich fusions are created is illustrated in Figure 3.5. Four protein loops that 
were not covered using the Exo deletion approach were targeted for sandwich fusions: those 
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between putative helices II and III (loop No. 3), III and IV (loop No. 4), V and VI (loop No. 6), and 
VIII and IX (loop No. 9). 
Before the sandwich fusions could be made, however, a template had to be constructed that 
only contained gtrIV and not phoA/lacZ. As such, phoA/lacZ was excised from pNV1473 by 
carrying out a double digest with NruI and Ecl136II (Figure 3.6). The resulting 4.7 kb vector was 
cut out of the agarose gel, column purified and religated. The ligation mix was transformed into 
electrocompetent XLl-blue cells and plated out onto agar plates containing chloramphenicol. The 
resulting clones were screened via XbaI restriction digests. Following this, one out of 7 positive 
clones was chosen and sequenced for confirmation. This new construct, pNV1914, would now be 
used to create the sandwich fusions. The NruI sites were then introduced into the gtrIV sequence at 
the points of interest using site-directed mutagenesis (pNV1914 as template). The primers used were 
GtrIVR93NruIF and GtrIVR93NruIR (to target the loop between helices 2 and 3 at residue R93), 
GtrIVK117NruIF and GtrIVK117NruIR (loop between helices 3 and 4 at residue Kl 17), 
GtrIVA181NruIF and GtrIV A181NruIR (loop between helices 5 and 6 at residue A181), and 
GtrIVR375NruIF and GtrIVR375NruIR (loop between helices 8 and 9 at residue R375). The 
changes made to the gtrIV DNA and amino acid sequences were as conservative as possible. The 
resulting PCR products were run on gel to check for successful amplification (Figure 3.7a). The 
mutated constructs were identified using NruI digests and sequenced to confirm the mutation. 
Retention of gtrIV function was confirmed by transforming these constructs into SFL1616 and 
performing agglutination tests with Type IV antisera (Denka Seiken) to test for serotype conversion 
from serotype Y to serotype 4a. 
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digests yielded 1.5 kb phoA/lacZ fragments to be used in for ligation with the amplified vectors 
containing the Nrul sites to create the respective sandwich fusions. d) Purified vectors digested 
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Upon creation of the mutated vectors, phoA/lacZ was then excised from pMA632. In order to 
maintain the correct frame when inserted in gtrIV, 3 different sets of double digests (Nrul/Stul, 
Ehel/Ecl136II, and Smal/EcoRV) needed to be carried out (Figure 3.7 band c). All the vectors were 
then Nrul digested while inserts were cut from the gel and purified (Figure 3.7d). The Nrul/Stul 
digested phoA/lacZ was blunt-end ligated with the NruI-digested A 181 construct. Likewise, the 
Ehel/Ecl136II digested phoA/lacZ was blunt-end ligated with Nrul digested R93 construct while the 
SmaI/EcoRV digested phoA/lacZ was blunt-end ligated with Nrul digested constructs Kl 17 and 
R375. The ligation mixes were transformed into JM109 and colonies showing colouration on DI 
plates were investigated further. The R93, Kl 17, Al 81 and R375 transformation plates had 200 
colonies (30 red), 100 colonies (30 red), 100 colonies (10 blue) and 50 colonies (5 red) respectively. 
The resulting red and blue colonies were then screened using restriction digests (Nhel) (Figure 3 .8). 
Nhel was chosen as it was one of the restriction enzymes used in cloning gtrIV into pBCSK in the 
first place. Therefore, it is present in all the constructs, including the positive control pNV1914. 
They were then sequenced using the PhoSeqNewR and M13R primers to confirm that phoA/LacZ 
was inserted in-frame. 
The final constructs bearing the sandwich fusions were pNV1924 (R93), pNV1925 (Kl 17), 
pNV1926 (A181) and pNV1927 (R375). Sandwich fusions R93, A181 and R375 reported red, blue 
and red colouration, respectively, and were in agreement with the model. This was confirmed using 
enzyme assays (Table 3.2). R93 and R375 had NAR of 1: >100 while a181 had a NAR of >100:1. 
However, Kl 17 was in conflict with this model as it was predicted to be localised within the 
periplasm but it reported a red colouration and a NAR of 1 :> I 00. This was indicative of a 
cytoplasmic localisation. 
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Figure 3.8: Nhel digests of the various red and blue colonies from the sandwich fusion ligations 
for R93, Kl 17, A181 and R375. Four R93 red colonies displayed a 6.2 kb band. All 7 Kl 17 red 
colonies had a 6.2 kb band. Three A181 blue colonies, displayed 6.2 kb bands. Only R375 red 
colony 3 displayed the expected 6.2kb linearized fragment. pNV1914 was also digested and run 
as a control showing a 4. 7 kb band. M= Molecular weight marker 
Table 3.2: Analysis of gtrIV-p hoA/lacZ fusions and gtrI V-p hoA/lacZ-gtrI V sandwich fusions for 
GtrIV topology determination. 
Sample AA1 Colour2 Average Average %AP5 NAR7 Location ID AP3 BG4 %BG6 (AP:BG) on Model8 
Random C-terminal Fusions 
B1925 A15 Purple 311 ± 9 25 ± 2 32.6% 16.1% 2:1 t.1 
B1910 N29 Blue 356 ± 47 1# 37.3% 0.6% 52:1 p.2 
B1924 P38 Blue 357 ± 44 2# 37 .5% 1.3% 24:1 p.2 
B1907 N41 Blue 296 ± 47 1# 31 .1% 0.6% 38:1 p.2 
B1935 G42 Blue 195 ± 28 3±1 20.5% 1.3% 20:1 p.2 
B1908 L56 Blue 133 ± 29 4±1 14.0% 2.6% 5:1 p.2 
B1931 F60 Blue 383 ± 25 1# 40.2% 0.6% 57:1 p.2 
B1919 Q186 Purple 9 ± 91 15 ± 2 0.9% 9.7% 1: 11 t.4 
B1913 1200 Red 22± 4 132 ± 6 2.3% 85.1% 1 :34 t.4 
B1926 N235 Blue 292 ± 51 0# 30.6% 0.0% >100:1 p.6 
B1904 L240 Blue 394 ± 20 1# 41.4% 0.7% 58:1 p.6 
B1921 L246 Blue 660 ± 39 1# 69.3% 0.7% 97:1 p.6 
B1922 N251 Blue 962* ± 59 1# 100.9% 0.9% >100: 1 p.6 
B2338 N255 Blue 553 ± 30 0# 58.1% 0.1% >100:1 p.6 
B1905 D261 Blue 385 ± 55 2# 40.4% 1.2% 33:1 p.6 
B1909 S300 Blue 426 ± 21 4±1 43.6% 2.8% 16:1 p.6 
B1923 M310 Blue 589 ± 15 1 ± 1 61.8% 0.1% - >100: 1 p.6 
B1920 V359 Purple 269 ± 34 9±1 28.2% 5.5% 5:1 t.6 
B1911 Q393 Purple 12 ± 3 8±2 1.2% 4.9% 1 :4 t.7 
PCR-Constructed Fusions 
B2340 V102 Red 2# 121 ± 17 0.2% 78.2% 1:>100 c.3 
B1937 D146 Blue 953 ± 35 7±1 100.0% 4.3% 23:1 re (p.4) 
B2343 V155 Red 6±2 71 ± 9 0.6% 45.8% 1 :76 re (c.4) 
B2405 K162 Red 5# 11 # 0.5% 7.1% 1: 14 re (c.4) 
B2346 D169 Red 3# 79 ± 17 0.3% 51.1% 1:>100 re ( c.4) 
B1936 D406 Blue 177 ± 40 1# 18.6% 0.9% 20:1 p.8 
B2339 K437 Red 5±1 155** ± 8 0.5% 100.0% 1:>100 c.9 
Sandwich Fusions 
B2341 R93 Red 0# 10 ± 2 0.1% 21.3% 1:>100 c.3 
B2345 K117 Red 0# 14 ± 2 0.3% 29.4% 1:>100 c.3 
B2342 A181 Blue 135+ ± 25 . # 100.0% 0.3% >100:1 re (p.4) 0 0 
B2344 R375 Red 1 ± 1 47++ ± 7 0.4% 100.0% 1:>100 c.7 
1 Position of the last residue of GtrIV followed by phoA/lacZ, 2 Colour of colony as seen on dual indicator plates, 3,4 Activities of the fusions , 
average of four independent experiments with standard deviations of each activity, 5·6 Percentages of AP and BG activities measured relative to 
the maximum activity in the set, 7Normalised AP:BG activity ratio (NAR) rounded to the nearest integer. 8Location of the fusion on the adjusted 
topological model of GtrIV(Figure l); c, cytoplasm; p, periplasm; t, transmembrane helix; re, re-entrant loop. *Highest truncation AP, **Highest 
truncation BG, ~ighest Sandwich fusion AP , ~ighest sandwich fusion BG. Since the random C-terminal fusions and PCR mediated fusions 
brought about truncated protein fused to the dual reporter, they were taken as one data set and the highest respective AP and BG values between 
them was used to calculate the NAR values. The NAR values for the sandwich fusions were calculated separately based on the highest AP and 
BG values obtained from all the sandwic!i fusions alone . #Standard deviations were less than 0.5 and not included. 
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3.4 Creation of PCR-based fusions 
In parallel with the sandwich fusions, before a definitive model could be put forth, several 
PCR based fusions were also created to shed light on the middle portion of GtrIV that contains the 
putative re-entrant loop. The method of how the PCR-constructed fusions were carried out is shown 
in Figure 3.9. Using this method, four PCR-based fusions were created (V102, V155, D169 and 
K43)8. Fusions R93 and Kl 17 indicated that a large cytoplasmic loop may be present between 
transmembrane helices II and III. As such, a fusion at V102 would confirm this. V155 and D169 
were chosen to confirm the presence of a re-entrant loop. A fusion point at K348 was to confirm the 
cytoplasmic localisation of the c-terminal tail of GtrIV. The reverse primers used to create these 
fusions were GtrIVV102HpaIR, GtrIVV155HpaIR, GtrIVD169HpaIR and GtrIVCtermHpaIR. In all 
cases, the template was pNVl 493 and the forward primer was PhoFHpaI, which anneals at the 
beginning of the phoA/lacZ sequence. All the primers contained an HpaI restriction site for 
screening purposes. The resulting PCR products were treated with DpnI to remove template DNA, 
run 0.7% agarose gel to confirm for successful amplification (Figure 3.10) and column purified. The 
purified DNA was then digested with HpaI, column purified once more and then self-ligated. The 
ligation mixes for each fusion were transformed into electrocompetent JMl 09 cells and plated out 
onto agar plates containing chloramphenicol. The resulting clones were screened via HpaI digests 
and sequenced with PhoSeqNewR primer to confirm that the fusions were in-frame. Upon 
confirmation of the fusions, they were then patched onto DI plates to observe for colour. 
The PCR-constructed K437 displayed a red colour along with a NAR of 1 :> 100 that 
confirms that the C-terminal end is cytoplasmic. Truncation fusion Vl 02 reported a red colouration 
on DI plates and a high J?_G NAR compared to AP (1:>100). This fusion was in between both 
sandwich fusions R93 and Kl 17 that displayed NAR values and colouration favouring a higher BG 
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ratio to AP and a cytoplasmic localisation. According to these results, the model was modified 
accordingly such that transmembrane helix III from the consensus mode (Figure 3.2) was pushed 
into the cytoplasm along with periplasmic loop No. 4. This consequently would invert 
transmembrane helix IV, thus allowing the consensus loop No. 5 (containing D146) to be localised 
in the periplasm. However, inverting loop No. 5 into the periplasm also meant that a large 
periplasmic loop between the modified transmembrane helices III and IV spanning 4 7 amino acids 
was created by including transmembrane helix V of the consensus model. Truncation fusions VI 55 
and D169 were evenly spaced between D146 and A181 and helped to verify this. Both fusions 
displayed red colouration and NAR values 1 :76 and 1:>100, respectively. In order to satisfy the 
current results, a re-entrant loop was introduced in the proposed model that completely traverses the 
plasma membrane into the cytoplasm and loops back up into the periplasm such that V155 and 
D 169 are both localised in the cytoplasm. The reasoning behind this is -discussed in detail in the 
Section 3.5 (discussion). Fusion K162, which lies in-between V155 and D169, also reported a red 
colour on the DI plates. However, it had a relatively low NAR compared to its flanking fusions and 
the possible reasons behind this are also discussed in Section 3 .5 ( discussion). 
Based on all the fusions and the final NAR values, a finalised topology model was proposed 
(Figure 3.11). This model shows that GtrIV has 8 transmembrane helices instead of the predicted 10. 
Both the N-terminal and C-terminal ends are localised in the cytoplasm. GtrIV is seen to have two 
large periplasmic loops namely, loop No. 2_ and loop No. 6. These two loops are hypothesised to be 
catalytically active during glucosylation. The model also shows the presence of a re-entrant loop that 
starts at the periplasmic face transmembrane helix III and traverses down to the cytoplasm loops 
towards the plasma membrane before traversing through the cell membrane back to the periplasm. 
This model satisfies all fusion points and their respective NAR values. 
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Figure 3.11: Final GtrIV topology model after the creation of gtrIV-phoA/lacZ fusions by the 
Exo III deletion and PCR-based approaches, and gtrIV-phoA/lacZ-gtrIV sandwich fusions. In this 
model, GtrIV is shown to have 8 transmembrane helices and two large periplasmic loops. All 
Exo III mediated fusions are indicated with the closed circles while PCR mediated fusions are 
indicated with the crosses. All sandwich fusions are indicated with the stars. Blue coloured stars, 
circles and crosses depict fusions that have high PhoA NARs and appear blue on DI plates. 
Similarly, the ones in red depict fusions that have high Lacz NARs and appear red on DI plates. 
All purple fusions are seen to have occurred within transmembrane helices. The proposed Re-
entrant loop which traverses the plasma membrane from the periplasm into the cytoplasm, 
forming a cytoplasmic loop, occurs between transmembrane helices III and IV. All fusions have 
been labelled with the residue at which the fusion with PhoA/LacZ takes place or, in the case of 
sandwich fusions, where the dual reporter protein has been inserted. 
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3.5 Discussion 
Elucidation of the structure of membrane proteins such as GtrIV and their orientation across 
the membrane is required in order to make predictions about their mechanism of action. To 
experimentally verify the hypothetical GtrlV topological model, three different fusion approaches 
were used. The nested deletion system, used in a previous study for topology determination of GtrIV 
(Nair A, 2006 Honours Thesis; Nair et al, 2011 ), which utilised exonuclease III (Exo III) deletion 
from the end of the gtrIV gene followed by fusion with phoA/lacZ, resulted in about 200 coloured 
colonies on DI plates. Subsequent screening of these colonies and sequence analysis yielded 19 
unique in-frame GtrIV/PhoA-LacZ fusion proteins. The colourations displayed by these 19 fusions 
were in agreement with the topology model. To further check if these fusions are in agreement with 
the model, alkaline phosphatase activity (AP) and ~-galactosidase (BG) activity for these 19 in-
frame fusions were measured via enzyme assays for AP and BG activity and the Normalised 
Activity Ratios (NARs) were calculated. The enzyme assays were carried out once all sandwich 
fusions and PCR-mediated fusions had been created and included all fusions (Exo III, PCR-
mediated and sandwich fusions) (Table 3 .2). The NAR values were generally consistent with the 
previously observed coloured colonies. Most of the ExoIII mediated fusions were seen to occur in 
the two large putative periplasmic loops. Given that the consensus model shows that all the 
cytoplasmic loops are relatively small, there will only be a smaller chance of an in-frame fusion 
occurring within these loops. According to Alexeyev and Winkler (2002), NARs greater than 2: 1 or 
lower than 1 :2 indicate that at least 67% of the reporter activity is properly localised. Alexeyev and 
Winkler (1999) also stated that the reliability of NARs in providing data about reporter membrane 
~ 
localization is related to the size and diversity of the set of fusions and can be tested by choosing the 
second highest reference pqint in calculating the NARs. This was performed (results not shown), 
and the NARs remained consistent with the previously a.etermined localization of the reporter thus 
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fortifying our confidence in the finalized topology of GtrIV. All the computer programs did not give 
the same results and therefore, this highlights the importance of verifying the computer based 
consensus model. Fusion 1200 reported a red DI colouration and a NAR of 1 :34. Although this is 
evidence of cytoplasmic localisation, it showed a high AP activity of 22. Seeing as it also had a 
substantially high BG activity of 132, it suggests that this fusion is in agreement with the topology 
model and located in close proximity to the cytoplasmic face of transmembrane helix IV. Alexeyev 
and Winkler (1999), state that purple fusions result as an association of the fusion to a 
transmembrane region. This is not an exclusive rule, as seen with fusion 1200. The red DI 
colouration could be a result of the fusion's overwhelmingly higher BG activity coming to the fore. 
A total of 4 purple fusions were obtained from Exo III deletions. Fusions A15, Q186, V359 and 
Q393 have NAR values of 2:1, 1:11, 5:1 and 1:4, respectively. Fusion V359 shows periplasmic 
localisation while fusions Ql 86 and Q393 show cytoplasmic localisation. Though their NAR values 
suggest that these fusions are either localised in the periplasm or cytoplasm, it can be seen in table 
3 .2 that among these four fusions, the lowest average AP activity is 9 while the lowest average BG 
activity is 8. This therefore indicates that some level of AP and BG activity is present in these 
fusions. The varying NAR values obtained is attributed to the fact that the %AP values are obtained 
using highest AP activity of 976, while the %BG values are obtained using the highest BG activity 
of 155. 
The topology of GtrIV was further elucidated by using two more strategies. These include a 
PCR-based approach and the use of sandwich fusions. Using the PCR-based fusion technique, it 
allowed us to exactly fuse the dual reporter to predetermined points in the protein. The second 
method involved the construction of sandwich fusions. A sandwich fusion can indicate a more 
accurate representation of topology since the whole protein is present with the dual reporter 
sandwiched in the middle. These two methods generated a host of constructs. Fusions D 146, D406 
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and K438 were obtained via PCR based fusions. R93, Kl 17, A181 and R375 were generated using 
gtrIV/phoA-lacZ/gtrIV sandwich fusions. A NAR value of 1:>100 for the PCR-constructed red 
fusion K438 confirms that the C-terminal end is cytoplasmic. Fusion D406 with a NAR value of 
20: 1 indicated that loop No. 10 (from consensus model shown Figure 3 .2) is in the periplasm. While 
both these fusions satisfied the consensus model, D 146 was observed to display blue colouration 
' 
with a NAR value of 21: 1. This fusion was in contradiction to the hypothetical model, which 
predicts D 146 to be localised in the cytoplasm between transmebrane helices IV and V. Sandwich 
fusion Kl 17 displayed a NAR value of 1:>100 that corresponded with its red colouration and 
confirms its localisation to the cytoplasm. 
TMpred and HMMTOP topology programs predicted similar models in which Kl 17 was 
predicted to be in the cytoplasm and D 146 was predicted to be in the peiiplasm. Truncation fusion 
V102 which reported a red colouration on DI plates and a high BG NAR compared to AP, strongly 
suggests that GtrIV had a cytoplasmic loop between transmembrane helices II and III. This fusion 
was in between both sandwich fusions R93 and Kl 17 that displayed NAR values and colouration 
favouring a higher BG ratio to AP and a cytoplasmic localisation. According to these results, the 
model was modified accordingly such that transmembrane helix III from the consensus mode was 
pushed into the cytoplasm along with periplasmic loop No. 4. This consequently would invert 
transmembrane helix IV, thus allowing the consensus loop No. 5 (containing D146) to be localised 
in the periplasm. However, inverting loop No. 5 into the periplasm also meant that a large 
periplasmic loop between the modified transmembrane helices III and IV spanning 4 7 amino acids 
was created by including transmembrane helix V of the consensus model. To support this theory, 
truncation fusions V155 and D169 were then designed so that they were evenly spaced between 
D146 and A181, to verify the newly modelled periplasmic loop. Both fusions displayed red 
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colouration and NAR values of high BG to AP ratios. In order to satisfy the current results, a re-
entrant loop was introduced in the proposed model that completely traverses the plasma membrane 
into the cytoplasm and loops back up into the periplasm such that Vl 55 and D 169 are both localised 
in the cytoplasm. Analysis of the TMS prediction algorithms indicated that throughout the protein 
sequence, the transmembrane helices were predicted as clear hydrophobic peaks. However, between 
amino acid regions P 140-Il 87, two double peaks exist which can be deduced as transmembrane 
regions (Figure 3.12). This trend was also witnessed for the topology prediction of Gtrlc (Ramiscal 
et al., 2010). The blue fusions obtained via Exo III deletions confirmed the periplasmic locations of 
loop No. 2 and loop No. 6, while blue truncation fusion D406 confirmed that loop No. 8 (Figure 
3 .11) is in the periplasm. The presence of two large periplasmic loops gives weight to the hypothesis 
that glucosylation takes place in the periplasm. Therefore, these two loops provide excellent 
candidates for GtrIV functional studies. Red fusions 1200 and K438 -confirm the cytoplasmic 
localization of loop No. 5 and the C-terminus of Gtrl, respectively. Sandwich fusion R375 confirms 
the cytoplasmic loop No. 7, while sandwich fusions R93 and Kl 17 along with truncation fusion 
Vl 02 show that loop No. 3 of GtrIV is indeed a large cytoplasmic loop, uncharacteristic to the other 
Gtrs. Such a large cytoplasmic loop is known to exist in another protein involved in S. flexneri O-
antigen acetylation, O-acetyltransferase (Oac) (Thanweer et al., 2009). Since glucosylation of the O-
antigen is thought to occur in the periplasm, it may play a part in helping to maintain the structural 
integrity of GtrIV during the glucosylation process. Blue fusions D 146 and Al 81, together with red 
fusions V155 and D169 suggest the presence of a re-entrant loop between the amino acid regions 
P140 - Il 87 that starts from the periplasm and traverses through the plasma membrane into the 
cytoplasm, forming an intramembrane dipping segment which then traverses back into the 
periplasm. This unique re-entrant loop structure was put forward following comparisons with Gtrlc, 
the closest structural homologue of GtrIV and is hypothesised to provide structural . flexibility in 
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order to facilitate interaction between periplasmic loop No.2 and periplasmic loop No. 6 (Nair et al, 
2011). As mentioned before, Gtric has an almost identical topology to that of GtrIV. Ramiscal et al 
(2010) have also shown that a Gtr-conserved re-entrant loop exists at the lateral centre of Gtric, 
between transmembrane helices IV and V. Unlike the re-entrant loops seen in Gtrll and GtrV 
(Korres and Verma, 2004; Lehane et al, 2005), Ramiscal et al (2010) proposed that it formed a 
double intramembrane dipping region which can be defined as a protein segment that does not 
completely penetrate the bilayer but briefly enters and exits the same membrane face (Lasso et al, 
2006). In light of the current results and considering that Gtric is the closest homologue to GtrIV, an 
intramembrane dipping region seems to exist in GtrIV between residues Vl55 and D169. As this 
region is rich in isoleucines (hydrophobic residue), it further supports the presence of such an 
intramembrane dipping region. However, the presence of a KKE tract within this region could also 
point to a cytoplasmic loop. Therefore, to reinforce this, a final truncation fusion was designed at 
K162. This fusion reported a red DI colouration and NAR of 1: 14. The relatively low NAR value 
and BG activity of Kl 62 (11) suggests that while in the cytoplasm, this loop might be folded such 
that it is close to the plasma membrane. There is a possibility of the presence of an intramembrane 
dipping region occurring within V155 and D169. In this case, the reported red colouration and 
subsequent BG enzymatic function 1nay have resulted from the effect of PhoA/LacZ weighing down 
the region such that it is pulled back into the cytoplasm. This could account for its low BG activity 
as compared to V155 and D169. However, without the use of visual technology such as X-ray 
crystallography, such structures are difficult to prove. Hence, the presence of a re-entrant loop 
. between transmembrane helices III and IV of GtrIV is proposed. This loop starts at the periplasmic 
face of the protein and traverses down into the cytoplasm before making its way back to the 
periplasm. Re-entrant loops have been documented in eukaryotic glutamate transporters ( Grunewald 
et al, 1998), in the bacterial potassium channel KcsA· (Doyle et al, 1998) and in various other 
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channels as reviewed by Harris-Warrick (2000). This proposed re-entrant loop may be of minimal 
influence on catalytic potential but may instead provide GtrIV with the conformational flexibility 
required to transfer a glucosyl group from a membrane lipid to the O-antigen, as proposed by Korres 
and Verma (2004) for the GtrV protein. 
3.6 Conclusion 
The present study provides the basis for the functional determination of glucosyltransferase 
IV involved in O-antigen modification. The topology of GtrIV was experimentally determined by 
creating different fusions between GtrIV and a dual-reporter protein, PhoA/LacZ. This study shows 
that GtrIV consists of 8 transmembrane helices, 2 large periplasmic loops, 2 small cytoplasmic N-
and C- terminal ends and a re-entrant loop that occurs between transmembrane helices III and IV. 
Although this topology differs from that of GtrI, Gtr II, Gtr V and Gtr X, it is very similar to that of 
Gtrlc. The discovery of a unique re-entrant loop and the existence of a conserved periplasmic Loop 
No 2 could help provide an insight in their mode of action in binding and attaching the glucosyl 
residue to the correct rhamnose of the O-antigen. 
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4.1 Introduction 
By identifying critical regions of a protein, it helps provide an insight and may also 
uncover vital clues to help elucidate its mechanism of action. According to the model of O-
antigen glucosylation, the Gtr(type) proteins have been hypothesised to catalyse the transfer a 
glucosyl group from undecaprenyl phosphate (UndP)-~-glucose to one of the specific sugars of 
the O-antigen repeat unit (Guan et al., 1999). The subsequent glycosidic linkage formed between 
the glucosyl group apd the sugar is deteremined via interactions of the Gtrs with the acceptor 
substrates (N-acetylglucosamine, Rhamnosel, II and III). Guan et al., (1999) have also 
postulated that the Gtrs may also be responsible in recycling the free UndP back to the 
cytoplasmic leaflet of the plasma membrane. It has been hypothesised that each Gtr has a 
~ 
conserved domain and a specific domain. Conserved domains may be involved in interactions 
with the donor substrate and are responsible for recycling of the lipid carrier. On the other hand, 
specific domains determine which O-antigen sugar is modified and by what linkage. Two 
potential segments within all Gtr(type) proteins might be involved in this process of O-antigen 
modification. These hypothetical segments include: the N-terminal segment responsible for the 
conserved interaction with the donor substrate UndP-Glucose, and the C-terminal segment 
responsible for the specific attachment of the glucosyl unit to the specific rhamnose of the 
growing O-antigen chain. 
The newly elucidated topology of GtrIV shows that it contains a large N-terminal 
periplasmic loop (loop No. 2) and an even larger C-terminal periplasmic loop (loop No. 6) (Nair 
et al, 2011). As O-antigen g1ucosylation is thought to occur in the periplasm, these two loops are 
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prime candidates for deletion experiments. As such, series of loop deletion experiments were 
carried out to investigate their importance to GtrIV function and to help pave the way 1n 
identifying critical residues that are situated within the deleted portions of the protein. 
Apart from creating deletions within a protein, identification of domains and essential 
regions for catalysis of membrane proteins can also be achieved by creation of chimeric proteins. 
This method has been successfully employed in the past to help identify functional domains of 
various membrane proteins (Buck et al, 1994; Giros et al, 1994; Nishizawa et al, 1995; Cosgriff 
) 
et al, 2000). More recently, Korres and Verma . (2006) successfully created chimeric proteins 
between GtrV and GtrX by swapping their periplasmic loops No. 2. The GtrV-GtrXLoop No. 2-
GtrV hybrid retained its native function of converting serotype Y to serotype 5a, thus 
demonstrating that loop No. 2 of Gtr(type) proteins may have a conservative role in O-antigen 
glucosylation. As GtrIV and Gtrlc have similar topologies, it is postulated that creating chimeras 
between these two structural homologues would shed some light into the theory that their 
periplasmic loops play similar roles in their respective functions. 
4.2 Identifying regions critical for GtrIV function via loop deletions 
4.2.1 Creation of loop No. 2 and loop No. 6 deletion constructs 
Multiple alignments of both the large periplasmic loops of GtrIV were carried out against 
the other Gtrs (see Figures 5.1 and 5.2 in Chapter 5). Although it was found that there was a low 
level of homology between the periplasmic loops, with the exception of some acidic residues in 
periplasmic loop No. 2, GtrIV loop No. 2 shares structural homology with the loop No. 2 of 
63 
~ 
CHAPTER4 
other Gtrs (Korre and Verma, 2004; Lehane et al, 2005; Korres and Verm0a, 2006; Ramiscal et al, 
2010) (Figure 4.1). Therefore, it is proposed that periplasmic loop No. 2 in all Gtrs may perform 
the conserved function of interacting with the UndP-Glucose and possibly recycling the lipid 
carrier back to the cytoplasmic face of the membrane. 
To prove the importance of GtrIV loop No. 2 in such function, it was deleted via PCR 
(Figure 4.2). The template DNA used for this deletion PCR was pNV1917 (encodes for GtrIV 
that has its C-terminal fused to PhoA/LacZ dual reporter protein) obtained during topology 
-, 
studies. This construct was chosen since GtrIV can be detected on a Western blot using anti-
alkaline phosphatase antibodies to determine its expression and assembly in the membrane. The 
strategy for creating this loop deletion construct is outlined in Figure 4.3. The primers used were 
IVLp2DelSmaIF and IVLp2DelSmaIR. Both primers contain SmaI sites for screening purposes. 
The resulting PCR products were treated with Dpnl to remove template DNA and verified for 
yield through agarose gel electrophoresis. The Dpnl treated PCR products were then purified and 
digested with Smal. Following this, they were self-ligated and transformed into electro-
competent XLl-Blue cells. DNA was extracted from the resulting clones and screened via Smal 
digests (Figure 4.4a). Clones that were digested by Smal were sent for sequencing to confirm for 
loop No. 2 deletion. The primers used for sequencing were PhoSeqNewR and A181HpaIR. The 
plasmid carrying the loop No. 2 deletion was named pNV1918. 
Loop No. 6 of GtrIV was found to contain 8 aspartic acid (D) residues and 7 glutamic 
acid residues (E) (15 negatively charged acidic residues in total) spread throughout the loop, and 
is hypothesised to be responsible for adding a glucosyl residue to the N-acetylglucosamine of the 
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constructs in this thesis. Namely, GtrIV loop No. 3 deletion, GtrIV loop No. 6 deletion, GtrIV 
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O-antigen repeat unit via an a 1, 6 linkage, thus converting serotype Y to serotype 4a. Korres 
and Verma (2006) have suggested that the acidic residue D380 in GtrV is important for GtrV 
function because it is believed to interact with the O-antigen to stabilise it so that the glucosyl 
residue can come in contact with the correct rhamnose. Based on . this hypothesis, any one or a 
combination of the 15 acidic residues may perform this stabilising function in GtrIV. It is also 
distinctly possible that these acidic residues compensate for the loss of the other acidic residues 
which would explain why there are three sets of paired acidic residues flanked on either side by a 
different acidic residue situated 7-9 residues away. To investigate this, a series of loop No. 6 
deletions that targeted each set of paired acidic residues together with the flanking acidic 
residues were constructed (Figure 4.2). A total of 4 different loop No. 6 deletion constructs were 
created. These were GtrIV loop No. 6 deletion, GtrIV loop No. 6 partial deletions 1, 2 and 3. The 
strategy in creating these deletions was similar to that used to create pNV1918. The template 
used for all the deletions was pNV1917 while the primers utilised were Lp8DelSmaIF and 
Lp8DelSmaIR (GtrIV loop No. 6 deletion); Lp8DelSmaIF and Lp8P _Dell SmaIR (GtrIV loop 
No. 6 partial deletion l); Lp8P _Del2SmaIF and Lp8P _Del2SmaIR (GtrIV loop No. 6 partial 
deletion 2) and finally, Lp8P _Del3SmaIF and Lp8DelSmaIR (GtrIV loop No.6 partial deletion 
3). The PCR products were Dpnl treated, run on gel for confirmation of amplification, column 
purified, self-ligated and transformed into electro-competent XL 1-Blue cells. Transf ormants 
from each transformation plate were screened by Smal digestion (Figure 4.4a and b ). Out of all 
the clones that were successfully digested by Smal, two from each deletion was sent for 
sequencing to confirm for their respective deletion. The primers used to sequence each deletion 
construct were PhoSeqNewR and A181HpaIR. Constructs bearing the different deletions were 
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termed pNV1928 (Loop No. 6 deletion), pNV1929 (Loop No. 6 partial deletion 1), pNV1930 
(Loop No. 6 partial deletion 2) and pNV1931 (Loop No. 6 partial deletion 3). 
4.2.2 Creation of loop No. 3 deletion construct 
Topology studies revealed that GtrIV also has a unique cytoplasmic loop No. 3 consisting 
of 30 amino acids. Considering that glucosylation occurs in the periplasm, the presence of this 
large cytoplasmic loop is unusual as it is not seen in the other Gtrs. To investigate its role in 
GtrIV function, this cytoplasmic loop was deleted. The same strategy (as above) was employed 
in creating this deletion construct. pNV 191 7 was the template used and the primers used for 
amplification were IVLp3DelSmaIF and IVLp3DelSmaIR. The resulting PCR product was 
treated with Dpnl, purified, digested with Smal, self-ligated and transformed into electro-
competent XLl-Blue cells. Resulting clones were screened via Smal digestion and sent for 
sequencing (PhoSeqNewR and Al81HpaIR primers) to confirm for the deletion. This construct 
was termed pNV1919. 
4.2.3 Functional analysis of loop deletion constructs 
The six deletion constructs pNV1918 (loop No. 2 deletion construct), pNV1919 (loop 
No. 3 deletion construct), pNV1928 (loop No. 6 deletion construct), pNV1929 (loop No. 6 
partial deletion 1 construct), pNV1930 (loop No. 6 partial deletion 2 construct) and pNV1931 
(loop No. 6 partial deletion 3 construct) were transformed into SFL1616 (serotype Y) for 
functionality testing using Type IV antisera. If these GtrIV deletion proteins were to retain their 
function, they would convert serotype Y into serotype 4a. As such, agglutination with Type IV 
antisera would result. The re~ults of all deletions were negative in a slide agglutination test using 
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Type IV antisera (Figure 4.5a). Although slide agglutination tests are accurate, there is a 
possibility that the deletions have caused a decrease in function of the protein. In such a scenario, 
the agglutination effect would be quite difficult to visualise. To overcome this effect, western 
immunoblots using Type IV antisera were performed on bacterial LPS extracted from the 
deletion mutants to confirm the slide agglutination results (Figure 4.5a). The results of the LPS 
immunoblots also showed that all the deletions were unable to convert serotype Y to serotype 4a. 
Deleting such large portions of a protein may have an effect on the structural stability of that 
protein, thus preventing it from being assembled in the bacterial cell membrane. To investigate 
this, western immunoblots were carried out on the membrane protein extracts of the various loop 
deletion constructs to determine whether the deletions had any effect on protein assembly in the 
membrane using anti-alkaline phosphatise antibodies (Figure 4.5b ). The membrane protein 
western blots revealed that both loop No. 2 and loop No. 3 deletion proteins were not present on 
the cellular membrane. Faint banding was picked up for all the loop No. 6 deletions except for 
loop No. 6 partial deletion 3. The intensity of the band suggests that it is present in almost the 
same quantity as the undeleted GtrIV. This suggests that the 19 amino acids that were deleted 
could play a part in the enzyme ' s catalytic function rather than marinating the proteins structural 
integrity. 
4.3 GtrIV loop No. 6 further deletions 
Based on the loop deletion results, four new deletion constructs that specifically targeted 
the 19 amino acid spanning region that made up loop No. 6 partial deletion 3 were created 
(Figure 4.6a). These further deletions were termed further deletions (FD) 1, 2, 3 and 4. The 
strategy used to create these-new deletion constructs was identical to the one used in creating the 
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Figure 4.5: Functional analysis of deletion constructs. a) LPS Western blots and slide agglutination 
results. Deletion constructs were transformed into a serotype Y strain (SFL 1616) to test for modification 
of O-antigen to serotype 4a. SFL 2324 is GtrIV fused to PhoA/LacZ and then transformed into SFLl 616. 
The bright band is indicative of the serotype conversion from serotype Y to serotype 4a. The rest of the 
deletions show absence of modification to serotype 4a when probed with Type IV antisera. Results of the 
slide agglutination assays are indicated below the Western blots. A score of +ve indicates a positive result 
while a score of -ve indicates a negative result. b) Western blots (using anti-alkaline phosphatase 
primary antibody) performed on the me1nbrane protein extractions of the various GtrIV loop deletion 
constructs that were fused to alkaline phosphatase. B2347 and B2348 were not detected, indicating GtrIV 
Loop No. 2 and Loop No. 3 deletions have a direct effect on the assembly of the protein in the cellular 
membrane. B2349, B2350 and B2352 were detected in lower amounts, the amount of protein that is 
asse1nbled in the cellular membrane in these three deletion mutants is 1nuch lower as compared to the 
fully intact protein (B2339). The intense band seen for B2351 is almost the saine as the fully intact 
protein. 
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Figure 4.6: Further deletions of GtrIV loop No. 6. a) The sequence of the 19 amino acids located in 
GtrIV loop No. 6, which were targeted for further deletion. The dashes in the sequences of GtrIV FDl, 
FD2, FD3 and FD4 indicate the amino acids that were deleted in each deletion set. Amino acid nu1nbers 
corresponding to the start and end of the peptide sequence are given below their respective residue. b) 
LPS Western blots of GtrIV deletion constructs that were transformed into SFL1616 (Serotype Y). 
Deletion constructs FD1(SFL2331) and FD2 (SFL2332) were able to convert serotype Y to serotype 4a, 
thus indicating functionality. The absence of bands for FD3 and FD4 indicates loss of function for these 
deletion mutants. c) Western blots of GtrIV Loop No. 6 further deletion constructs. All the further 
deletion constructs were detected when the me1nbrane extracts were probed with anti-alkaline 
phosphatase. This indicated that the deletion proteins (which are fused to PhoA/LacZ) are expressed. 
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previous loop No. 6 deletion constructs. Again, the template used for the PCR reactions was 
pNV1917. The primers used were IVLp6P.Del3FD1F and Lp8DelSmaIR (FDl); 
IVLp6P.Del3FD2F and IVLp6P.Del3FD2R (FD2); IVLp6P.Del3FD3F and IVLp6P.Del3FD3R 
(FD3) and finally, Lp8DelSmaIF and IVLp6P.Del3FD4R (FD4). Resulting clones were screened 
via Smal digests and confirmed by sequencing. A total of 4 constructs (FDl, 2, 3 and 4) were 
obtained and used to transform SFL1616. Functional analysis of GtrIV deletion constructs 
through slide agglutination and LPS Western blots revealed that the introduced deletions FD 1 
and FD2 were tolerated whereas the deletions present in FD3 and FD4 knocked out GtrIV 
function (Figure 4.6b ). Western blots of the membrane proteins extracted from these constructs 
show that all the four further deletion proteins were localised in the membrane (Figure 4.6c). 
4.4 Investigating periplasmic loop function of GtrIV by using chimeric 
proteins 
4.4.1 Creation of Gtrlc and GtrIV loop No. 2 chimeras 
As previous studies on other Gtr(type) proteins have shown that a degree of functional 
similarity exists between the Gtr(type) family, the role of loop No. 2 of GtrIV by creating chimeric 
proteins with its closest structural homologue Gtrlc was investigated. The accepted dogma is that 
topologically similar N-terminal periplasmic loops in all Gtr(type) proteins may perform the 
-- conserved functions of interacting with the UndP-glucose and possibly. recycling it to the 
cytoplasmic face. Thus, if both the N-terminal periplasmic loops No. 2 of GtrIV and Gtrlc play 
the same role in O-antigen modification, then swapping these two loops with each other should 
not abolish function of the native proteins. Via PCR amplification, the sequences encoding the 
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gtrlc and gtrIV loop No. 2 regions were amplified. pNVl 792 (carries gtrlc in tandem with 
phoA/lacZ in pBC SK) and pNVl 917 ( carries gtrIV in tandem with phoA/lacZ in pBC SK) were 
also amplified by PCR such that the sequences that encode for the loop No. 2 regions were 
excluded. A detailed schematic of this strategy is presented in Figures 4.7 and 4.8. After 
transformation into electro-competent XLl-Blue cells, transformants from each plate were 
screened via a series of Bglll and Mlul restriction digests (Figure 4.9a and b ). Successful 
digestion by both enzymes indicated that the inserts were ligated with their respective vectors in 
the correct orientation, thus regenerating the restriction sites. The positive clones were sequenced 
to confirm for correct insertion of the loop No. 2 coding sequences to their respective vectors. 
The GtrIV-Gtrlc loop No.2-GtrIV construct was labelled pNV1937 while the Gtrlc-GtrIV loop 
No.2-Gtrlc chimeric construct was labelled pNV1936. Table 4.1 shows what Gtrlc and GtrIV 
models would look like with their loop No 2 exchanged. 
4.4.2 Creation of Gtrlc-GtrIV loop No. 6-Gtrlc and GtrIV-Gtrlc loop No. 10-GtrIV chimeras 
In parallel to investigating the role of GtrN loop No. 2, we also investigated the role of 
the C-terminal periplasmic loop No. 6 of GtrN. Gtrs I, II, V and X have long periplasmic C-
terminal ends that have been hypothesised to be responsible for conferring serotype specificity. 
In contrast, as both GtrN and Gtrlc have short cytoplasmic C-terminal ends, their specific 
function is thought to be performed by the large periplasmic loops No. 6 and No. 10 for GtrN 
and Gtrlc, respectively. By using the same PCR-based approach for the creation of the loop No. 
2 chimeras, loop No. 6 of GtrN was replaced by loop No. 10 of Gtrlc and vice versa. Figure 
4.10 details the creation of pNV1938 (Gtrlc-GtrIV loop No. 6-Gtrlc chimera). The primers used 
to amplify pNVl 792 introduced Smal sites while the primers used to amplify gtrJV loop No. 6 
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Figure 4.7: Strategy for creating pNV1936 (Gtrlc-GtrIV loop No. 2-Gtrlc chimera). The primers 
GtrlcBodyMluIF and GtrlcBodyBglIIR were used to amplify most of pNVl 792 excluding the 
coding region of gtrlc loop No. 2. The amplified DNA was then treated with Dpnl to remove 
traces of parental DNA and purified. It was then digested with Bglll and Mlul to generate sticky 
ends for ligation. In parallel, the coding region for gtrIV loop No. 2 was amplified from 
-pNV1917 with the help of IVLp2BglIIF and IVLp2MluIR, run on 1.5% gel and the 
corresponding gel band was excised and purified. This purified product was subsequently 
digested with Bg/11 and Mlul to generate compatible sticky ends for ligation with the amplified 
. pNVl 792. The resulting product was termed pNVl 936. This hybrid construct contains most of 
pNVl 792, as well as the region encoding gtrIV loop No. 2. The insert is flanked by Bg/11 and 
Mlul restriction sites for screening purposes. 
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Figure 4.8: Strategy for creating pNV1937 (GtrIV-Gtrlc loop No. 2-GtrIV chimera). Most of 
pNV1917 was amplified with the primers GtrIVMluIF and GtrIVBglIIR such that the coding 
region of gtrIV loop No. 2 was excluded. Traces of parental DNA from the amplified DNA were 
removed by treatment with Dpnl. After DNA purification, sticky ends were generated by 
digestion with Bglll and Mlul. At the same time, the coding region for gtrlc loop No. 2 was 
amplified from pNVl 792 with the help of GtrlcLp2BglIIF and GtrlcLp2MluIR, run on 1.5% gel 
and the corresponding gel band was excised and purified. Compatible sticky ends were generated 
digesting the amplified DNA with Bglll and Mlul. The resulting product is pNV1937. This 
plasmid contains most of pNV1917, as well as the region encoding gtrlc loop No. 2. The insert is 
flanked by Bglll and Mlul restriction sites for screening purposes. 
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Figure 4.9: Screening of GtrIV+Gtrlc loop No.2 and Gtrlc+GtrIV loop No. 2 clones via BglII 
and Mlul restriction digests. a) 10 transformants from the GtrIV+Gtrlc loop No. 2 transformation 
plates were subject to BglII digests. Colonies 5-9 displayed bands at the expected 6.2kb region 
and were deemed to be successfully digested with BglII. 10 transformants from the Gtrlc+GtrIV 
loop No. 2 plates were also digested with BglII. Colonies 1, 2, 3, 4, 6, 7 and 9 produced the 
expected 6.3 kb bands and were deemed to be digested with BglII. b) GtrIV+Gtrlc loop No. 2 
colonies 5-9 and Gtric+GtrIV loop No. 2 colonies 1-4 were digested with Mlul for further 
confirmation. The resulting bands from GtrIV+Gtrlc loop No. 2 colonies 5-9 ran at 6.2 kb while 
the bands of Gtrlc+GtrIV loop No. 2 colonies 1-4 ran at ,.__,6.3 kb. These digests confirm that 
GtrIV loop No. 2 and Gtrlc loop No. 2 were inse1ied in the right orientation. M= Molecular 
weight marker. 
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Table 4.1: Predicted structures of the four chi1neric proteins created in this study between Gtrlc 
and GtrIV. 
Chimera Constructs 
Gtrlc 
GtrIV 
Gtr lV Lcop NO .l 
Gtrlc-GtrlV loo!! No. 2-Gtrlc 
GtrIV-Gtrlc loop No. 2-GtrIV 
Gu,V I..OCp No.& 
Gtrlc-GtrIV loop No.6-Gtrlc 
GtrlV-Gtrlc loo!! No.10-GtrlV 
C 
C 
Plasma 
M*. rr.b-ran 
Pt•sma 
Membran 
A 
Slide 
lutination 
MASFic Type IV 
+ve -ve 
-ve +ve 
-ve -ve 
-ve -ve 
-ve -ve 
-ve -ve 
Points of fusion : a) Gtrlc-GtrIV loop No.2-Gtrlc chimera :Gtrlc-F3 1/GtrIV-N27, GtrIV-Y68/Gtrlc-Vl00, b) GtrIV-Gtrlc loop No.2-GtrIV 
chimera: GtrIV-M26/Gtrlc-H32, Gtrlc-}.f99/GtrIV-S71 , c) Gtrlc-GtrIV loop No.6-Gtrlc chimera: Gtrlc-P382/GtrIV-T231 , GtrIV-K351 /Gtrlc-
V495 , d) GtrIV-Gtrlc loop No.10-GtrIV. chimera: GtrIV-S229/Gtrlc-T231 , Gtrlc-V381/GtrIV-D352. To test for Gtrlc function, the chimera 
constructs were transformed in to SFL1416 (Serotype la) to test for serotype conversion to serotype le using MASF le. As for GtrIV function, 
conversion to serotype 4a was tested by using Type IV antisera against constructs that were transformed into SFL1616 (serotype Y) . 
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Figure 4.10: Creation of pNV1938 (Gtrlc-GtrIV loop No. 6-Gtrlc chimera). The majority of 
pNVl 792 was amplified using the primers GtrlcBodySmaIF and GtrlcBodySmaIR to exclude 
the gtrlc loop no. 2 coding region. The PCR product was treated with Dpnl, purified and 
digested with Smal to generate blunt ends for ligation. The coding region for gtrIV loop No. 6 
was amplified from pNV1917 using GtrIVLp8HpaIF and GtrIVLp8HpaIR. The PCR product 
was run on 1.5% agarose gel and the corresponding band was excised. The gel fragment was 
then purified and digested with Hpal to generate blunt ends for ligation. Both sets of DNA were 
-ligated together to create pNVl 93 8. This plasmid contains most of pNVl 792, as well as the 
region encoding gtrIV loop No. 6. As two different restriction sites were used in the PCR 
amplification, both sites are destroyed upon ligation. As a result, the insert is not flanked by any 
restriction sites. 
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introduced Hpal sites. Following amplification by PCR of these sequences, restriction digests 
with Smal (amplified gtrlc) and Hpal (amplified gtrIV loop No. 6 coding region) was carried out 
followed by ligation of gtrIV loop No. 6 with gtrlc and transformation of the ligation mix into 
XLl-Blue cells. Because the restriction sites were dissimilar, recombinant plasmids carrying the 
correct chimeric construct were therefore not expected to contain a Sm a I restriction site. As 
pNVl 792 already contains a Hpal site, the resulting transformants were screened via Smal 
digestion (Figure 4.11 ). All clones that were not digested with Smal were selected and sequenced 
to confirm that the gtrIV loop No. 6 coding region was inserted in- frame within gtrlc. 
To create pNV1939 ((GtrIV-Gtrlc loop No. 10-GtrIV chimera) (detailed in Figure 4.12), 
pNV1917 was amplified with the primers GtrIVBodySmaIF and GtrIVBodySmaIR to exclude 
the gtrIV loop No. 6 coding region. The gtrlc loop No. 10 coding region was amplified from 
pNVl 792 with the help of the primers GtrlcLpl0SmaIF artd GtrlcLpl0SmaIR. All four primers 
incorporated Smal sites into the amplified DNA. After transformation of the ligation mix into 
electro-competent XL 1-Blue cells, recombinant plasmids carrying this chimeric construct were 
therefore expected to have two regenerated Smal sites flanking the gtrlc loop No. · 10 sequence 
within gtrIV. All resulting transformants were screened via Smal digestion (Figure 4.13). Clones 
that exhibited two bands ( ~6. lkb and 0.3kb) were sent for sequencing to confirm that gtrlc loop 
No. 10 was successfully inserted in the correct orientation. 
4.4.3 Functional analysis of Gtrlc and GtrIV chimeric proteins 
Functional analysis of the various GtrIV and Gtrlc chimeric proteins was carried out via 
slide agglutination using Type IV antisera and MASF le (monoclonal antibodies specific to 
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Figure 4.11: Screening of Gtric-GtrIV loop No. 6-Gtrlc chimeras via Smal digestion. 24 
colonies from the Gtrlc-GtrN loop No. 6-Gtrlc transformation plate were digested with Smal. 
Colonies 6, 8 and 19 run the same as the uncut control (U). This indicates that they were not 
digested by Smal. These colonies also ran differently from the Smal digested control (C) 
pNV1928 (GtrIV loop No. 6 deletion constluct). M= Molecular weight marker 
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Figure 4.12: Creation of pNVl 939 (GtrIV-Gtrlc loop No. 10-GtrIV chimera). The majority of 
pNV1917 was amplified using the primers GtrIVBodySmaIF and GtrIVBodySmaIR to exclude 
the gtrIV loop no. 2 coding region. The PCR product was Dpnl treated, purified and digested 
with Smal to generate blunt ends for ligation. In parallel, the coding region for gtrlc loop No. 10 
was amplified from pNVl 792. The resulting PCR product was run on 1.5% agarose gel and the 
corresponding band was excised. Upon purification and Smal digestion, both sets of DNA were 
ligated together to create pNV1939. This hybrid construct contains most of pNVl 792, as well as 
the region encoding gtrlc loop No. 10. The insert is flanked by Smal sites for screening purposes. 
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U= Uncut pNVl 792 (Gtr le fused to PhoA/LacZ) 
Figure 4.13: Screening of GtrIV-Gtrlc loop No. 10-GtrIV chimeras with the help of Smal 
restriction digests. 18 transformants from the GtrIV-Gtrlc loop No. 10-GtrIV transformation 
plate were digested with Smal. Colonies 1 and 15 displayed two bands at the expected sizes of 
6.1 kb and 0.3 kb. The rest of the colonies did not display the smaller 0.3kb band. This meant 
that they were most probably the vector (GtrIV minus loop No. 6) that self-ligated without the 
insert (Gtrlc loop no. 10). M= Molecular weight marker. 
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serotype le) (Table 4.1). The hybrid Gtrlc constructs containing loop No. 2 of GtrIV and loop 
No. 6 of GtrIV failed to convert serotype la to serotype le. Similarly, the hybrid GtrIV 
constructs containing loop No. 2 of Gtrlc and loop No. 10 of Gtrlc were unable to convert 
serotype 1 a to serotype 1 c. To confirm the slide agglutination results, LPS western blots utilising 
Type IV antisera and MASFic as the primary anitbodies, were performed (Figure 4.14a and b ). 
Addition of foreign loops to both the Gtrs may have compromised their structural integrity and 
as a result, prevented them being assembled on the bacterial membrane. This would in tum result 
in lack of serotype conversion. Therefore, the next step was to determine if these chimeric 
proteins were assembled in bacterial membrane. To confirm for assembly in the membrane, 
Western blots (using anti-alkaline phosphatase antibodies) were carried out on the membrane 
protein extracts of each chimeric protein (Figure 4.14c ). Of the four chimeric proteins created, 
only the Gtric-GtrIV loop No. 2-Gtrlc chimera was not detected by the blot. Its non-functional 
hybrid GtrIV counterpart however, was shown to have been assembled in the membrane. These 
results indicated that all the chimera, except for Gtrlc-GtrIV loop No. 2-Gtrlc were localised in 
the cell membrane. 
4.5 Discussion 
4.5.1 Loop deletions 
The recently solved topology of GtiIV has enabled us to further characterize its mode of 
action by identifying important regions and residues, thus giving us greater insight into how 
these glucosyltransf erases are able to modify the O-antigen and confer serotype specificity. 
Based on the widely accepted notion that glucosylation is thought to occur in the periplasm, the 
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Figure 4.14: Western i1n1nunoblots of LPS extractions and 1nembrane protein extractions of all 
chimeras between Gtrlc and GtrIV. a) The chimeras were transformed into SFL1416 (serotype la) to test 
for modification of the O-antigen to serotype le by probing with MASF le. All the chimeras were non-
functional. b) Chimeras between GtrIC and GtrIV were also transformed into SFL1616 (serotype Y) to 
test for modification of O-antigen to serotype 4a by probing with Type IV antisera. All chimeras were 
found to be non-functional. c) Wes tern immunoblots of membrane protein extracts of all chimeric 
constructs. Gtrlc fused to PhoA/LacZ is 111 kDa while GtrIV fused to PhoA/LacZ is 108kDa. With the 
exception of B2357, the 1ne1nbrane extracts of all the other hybrid constructs show bands similar to the 
positive controls, thus indicating localisation of the chimeras in the bacterial me1nbrane. 
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two large periplasmic loops of GtrIV (loop No. 2 and loop No. 6) were targeted to investigate 
their role in GtrIV function. At the same time, GtrIV was found to have a large 30 amino acid 
spanning cytoplasmic loop (loop No. 3). As such a loop is not found in other members of the 
Gtr(type) family of Shigella flexneri. It was also targeted for functional studies. 
A total of 6 loop deletions were performed on GtrIV to help identify critical regions 
within the protein. The loop No. 2 and loop No. 3 deletion proteins were found to have abolished 
GtrIV function. Membrane protein western blots subsequently revealed that both deletion 
proteins were not present in the cellular membrane. This effectively meant that the deletions 
prevented GtrIV from being assembled in the cellular membrane. The deleted loops could have 
been important for the structural integrity of the GtrIV and their deletion could have led to the 
disruption of van der Waals forces thus affecting the hydrophobicity of the mutant protein 
(Fiedler et al., 2010). This would have resulted in protein misfolding, thereby potentially causing 
hydrophobic regions within the protein to be exposed to the extracellular environment. 
Consequently, such an occurrence would likely prevent the protein from being inserted into the 
membrane. Harrington and Ben-Tal (2009) have stated that the stability of the tertiary protein 
structure is highly dependent on inter-helical interactions. These include hydrogen bonds, salt 
bridges, aromatic interactions and closely packed residue interaction help stabilise the tertiary 
protein structure. Therefore, it can be assumed that removing loop No. 2 and No. 3 could have 
disrupted these inter-helical interactions and led to an unstable, misfolded protein. These aberrant 
proteins would then aggregate within the cytosol and be targeted for degradation by cellular 
proteases (Martinez-Alonso et al., 2009). The deleted segments could also have played a role in 
helping GtrIV localise in the membrane. It is known that transmembrane proteins contain signal 
72 
·- . ·- .. ---· ~ 
CHAPTER4 
sequences that function as both the targeting and recognition signal for the cell's translocation 
machinery (Driessen et al., 2001, Fekkes & Driessen, 1999). Found in the N-terminal and C-
terminal regions of the protein, the signal sequences have an impact on the overall charge of the 
N-terminal and C-terminal regions of the protein. This overall charge is then recognised by 
cellular transport machinery which translocates the protein to its designated location in the cell 
(Fekkes & Driessen, 1999). Hence, by deleting loops No. 2 and No. 3 from GtrIV, the overall 
charge of the N-terminal region may have been modified preventing localisation of the mutant 
protein to the membrane. 
Though all the loop No. 6 deletions also prevented GtrIV from functioning, the weak 
signals obtained from their membrane protein western blots (loop No. 6 deletion and two of the 
three loop No. 6 partial deletions) indicated that there was a small amount of protein localised on 
the bacterial membrane as compared to the fully intact protein. Again, it can be seen that the 
deletions would have caused a conformational change in GtrIV, thus affecting its native ability to 
localise in the membrane. This would in tum lead to a negligible amount of O-antigen 
modification, too little to be picked up in the LPS western blots. Also, such a confom1ational 
change could have rendered the proteins to be non-functional anyway. However, in B23 51 (loop 
No. 6 partial deletion 3) the amount of protein that was assembled in the bacterial membrane was 
almost as high as the amount of the intact GtrIV. This, coupled with the loss of functionality of 
the deleted protein, provides us with an insight that the missing 19 amino acid segment of loop 
No.6 partial deletion 3 could contain residues that may be part of a catalytic site present in the 
large periplasmic loop No. 6. This led us to carry out the 4 further deletions to zero in on the 
exact region within these 19 amino acids that _could potentially be the catalytic site. Slide 
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agglutination and LPS westerns revealed that FD 1 and 2 yielded functional proteins while FD 3 
and 4 resulted in non-functional proteins. On the other hand, western blots of the membrane 
proteins extracted from these constructs show that all the four further deletion proteins were 
localised in the membrane. This is in agreement with the hypothesis that the missing segments 
may be part of a catalytic site present in the large periplasmic loop No. 6 that might not only be 
responsible for interaction with the glucosyl residue to be attached to the O-antigen, but also with 
potential interactions between GtrIV, GtrA and GtrB. As such, the next step would be to carry 
out site directed mutagenesis experiments that target all the amino acids that are within FD 3 and 
4. This will allow us to pinpoint critical residues within this segment. Identification of such 
residues will help us in understanding the mechanism of action of GtrIV. 
4.5.2 Chimeric proteins between Gtrlc and GtrIV 
Chimeric proteins were created between GtrIV and its closet structural homologue, Gtrlc. 
They were created in an attempt to test the well held hypothesis that topologically similar N-
terminal periplasmic loops in all Gtr(type) proteins may perform the conserved functions of 
interacting with the UndP-glucose and possibly recycling it to the cytoplasmic face. In light of 
this, two loop No. 2 chimeras were created by swapping loop No. 2 of GtrIV with that of Gtrlc 
and vice-versa. However, slide agglutination and LPS western blots have revealed that both 
chimeras had lost their native function. Membrane protein western blots showed that Gtric-GtrIV 
loop No. 2-Gtrlc chimera was not detected by the blot, unlike its GtrIV counterpart. This 
indicates that although loop No. 2 is topologically conserved, its low sequence identity cannot 
necessarily establish a functional protein as observed in the GtrV-GtrX Loop No .2-GtrV 
chimera (Korres and Verma, 2006). In retrospect, it is possible that the loop No. 2 of both 
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proteins may contain unique amino acid residues that are critical for its conserved interaction 
with the UndP-Glucose precursor, owing to the fact that the active sites for both these proteins 
might require slightly different tertiary structures in order to interact specifically with the O-
antigen (Nair et al, 2011). For the GtrIV-Gtrlc loop No. 2-GtrIV chimera, the results imply that 
specific interactions between residues present in its native loop No. 2 ( of GtrIV) are required to 
form a catalytic site that facilitates O-antigen modification. On the other hand, the absence of 
assembly in the bacterial membrane of the Gtrlc-GtrIV loop No. 2-Gtrlc chimera suggests that 
GtrIV loop No. 2 has compromised the structural integrity of the Gtrlc protein which would have 
resulted in a misfolded protein that was unable to be translocated to the plasma membrane and 
subsequently, would have most probably been degraded. 
The large C-terminal periplasmic loops of GtrIV and Gtrlc (loop No. 6 and loop No. 10 
respectively) were also swapped between the two proteins to test the hypothesis that these loops 
are responsible for conferring serotype specificity of their respective Gtrs. Slide agglutination 
and LPS Western blots revealed absence of modification to respective serotypes. Membrane 
protein western blots revealed that both hybrid proteins were localised in the cellular membrane. 
As both large periplasmic loops contain over 100 amino acids each (123 amino acids in loop No. 
6 of GtrIV and 120 amino acids in loop No. 10 of Gtrlc), each loop can possibly accommodate 
its own unique tertiary structure that would contribute to the serotype specificity of O-antigen 
modification. Therefore, in absence of this, GtrIV and Gtrlc would not be able to carry out their 
specific functions. Alternatively, the stluctural integrity of each chimeric protein may have been 
compromised with the addition of the foreign loop. The loss of function for Gtrlc-GtrIV loop No. 
6-Gtrlc and GtrIV-Gtrlc loop No.10-GtrIV chimeras can also be attributed to the importance of 
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the two C-terminal periplasmic loops in conferring serotype specificity through the addition of 
glucosyl residues to the O-antigen in a site and linkage specific manner. As both loops span more 
than 100 amino acids each, this would facilitate intra-loop and inter-loop interactions that may 
contribute to serotype specificity and O-antigen modification. 
4.6 Conclusion 
Based on the newly elucidated topology of GtrIV, the roles of the N-terminal and C-
terminal periplasmic loops of GtrIV (loop No. 2 and loop No. 6) were investigated by carrying 
out a series of loop deletions. As GtrIV was also found to contain an unusual (compared to the 
other Gtrs) cytoplasmic loop No. 3, it was also deleted to investigate its function. It was found 
that the loop No. 2 and No. 3 deletions knocked out GtrIV function by preventing the protein 
from assembling in the bacterial membrane. By sequentially deleting loop segments in loop No. 
6, the presence of a potential catalytic site located between resides D260 to W269 was 
hypothesised. To further investigate the roles of conserved or specific functions of the two 
periplasmic loops of GtrIV, loop swap experiments between the N-terminal periplasmic loops 
and the C-terminal periplasmic loops were undertaken. The resulting hybrids lost their native 
function and were unable to substitute function to the other protein. This signifies the importance 
of both loops in GtrIV function. 
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CHAPTER 5 
5.1 Introduction 
As mentioned in chapter 4, functional analysis of a protein helps to provide an insight 
into areas responsible for its mechanism of action. As such, residues critical for the function of a 
protein can be identified from data gained as a result of mutations that lead to a change of the 
protein's function (loss of function or hyper-function). The ability to change a specific amino 
acid and thereby modulate catalysis has been invaluable in determining which residues are 
directly involved in a reaction. Site-directed mutagenesis employed in functional studies involves 
amino acid replacement, deletion and insertion of varying lengths of amino acid stretches 
(Alexeyev & Winkler, 2002). It has allowed the consequences from a wide array of side chain 
substitutions to be assessed and has been instrumental, in conjunction with other techniques, in 
unraveling energetic, functional, structural, and dynamic properties of the protein matrix 
(Brockhausen et al., 2008). Only a small fraction of the residues of an enzyme directly 
'---'" 
participate in catalysis. These residues that are critical may not only be involved directly in 
catalysis but also in interacting with substrates and other proteins in a complex (Brockhausen et 
al., 2008). They may also be responsible for maintaining the structural integrity of the protein 
sue~ that other critical residues may form the catalytic site (Alexeyev & Winkler, 2002). 
The identification of critical residues in Gtr IV is being · reported for the first time. 
Previous studies have highlighted critical residues in GtrII and GtrV. Lehane et al., (2005) 
identified 4 residues (E40, F414, C435 and K478) that abolished function in GtrII when mutated 
to alanine. Furthermore, a previous study by Chen et al., (2003) identified residue C437 to be 
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critical in GtrII. As for GtrV, Korres & Verma (2006) reported that two N-terminal residues (E42 
and D43) and one C-terminal residue (D380) were found to be critical. 
5.2 Previous work 
Despite the fact that a number of residues have been targeted, thus far, site-directed 
mutagenesis work on GtrIV has not yet uncovered any critical residues. The aspartic acid 
residues D23, D31 and D33 located in the periplasmic loop No. 2 of GtrIV were targeted based 
on a series of alignments showing that these residues are conserved among all the Gtrs. D23 was 
found to be conserved between in all Gtrs as shown by Lehane et al, (2005) (Figure 5. la). 
Residue D31 was chosen on the basis that it may work together with D33 as a kind of a motif as 
seen in other glucosyltransferases which form the catalytic site (Breton & Imberty, 1999) (Figure 
5.1 b ). Furthermore, some alignments showed that D31 lines up with critical residues found in 
other Gtrs. D33 was found to be conserved when another alignment was carried out by Korres & 
Verma (2006) (Figure 5.lc). Residues D31 and D33 were then mutated in the same construct to 
investigate whether they worked in tandem with each other. The resulting mutant tested positive 
for serotype conversion indicating that GtrIV was still able to function (Nair A, Honours thesis 
2006). 
Several other residues located within GtrIV loop No. 6 were also targeted as it was 
thought that this loop may be responsible for modifying the O-antigen in a sugar and linkage 
specific manner. Single point mutations were introduced on F273, D276 and C288. F273 and 
D276 were targeted solely on the fact that they lined up with a critical phenylalanine F414 in 
GtrII and an aspartic acid residue D380 in GtrV respectively (Figure 5.2a and b). Both mutations 
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Figure 5.1: (a) Manual alignment of the N-terminal sequences (loop No. 2) of S. flexneri Gtr 
proteins (Lehane et al., 2005). The positions of the conserved acidic residues are shown in red; 
(b) An alternative alignment of the N-terminal sequences of all the Gtrs shows that D31 in 
GtrIV is conserved. Acidic residues are in red. (c) A best fit analysis performed by Korres and 
Verma (2006) of the first periplasmic loop No. 2 present in all Gtrs. The conserved aspartic 
acid (D) is shown in red. Acidic residues near the conserved residues are indicated in bold. 
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Figure 5.2: C-terminal alignments of the various Gtrs. (a) F273 of GtrN lines up with F414 of 
GtrII (phenylalanine residue found critical in GtrII). (b) A manual alignment shows that D276 
of GtrN lines up with D3 80 of GtrV ( critical aspartic acid residue). 
----,--•··-··: - "' 
CHAPTER 5 
did not affect GtrIV function (Nair A, Honours thesis 2006). Previously, Lehane et al., (2005) 
and Chen et al., (2003) had shown that cysteine residues C435 and C437 in the large periplasmic 
C-terminus of GtrII, are essential for function. Thus, C288 was selected as it was thought to form 
a disulphide bond with C263 in GtrIV loop No. 6 and was non-critical. 
Apart from mutating single residues, to further investigate the importance of the 
negatively charged acidic residues occurring within loop No. 6, three sets of paired residues 
DE261, ED283 and ED326 were mutated to double alanines (AA261, AA283 and AA326) by 
site-directed mutagenesis. Functional analysis of all constructed mutants showed agglutination to 
Type IV antiserum when introduced into SFL1616. A full summary of the residues already 
targeted, along with the reasoning behind their selection is shown in Table 5 .1. Figure 5 .3 shows 
the location of the residues in GtrIV. All these residues are non-critical for GtrIV function (Nair 
A, Honours thesis 2006) 
5.3 Acidic residues in GtrIV 
It is postulated that acidic residues might interact with UndP-Glucose (N-terminal 
periplasmic loop) or involved in attaching the glucosyl group to the specific rhamnose of the 0-
antigen (C-terminal periplasmic loop) (Korres & Verma, 2006). As there are a total of 20 acidic 
residues located within the periplasmic loops No. 2 (5 residues) and No. 6 (15 residues) of 
GtrIV, the first step was to target all the remaining acidic residues within the two large 
periplasmic loops individually (Figure 5.4) In loop No. 2, the three remaining residues D49, E58 
and E67 were targeted. Likewise, all the individual acidic residues in loop No. 6 were targeted 
(E254, D267, D274, E294;- D299, D317, E334 and E347). The template DNA, pNV1917 
79 
- -•~-,,-··- . -- ~ 
Table 5.1: Residues targeted by site-directed mutagenesis based on bioinformatic analysis. The 
rationale for choosing each residue and the primers used for each mutation are also listed below. 
~~s~~fte·;-J.r. ~~K,,•··,:, ~,,-_r;:;:'J~ ·,:;,,:·· R~t~o~ar~· - , . . • • C .•• ' .. C . ''° - .,- Primers 
D23 IAn alignment done by Lehane et al., (2005)1 D23ForA 
D31 
showed that it lined up with a critical aspartic 
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D23RevA 
Negatively charged residue found close tol D31ForA 
D33. Found to line up with critical aspartic 
acid residues of other Gtrs 1n some 
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function. 
D31RevA 
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all the Gtrs D33ReverseA 
F273 Lines up with a critical F residue found in thel F273ForwardA 
C-terminus of GtrII F273ReverseA 
D276 ILines up with a critical D residue found in thelD276ForwardA 
. 
. . D276ReverseA C-term1nus of GtrV (H. Korres, PhD Thesis, 
2006) 
C288 IThought to form a disulphide bond with C263 .I C288ForwardA 
C28 8ReverseA 
DE261 ID and E paired residues found in Loop No. 6 I DE261ForAA 
DE261RevAA 
ED283 IE and D paired residues found in Loop No. 6 I ED283ForAA 
ED283RevAA 
ED326 IE and D paired residues found in Loop No. 6 I ED326ForAA 
ED326ForAA 
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Loop No. 2 
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Loop No. 3 
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Cytoplasm 
Figure 5.3: ModeLof GtrIV showing only periplasmic located residues. Highlighted residues 
were targeted by site-directed mutagenesis based on multiple alignments of all Gtrs. Residues 
D31 and D33 are in loop No. 2 while F273 , D276 and C288 are located within loop No. 6. 
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Figure 5.4: Negatively charged residues found on loop No. 2 and loop No. 6 (in pink). A total 
of 20 negatively charged residues are present. In loop No. 2, residues D49, E58, E67 were not 
targeted previously and therefore, were targeted in this study. The number of negatively 
charged residues scattered throughout loop No. 6 seems to suggest that these residues may 
have a compensatory effect in the event of a mutation involving negatively charged residues. 
Negatively charged residues -that occur in pairs are DE261, ED283 and ED326. 
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carrying gtrIV fused to phoA/lacZ was used for all site-directed mutagenesis reactions. Each 
residue was mutated to an uncharged alanine. Upon confirmation of DNA amplification, the 
DNA was treated with Dpnl, transformed into electrocompetent XLl-Blue cells. DNA from 3 
resulting colonies taken from each transformation plate was extracted and sent for sequencing. 
Constructs encoding the mutated proteins were then transformed into SFL 1616 and 
transformants were tested for agglutination with S. jlexneri Type IV antiserum. All mutants were 
able to convert serotype Y to serotype 4a, indicative of a functional GtrIV. Table 5.2 lists all the 
acidic residues targeted and their slide agglutination results. 
5.4 Residues within GtrIV loop No. 6 partial deletion 3 
The difference in structure between GtrIV and the other Gtrs (except Gtrlc) could mean 
that other residues may be involved in forming the catalytic site either independently or in 
tandem with the residues that were initially selected. The results of the loop deletion experiments 
carried out in Chapter 4 has helped narrow down the region of the protein which is directly 
involved with its catalytic activity. It has highlighted a distinct possibility that this 19 amino acid 
spanning region may contain 1 or more critical residues. Therefore, instead of · resorting to 
random selection .. of other residues within GtrIV loop No. 6, this region was now targeted to 
identify the amino acids of interest residing within it (Figure 5.5). 
5.4.1 Site-directed mutagenesis of all individual residues within further deletions 3 and 4 
GtrIV further deletions 3 and 4 (FD 3 and 4) (see Chapter 4) were shown to have 
knocked out the serotype converting ability of GtrIV (Nair et al., 2011). Thus, all the amino 
acids that made up these two further deletions were mutated to alanine individually and their 
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Table 5.2: List of the remaining acidic residues within GtrIV that were targeted and their slide 
agglutination results. All mutants exhibited agglutination against S. flexneri Type IV antisera. 
Construct 
D49 
E58 
E67 
E254 
D267 
D274 
E294 
D299 
D317 
E334 
E347 
~-.. - -.-: --·- •. I.:, 
Agglutination 
(Type IV) 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
Loop No. 6 
Peri plasm 
Plasma Membrane 
Cytoplasm 
Figure 5.5: Residues located within GtrIV loop No. 6 partial deletion 3. The 19 residues within 
the purple highlights make up GtrIV loop No. 6 partial deletion 3. Residues in yellow were the 
individual residues that were targeted for site-directed mutagenesis. They are C263 , 1264, G265, · 
V266 and W269. A268 was not targeted as it is already an alanine. All acidic residues are shown 
in pink. 
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effects on GtrIV were studied. The amino acid targets are shown in Figure 5.5. Of the 9 amino 
acids within FD 3 and 4, only C263, 1264, 0265, V266 and W269 were mutated. A268 was not 
mutated as it is an alanine while DE261 and D267 have already been mutated. All amino acids 
were mutated to alanines via the same site-directed mutagenesis protocol described above. The 
template used was pNV 1917. Once the mutations had been confirmed, functional analysis was 
carried out by transforming the mutated constructs into SFL 1616. Following this, slide 
agglutination was carried out with S. flexneri Type IV antiserum and agglutination was observed 
for all the mutants. As such, it was concluded that the amino acids within this region, when 
mutated individually, were not critical for GtrIV function. A summary of all the residues that 
were mutated within GtrIV loop No. 6 partial deletion 3 is shown in Table 5.3. 
5.4.2 Cumulative mutation of acidic residues within Gtr/V loop No. 6 partial deletion 3 
Because of the large number of acidic residues present within GtrIV loop No. 6. There is 
a chance that they work in tandem with one another. Also, the other acidic residues could act to 
compensate for the loss of any other acidic residue within this large periplasmic loop. To 
investigate this, the ·acidic amino acids within GtrIV loop No. 6 partial deletion 3 were mutated 
in combination of one another (Figure 5 .5). Ther~ were a total of 4 acidic residues in this region, 
namely, E254, D26), E262 and D267. Seeing that the paired residue mutant DE261 (pNV1958) 
was still functional, it was used as a template to knock out E254 and D267 in tandem. 
Confirmation of the mutants resulted in two new mutant constructs E254 + DE261 (pNV1964) 
and DE261 + D267 (pNV1965). In parallel, E254 was mutated in tandem with D267. The 
template used for this site-directed mutagenesis PCR was pNV1950 (D267 mutant). Sequence 
confirmation of resulting clones led to the creation of pNVl 966 (E254 + D267). All three 
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Table 5.3: Table of residues located within GtrIV loop No. 6 partial deletion 3 that were mutated 
to alanine (neutral charge). 
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constructs were then transformed into SFL 1616 and tested for agglutination with S. flexneri Type 
IV antiserum (Table 5.3). Agglutination was observed for the mutants E254 + D267 (SFL2291) 
and E254 + DE261 (SFL2294). However, no agglutination was seen for the mutant DE261 + 
D267 (SFL2305). As mentioned in chapter 4, there is a possibility that decreased protein 
function makes agglutination hard to visualise (though it may be present). Therefore, bacterial 
LPS was extracted from these mutants and western blots using Type IV antisera was performed 
on them (Figure 5.6a). The western blots confirmed that the DE261 + D267 mutant was non-
functional. This result meant that the function of GtrIV was affected when 3 acidic residues 
within the targeted region were knocked out in tandem . 
The possibility that only two out of the three residues may be sufficient for knocking out 
GtrIV function was explored. As DE261 was mutated as a pair, the effect of each residue 
mutated individually (D261 and E262) in tandem with D267 was examined. To obtain these 
mutants, site-directed mutagenesis was carried out using pNVl 965 (D267 + DE261 triple 
. mutant) as a template. In this case, specific mutagenic primers were used to restore the mutated 
residues back to the original amino acid to obtain the double mutants. Therefore, · to obtain a 
D261 + D267 double mutant, mutagenic primers GtrIV A262EFor and GtrIV A262ERev were 
designed such that . A262 in the triple mutant was reverted back to E262, thus rendering the 
construct with mutations at D261 and D267. In the same vein, the E262 + D267 double mutant 
was obtained with help of the mutagenic primers GtrIV A261DFor and GtrIV A261DRev that 
reverted A261 back to D261. Confirmation of the mutants resulted in two new mutant constructs 
D267 + D261 (pNV1988) and D267 + E262 (pNV1990). Subsequent functional analyses of 
these constructs were carried out by transforming them into SFL1616 and testing for 
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Figure 5.6: Functional analysis of all mutations involving aspartic acid and glutamic acid 
residues that occur in GtrIV loop No. 6 partial deletion 3 (N251 to W269). a) LPS Western blot 
results. All mutant constructs were transformed into a serotype Y strain (SFLl 616) to test for 
modification of the O-antigen to serotype 4a. SFL2324 is GtrIV fused to PhoA/LacZ and then 
transformed into SFL1616. The binding of LPS to the antibody is indicative of serotype 
conversion from serotype Y to serotype 4a. All mutants, except for the DE261 +D267 triple 
mutant, were positive for serotype conversion to se:rotype 4a when probed with Type IV antisera. 
The LPS western blots confirm that the DE261 +D267 triple mutations abolish GtrIV function 
and this cease in function only occurs when all three residues (D261, E242 and D267) are 
mutated in tandem. b) Western blots (using anti-alkaline phosphatase primary antibody) 
performed on the membrane protein extractions of the various GtrIV point mutants that were 
fused to alkaline phosphatase. All the mutant constructs were detected when the membrane 
extracts were prob.ed with anti-alkaline phosphatase. This indicated that the mutant proteins 
( which are fused to PhoA/LacZ) are expressed and localized in the cellular membrane. 
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agglutination with S. flexneri Type IV antiserum (Table 5.3). Agglutination was observed for 
both mutants. This result was then confirmed by LPS western blots (Figure 5.6a) 
To determine whether the D267 + DE261 triple mutant had an effect on protein 
assembly, western blots using anti-alkaline phosphatase antibodies were carried out on the 
membrane protein extracts on all the double and triple mutants (Figure 5.6b ). The membrane 
protein western blots revealed that, as expected, all the mutants were found to be assembled on 
the bacterial membrane. This result indicates that the DE261 + D267 triple mutant had abolished 
the function of GtrIV without compromising its ability to localise in the bacterial membrane. 
5.5 Investigation into critical residues within the re-entrant loop 
Previous studies have predicted that the re-entrant loops present in members of the Gtr 
family are important in structural stability of their respective Gtrs. Furthermore, it is believed 
that the re-entrant loops confer flexibility to the Gtr proteins allowing their respective 
periplasmic N-terminal and C-terminal regions to come into contact and interact during serotype 
conversion (Korres & Verma, 2004, Ko1Tes & Verma, 2006). It was recently discovered that a 
praline residue, P194 of Gtrlc, when mutated, led to a non-functional Gtrlc (Wang A, Honours 
thesis 2011). P194 is the only praline residue present within the Gtrlc re-entrant loop. As GtrIV 
is the closest structural homologue to Gtrlc, it was found that a praline residue Pl 54 was present 
within the re-entrant loop of GtrIV (Figure 5.7). As such, this residue was mutated to investigate 
if it plays the same role in GtrIV as it does for Gtrlc. 
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Figure 5.7: Residues located within the re-entrant loops of Gtrlc and GtrIV. P194 is the only 
proline residue present in the re-entrant loop of Gtrlc. Likewise, it can be seen that Pl 54 is the 
only proline residue present within the GtrIV re-entrant loop. 
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By carrying out the same site-ditected mutagenesis protocol as above, pNV1917 (GtrIV 
fused with PhoA/LacZ) was used as a template for the PCR in conjunction with the primers 
P154AF and P154AR. Upon confirmation, the mutant construct, termed pNV1997, was then 
transformed into SFL1616 to test for GtrIV function. Slide agglutination tests with Type IV 
antisera were positive. Thus, the mutant GtrIV had retained its ability to convert serotype Y to 
serotype 4a. Therefore, this suggests that although both Gtrlc and GtrIV are structurally similar, 
the functions of their re-entrant loops are unique to each Gtr. As a result of this, different 
residues may be involved for the function of their respective re-entrant loops. 
5.6 Discussion 
Bioinformatics was of limited use in finding conserved residues between the Gtrs, due to 
the varying lengths of the Gtrs and the low homology between them. Another potential problem 
with bioinformatics analysis was the fact that the topology of GtrIV is different from the other 
Gtrs as it had a short cytoplasmic C-terminal end as compared to the long periplasmic C-terminal 
ends in the other Gtrs, thus giving rise to the hypothesis that the large periplasmic loop No. 6 of 
GtrIV is critical for function. Therefore, only the negatively charged residues (aspartic acid and 
glutamic acid) located throughout GtrIV were targeted as they have been found to be critical in 
other Gtrs (Lehane et al, 2005, Korres & Verma, 2006). 
A total of 22 site-directed mutagenesis experiments were conducted. All of them 
involved mutation of the target residues to alanine (no charge). This was important as replacing a 
negatively charged residue with a positively charged residue may affect the overall charge of the 
region and effect protein function (Ulmschneider & Sansom, 2001; Johansson & Lindahl, 2006). 
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Therefore, subsequent loss of GtrIV function would be due to the change in charge rather than 
the loss of the targeted amino acid. By replacing each charged amino acid to alanine, it allows 
the effect of their charged side chains on GtrIV to be observed. The first 11 mutagenesis 
experiments targeted all acidic residues ( aspartic acid and glutamic acid) located within 
periplasmic loops No. 2 and No. 6. The acidic residues D49, E58 and E67 located in the 
periplasmic loop No. 2 of GtrIV were targeted based on the belief that these negatively charged 
residues might be important in catalysis for the transfer and attachment of the glucosyl residue to 
the O-antigen as previously documented in glycosyltranferases (Breton and Imberty, 1996). 
Also, conserved aspartic (D) or glutamic (E) acid residues have been shown to reside within the 
active sides of enzymes such as lactose synthase (Gal-Tl) as well as the Bacillus subtifis 
glycosyltransferase SspA (Chamrock & Davies, 1999; Ramakrishnan & Qasba, 2001). Critical 
aspartic acid (D) residues have also been discovered in the Sinorhizobium meliloti 
glucosyltransferase ExoM (Garinot-Schneider et al., 2000). To add weight to the notion that 
negatively charged residues play important roles in glycosyltransferases, in recent times, critical 
aspartic acid residues were also discovered in glycosyltrasnferase AglD of Haloferax volcanii 
(Kaminski & Eichler, 2010). In addition, the discovery of a critical aspartic acid residue (D43) 
and its adjacent glutamic acid residue (E42) in GtrV, coupled with the discovery of a critical 
glutamic acid residue (E40) in GtrII (Lehane et al., 2005), seemed to point to a conserved 
element in the mechanisms of action of the Gtrs. However, all acidic residues in GtrIV loop No. 
2 along with the rest of the single mutations that are located in loop No. 6 were found to be non-
critical. Because of the major structural differences between GtrIV and the other Gtrs, this result 
was not surprising as GtrIV may have a different mode of action compared to the other Gtrs. 
Therefore, it is possible that the acidic residues within GtrIV loop No. 2 work together in tandem 
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with each other. This can be investigated by cumulatively knocking out each acidic residue 
present in loop No. 2. 
Loop No. 6 of GtrN was found to contain 15 acidic (negatively charged) residues that 
are spread throughout the loop. Korres & Verma (2006) have suggested that the acidic residue 
D380 in GtrV is important for GtrV function because it is believed to interact with the O-antigen 
to stabilise it so that the glucosyl residue can come in contact with the correct rhamnose. Based 
on this hypothesis, any one or more of the 15 acidic residues may perform this stabilising 
function in GtrN. There is also a possibility that these acidic residues compensate for the loss of 
the other acidic residues. This could account for the acidic residues DE261, ED283 and ED326 
being non-critical. This meant that the other acidic residues could be working in tandem with the 
already targeted residues. The loop deletion experiments carried out in Chapter 4 helped to 
narrow down the search for potential residues to 19 a1nino acids. Of these 19 amino acids, the 
further deletion experiments adjusted that focus to 9 residues. All the residues, when mutated 
individually (C263, 1264, 0265, V266 and W269) did not abolish GtrIV function. However, 
when the acidic residues within this region were mutated in tandem with each other, it was found 
that the DE261 + D267 triple mutant was non-functional. The membrane protein westerns 
revealed that this ti;-iple mutant was localised in the bacterial membrane. As such, this result 
strongly suggests that the residues D261, E262 and D267 are part of a catalytic site located on 
GtrN loop No. 6. Three acidic residues within GtrV (E42, D43 and D380) were found to be 
critical for its function (Korres & Verma, 2006). Of these three residues, E42 and D43 are 
located in loop No. 2 while D380 is located within the periplasmic C-terminal tail. It has been 
suggested that they may be involved in the formation of the active site and be responsible for the 
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specific al, 3 linkage that gives rise to serotype 5a, while the re-entrant loop with specific 
rotational movements brought about by specific amino acid interactions is able to facilitate the 
addition of the glucosyl residue to the correct rhamnose of the O-antigen (Korres & Verma, 
2006). In the case of GtrIV, residues D261, E262 and D267 may be responsible for the specific 
al, 6 linkage that gives rise to serotype 4a. Indeed, this would explain why the all the acidic 
residues that were targeted in the periplasmic loop No. 2 did not have an effect of protein 
function unlike other members of the Gtr(type) family. In addition, this could also be the reason 
why GtrIV has this unique feature of the paired negatively charged residues occurring within 
periplasmic loop No. 6. 
Apart from periplasmic loop No. 2 and No. 6, the re-entrant loop was another source of 
interest, albeit a brief one. Previous studies on Gtrlc showed that P 194 was critical for its 
function (Wang A, Honours Thesis 2011 ). It was hypothesised that it may be part of a "hinge" 
mechanism that allows loop No. 2 and loop No. 10 of Gtrlc to interact with each other. With this 
in 1nind, we sought to test the function of P 154 of GtrIV as it may be carrying out a similar role 
in this protein. This was the only proline residue within the re-entrant loop, similar to Gtrlc 
(Pl 94). Studies have indicated that proline residues act as a structural disrupter of secondary 
protein structures such as alpha helices and beta sheets (Williamson, 1994). In addition, proline 
residues have been considered a dominant factor for the stability of thermophile enzymes by 
improving the potential of hydrophobic interactions (Suzuki et al., 1991). When these facts are 
considered, it hinted that P154 may be vital for the stability of GtrIV when it undergoes the 
conformational change during its catalytic activity. However, when P154 was mutated to alanine, 
the resulting mutant was still. functional thus further underlining the fact that though GtrIV and 
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Gtrlc are close structural homologues, each protein has evolved such that they have unique 
modes of action and their re-entrant loops may play different roles with regard to O-antigen 
glucosylation. 
5. 7 Conclusion 
A total of 20 negatively charged amino acids that occur throughout GtrIV were mutated 
to alanine to investigate their role in GtrIV function. When mutated individually, they did not 
have an effect on protein function. However, three of these acidic residues D261, E262 and 
D267, when mutated in tandem, were found to abolish function of GtrIV. They are located in the 
periplasmic loop No, 6 and are thought to be involved in the interaction with the donor and 
acceptor substrates that help confer serotype specificity in O-antigen glucosylation. A proline 
residue (P154) located within the re-entrant loop was found to be non-critical. This study has 
provided a strong hint that the unique occurrence of the paired acidic residues located within 
GtrIV loop No. 6 may be working in tandem with the other acidic residues within their vicinity 
to form a potential catalytic site(s). Identifying these sites will be crucial to understanding the 
mode of action this topologically unique enzyme. 
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6.1 Introduction 
There are very few biochemical properties that distinguish Shigella from enteroinvasive E. 
coli (EIEC), which are also a major cause of dysentery (Yang et al., 2005). Indeed, some O-antigens 
associated with EIEC are identical to those found in Shigella spp (Cheasty and Rowe, 1983). It is 
also well documented that many plasmid-associated virulence determinants are common in both 
EIEC and Shigella (Lan et al. , 2001). Yang et al (2005) have reported that the Shigella 
chromosomes share most of their genes with that of E. coli K-12 strain MG1655, but there is 
extensive diversity of putative virulence genes, mostly acquired via bacteriophage-mediated lateral 
gene transfer (Yang et al., 2005). Conversion evolution involving gain and loss of functions, 
formation of pseudogenes, insertion sequence (IS) mediated DNA rearrangements and 
bacteriophage-mediated gene acquisition has seen Shigella spp. evolve to become highly specific 
human pathogens with variable epidemiological and pathological features (Yang et al., 2005). 
The association between O-antigen modification and temperate bacteriophages in S. flexneri 
has been known for many years. Although the bacteriophages characterized to date are 
morphologically diverse, in all cases, the O-antigen modification genes are located immediately 
downstream of the phage attP site, which is preceded by the int and xis genes in the bacterial 
chromosome (Verma et al., 1993; Bastin et al., 1997; Huan et al. , 1997 a & b; Mavris et al., 1997; 
Adhikari et al., 1999; Guan et al., 1999; Allison & Verma, 2000). Guan and Verma (1998) 
demonstrated the role played by bacteriophage mediated serotype conversion by successfully 
inserting a serotype conversion gene cluster into the chromosome of SFL124 through the use of a 
bacteriophage-based site-specific integration system. By cloning an integrase gene (int) , an 
attachment site (attP) and a glucosyl transfer gene cluster from bacteriophage SfX into a suicide 
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vector, and subsequently introducing it into SFL124, they obtained a S. flexneri strain that expressed 
serotype X somatic antigen specificity (Guan & Verma, 1998). Recently, Sun et al., (2011) sought 
to reveal possible roles played by the serotype-converting phages in the emergence of new serotypes 
in nature by engineering a novel serotype, named serotype 1 d through the infection of S. flexneri 
serotype X strains with a Sfl phage or by sequential infection of serotype Y strain with SfX and Sfl. 
Apart from bacteriophage mediated genetic transfer, the Shigella chromosome contains 
numerous IS elements and markers of genomic rearrangements (Buchrieser et al., 2000; Jin et al., 
2005). IS elements are ubiquitous in bacterial genomes and important factors in evolution (Badia et 
al., 2006). The IS insertion can cause gene inactivation, activate cryptic genes or alter the expression 
of adjacent genes. Roberts et al. (2005) reported that the presence of an IS element interrupted and 
inverted serotype 2a serotype-conversion locus within the chromosome of SFL124 (serotype Y), 
thus indicating that this strain was derived from a serotype 2a background. 
Adams et al (2001) have described a glucosylation cassette that generates the serotype 4a in 
S. flexneri in E. coli K12. Even though serotype 4a in S. flexneri is thought to be brought about by 
the temperate bacteriophage SfIV, its isolation and characterisation has proved elusive. Thus far, I 
have managed to experimentally establish the topology of GtrIV. At the same time, site-directed 
mutagenesis and loop deletions have allowed us locate a potential active site within this protein. 
However, at the present time, not much is known about the serotype 4 strains that are circulating in 
the wild. Therefore, I sought to investigate the genetic diversity of the wildtype serotype 4 strains 
( 4a and 4b) that have been isolated from developing countries such as Vietnam and Bangladesh and 
also in rural parts of Japan. The main purpose of this study was to gain an insight into the evolution 
.. 
of the wildtype serotype 4 strains circulating within these regions. In short, I wanted to determine if 
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there was any genetic variation of the gtrIV gene amongst the different isolates. By doing so, it 
would enable me to carry out comparative analysis to establish the level of genetic variation of gtrIV 
occurring within each region. At the same time, I also wanted to determine whether the level of 
diversity (if any) was region specific or common to all the wildtype strains regardless of where they 
were isolated from. Another key insight to be gained would be the fact that if gtrIV mutations are 
seen to occur within each strain, without affecting GtrIV function, it would help us narrow down our 
search for residues critical for the protein's function. Identification of genetically variant serotype 4 
-strains may also provide us with potential candidates for the isolation and characterization of the 
cryptic SfIV. 
6.2 Confirmation of serotype 4 strains through slide agglutination 
Currently in our laboratory strain library, out of the two hundred odd strains isolated from 
Vietnam, Bangladesh and Japan, 28 of them were typed as serotype 4a, 4b or just serotype 4. These 
strains of interest were streaked out from their glycerol stocks onto LB agar plates. A series of slide 
agglutination tests were carried out on the strains to confirm their serotypes. Table 6.1 lists the 28 
different strains and their slide agglutination results against Type IV antisera (Denka Seiken). A 
total of 21 strains displayed agglutination to Type IV antisera. The remaining 7 strains (SFL1304, 
SFL1328, SFL2183, SFL2187, SFL2193, SFL2234 and SFL2265) did not agglutinate with Type IV 
aritisera. As typical serotype 4a strain agglutinates to both Type IV and Group 3, 4 antisera, slide 
agglutination assays were also carried out against Group ·3, 4 antisera. From Table 6.1, it can be seen 
that 8 out of the 12 strains tested as Type IV positive strains isolated in Vietnam also agglutinated 
with Group 3, 4 antisera. In contrast, SFLl 714, SFLl 767, SFLl 768 and SFLl 769 (all isolated from 
Vietnam) did not agglutinate .with Group 3, 4 antisera. Similarly, all the Bangladeshi strains except 
SFL1523 also failed to agglutinate with Group 3, 4 antisera. As for the Japanese strains, SFL1294 
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Table 6.1: Summary of slide agglutination, PCR and Southern blot results of wildtype S.flexneri 
strains originally typed as serotype 4a, 4b or 4 against the various antisera 
SFL1254 4a + + - - -
- + + SFL1255 Control 4b + + + - + - - -SFL1294 4a + + - - -
- + + SFL1295 4a + + - - -
- + + SFL1304 4a - + 
SFL1305 Japan 4b + + + - - - - -SFL1314 4a + - - - - - + + SFL1328 4a - + 
SFL1522 4 + - - -
-
- + + SFL1523 4 + + - - -
- + + SFL1524 Bangladesh 4 + - -
- - - + + SFL1525 4 + - - -
- - + + SFL1526 4 + - - -
-
- + + SFL1714 4a + - - -
-
- + + SFL1758 4 + + - - - - + + SFL1767 4a + - - -
-
- + + SFL1768 4a + - -
-
- - - + + SFL1769 4a + - -
-
- - + + SFL2175 4a + + - - - - + + SFL2176 4a·· + + - - - - + + SFL2178 4a + + - -
- - + + SFL2179 Vietnam 4a + + - - -
- + + SFL2180 4a + + - -
-
- + + SFL2183 4 - + 
SFL2187 4a - + - - -
- + + SFL2193 
· 4a - + 
SFL2234 4 
SFL2241 4a + + - -
- - + + SFL2265 4a 
SFL2271 4a + + - -
- - + + 
+ depicts a positive agglutination result 
- depicts a negative agglutination result 
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and SFL1295 agglutinated with Group 3, 4 while SFL1305 and SFL1314 did not. LPS western blots 
were carried out against Group 3, 4 antis era and confirmed the slide agglutination results of those 
particular strains (results not shown). As some of the strains were originally typed as serotype 4, this 
meant that they could have also been serotype 4b strains, which are characterized by agglutination to 
Type IV and Group 6 antisera. At the same time, they do not agglutinate with Group 3, 4 antisera. 
This meant that all the strains that agglutinated with Type IV antisera but not Group 3, 4 antisera 
might be serotype 4b. As a result of this, all the strains were tested against Group 6 antisera and 
were found to be non-reactive. 
Failure to agglutinate to Group 3, 4 antisera suggests that one of rhamnose sugars of the O-
antigen may be carrying another modification. Therefore, all the Type IV positive strains that did 
not agglutinate with Group 3, 4 were tested against the Group 7, 8, Type II and Type V antisera. 
Type I antisera was not used as the N-acetylglucosamine unit is already modified with a glucosyl 
residue that gives rise to Type IV modification. From table 6.1, it can be seen that all the strains 
were negative for agglutination against the additional antisera. If agglutination had occurred against 
any of these antisera, for example Type II, this meant that the O-antigen of that particular strain had 
glucosyl groups attached to the N-acetylglucosamine (Type IV modification) as well as rhamnose I 
(type II modification). However, it is also possible that the presence of additional modification 
together with Type IV O-antigen modification would have prevented the other serotype specific 
antisera from recognising it. In other words, although the Type IV antibodies were able to recognize 
the Type IV modification, the O-antigen could not be recognised by the other antisera even if their 
respective modifications were present due to the glucosyl group attached to the N-
acetylglucosamine. As such,_ a negative result for the slide agglutination would not necessarily mean 
that other O-antigen modifications are not present. The results in table 6.1 show that 2 strains 
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(SFL2234 and SFL2265) were negative to all serotypes and thus, were tested against Poly B antisera 
to confirm that they are S. flexneri to begin with and not some other errant strains caused by 
contamination on the agar plates ( as they were grown on plain LB agar plates without any antibiotic 
selection markers). 
6.3 Analysis of gtr/V sequences obtained from the wild type strains 
Upon confirmation of the presence of GtrIV in most of the wildtype strains, the next aim of 
this study was to analyse the nucleotide sequences of gtrIV within all these strains and compare 
them with the known gtrIV sequence. This would help us identify any possible mutations that may 
be present within the strains. Such analysis would help in identifying more critical residues. Hence, 
the 8 strains that did not agglutinate to Type IV antisera were of particular interest as successful 
amplification of gtrIV within these strains would indicate that the gene may possess critical 
mutations that abolished GtrIV function. The main strategy to obtain the gene sequences involved 
the use of colony PCR. After all the strains were streaked out onto LB agar, DNA was extracted as 
described in Section 2.3 .2.1. Amplification of gtrIV was carried out with the help of the primers 
pGEXBamHIF and pGEXXhoIR. From the resulting colony PCR, gtrIV amplification was seen in 
all strains except SFL1304, SFL1328, SFL2183, SFL2193, SFL2234 and SFL2265 (Figure 6.1). 
Since these strains had negative colony PCR results and failed to agglutinate against Type IV 
antisera, it can be concluded that they to do not have gtrIV. The PCR products of the other 22 strains 
were excised from 0. 7% agarose gel, purified and sequenced. Following this, the nucleotide 
sequence of each strain was aligned (using clustalW) with the gtrIV nucleotide sequence obtained 
from control wildtype serotype 4a (NCTC 8296). Similarly, the nucleotide sequences from each 
strain were translated into l;lmino acid sequences and aligned against the GtrIV sequence. The results 
for each strain are summarised in Table 6.2. It was found that most of the strains contained 2 or 
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Figure 6.1: Example of gel electrophoresis results of colony PCR carried out on the wildtype 
serotype 4 strains. Colony PCR was carried out on the 29 type 4 strains with the help of gtrIV 
specific primers. gtrIV amplification was seen on 21 of those strain_s. The gel photo above 
depicts positive amplification of gtrIV (1.3 . kb) from all 5 strains isolated from Bangladesh. 
SFL1253 (S. flexneri serotype 4a strain NCTC 8296) was used as the positive control. 
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Table 6.2: List of point mutations discovered within the various wildtype strains 
Nucleotide , 
Mutation 
gat ➔ gag 
aat ➔ tat 
0146 ➔ E 
I159 ➔ V · 
N231 ➔ Y 
No mutations 
All point mutations are highlighted in red. 
All Japan strains are in blue font. 
All Bangladeshi strains are in brown font 
All Vietnamese strains are in black font 
TM VIII= Transmembrane l,lelix VIII 
~ 
SFL2187 
· SFl1S22, SFL1769 
SFL1294, SFL1295, Sfl1525, SFL1767, 
SFL2175, SFL2176, SFL2179, SFL2180, 
SFL2271 
Re-entrant loop 
-~f~n!f;~~nt,1~~,:~,: 
Re-entrant loop 
toopNo. 6 
Loop No. 6 
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more point mutations that altered the amino acid composition of the resulting GtrIV. At the same 
time, there were a number of strains that bore no mutations and lined up perfectly with the Genbank 
sequence. It was also seen that there were no unique mutations found in any of the strains, with 
mutations being common amongst two or more strains. From the sequencing results, no distinct 
pattern of mutations was observed as the common mutations were not confined to strains isolated 
from the same region. 
With regards to SFL2187 ( did not agglutinate with Type IV antisera), it was found to contain 
3 unique mutations. All three mutations were found to occur within the re-entrant loop of GtrIV. As 
a result of this, a further test was required to prove that the mutations were indeed responsible for 
SFL2187's loss of GtrIV function, thus highlighting the importance of the re-entrant loop. pBCSK 
was blunt-end digested with Smal and the purified PCR product from SFL2187 was ligated with the 
digested vector and transformed into XLl-blue cells. With the help of blue-white screening, 5 
colourless (white) colonies were picked and sequenced to confirm that gtrIV of SFL2187 was 
inserted in the correct orientation. Following this, the plasmid ·was extracted from this clone and · 
transformed into SFL1616. This strain already contains gtrA and gtrB. Slide agglutination test using 
Type IV antisera was carried out and agglutination was evident. Thus, suggested that the lack of 
Type IV O-antigen modification witnessed in SFL2187 could have been due to an erroneous gtr A or 
gtr B rather than gtr IV 
6.4 Southern hybridization of the serotype 4 strains 
Although a serotype-converting phage ( the cryptic SflV) could not be· isolated from S. 
flexneri serotype 4a strains_, Adams et al (2001) managed to isolate and characterise the O-antigen 
modification genes from the S. flexneri serotype 4a strain NCTC 8296. The 3.8kb. chromosomal 
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fragment from NCTC 8296 contained all three serotype conversion genes. It was isolated through 
restriction digestion of the chromosomal DNA with BamHI (Figure 6.2). Until now however, not 
much is known about the rest of the S. flexneri 4a genome and its elusive phage SfIV. Using NCTC 
8296 (SFL1253) as a control, I sought to carry out a set of Southern hybridization experiments to 
determine if this fragment was of the same size in the other strains. The results from this would 
serve two purposes. Firstly, a difference in size would highlight the possibility of differential gene 
arrangement occurring within that particular strain. In parallel, it would also confirm the slide 
agglutination results and whether those negative strains actually contained gtrIV to begin with. To 
achieve this, genomic DNA was extracted from all the 28 strains (see Section 2.2.3). Once their 
yield was confirmed via agarose gel electrophoresis, they were digested with BamHI. The digested 
genomic DNA was then run on gel again and transferred onto a nitrocellulose membrane. The probe 
used was gtrIV amplified from pNVl 4 73 (Exo III template). A total . of l µg of gtrIV was labelled 
with the DIG easyHybrid probe. Once the probe had been prepared (see Section 2.16.2), the 
Southern blots were carried out as described in Section 2.16. The BamHI digests and the subsequent 
Southern blot results are shown in Figures 6.3 and 6.4. As the loading wells had collapsed, the 
results of SFL2271 are not shown in these two figures. The Southern results for the other samples, 
however, yielded results that were mostly expected. Single bands (3.8 kb in size) were seen for most 
of the strains that agglutinated against Type IV antisera while no bands were visible for strains 
negative for Type IV agglutination. Three strains, SFLl 314 (Japan), SFL 1522 and SFLl 526 (both 
Bangladesh) displayed ~ 10kb bands similar to the serotype 4b control rather than the 3 .8kb band 
seen in the serotype 4a control. This suggests that the three strains could have been serotype 4b 
strains originally and perhaps lost function of their O-acetyltrasferase (Oac ). Indeed, the lack of 
agglutination against Group 6 antisera (Oac specific) supports this idea. All the strains that did not 
display bands were subject to a repeat Southern blot to confirm the absence .of gtrIV within those 
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Figure 6.2: Illustration of the 3.8 kb chromosomal fragment that results from BamHI digestion 
of the genomic DNA ofNCTC 8296 (SFL1253). The fragment contains the Type N 
glucosylation cassette (gtrIV cassette). As such, this strain will be used as a control for all the 
Southern hybridization experiments. The Sphl site is located in the middle of gtrIVand this 
' 
digest can be us~d to investigate the genetic arrangement of the wild type serotype 4a strains 
upstream and downstream of gtrIV 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 
a) 
1. SFL 1253 (4a control) 
2. SFL 1255 ( 4b control) 
3. SFL 1294 (Japan) 
4. SFL 1295 (Japan) 
5. SFL 1304 (Japan) 
6. SFL 1305 (Japan) 
7. SFL1314(Japan) 
8. SFL 1328 (Japan) 
9. SFL 1522 (Bangladesh) 
10. SFL 1523 (Bangladesh) 
11. SFL 1524 (Bangladesh) 
12. SFL 1525 (Bangladesh) 
13. SFL 1526 (Bangladesh) 
14. SFL 1714 (Vietnam) 
1 2 19 20 21 22 23 24 25 26 27 28 29 
15. SFL 1758 (Vietnam) 
16. SFL 1767 (Vietnam) 
b) 17. SFL 1768 (Vietnam) 
18. SFL 1769 (Vietnam) 
19. SFL2175 (Vietnam) 
20. SFL2176 (Vietnam) 
21. SFL2178 (Vietnam) 
22. SFL2179 (Vietnam) 
23. SFL2180 (Vietnam) 
24. SFL2183 (Vietnam) 
25. SFL2187 (Vietnam) 
26. SFL2193 (Vietnam) 
27. SFL2234 (Vietnam) 
28. SFL2241 (Vietnam) 
29. SFL2265 (Vietnam) 
Figure 6.3: Geµ.omic DNA of the 27 wildtype strains (excluding SFL2271) digested with 
BamHI. All the digests were run on 0.7% agarose gels. For each digest, ~0.5 µg of genomic 
DNA was used. The 4a control for both gels is SFL1253 (NCTC 8296) while the 4b control used 
is SFL1255. The DNA for SFL2180 (lane 23) ran out of the well and as a result, the yield seen in 
the gel is low as compared-to the other digests. 
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Figure 6.4: The BamHI digested genomic DNA from Figure 6.3 was subjected to Southern 
hybridization with DIG-labelled gtrIV probe. a) Apart from the 4a and 4b controls, 7 strains 
displayed banding. Bangladeshi strains SFL1523, 1524 and 1525 had 3.8 kb bands similar to 
SFL1253 (4a control) along with SFLl 714 (Vietnam). On the other hand, SFL1314 (Japan), 
SFL1522 and 1526 (both Bangladesh) have bands (-..,10 kb) that are similar to SFL1255 (4b 
control), indicating that these strains are possibly 4b strains that have lost O-acetyltransferase 
function. b) 7 strains, apart from the 4a and 4b control displayed 3 .8 kb bands similar to SFL 
1253 ( 4a control). The faint band seen for SFL2180 (lane 23), corresponds to the low amount of 
DNA seen in Figure 6.3. 
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strains. This repeat also included SFL2271 (Figure 6.5a and b ). Another repeat was also carried out 
for SFL1305 (Figure 6.5c). It was seen that all the Type IV positive strains displayed 3.8kb bands 
under chemiluminsence, while all the Type IV negative strains were negative for hybridization to 
the gtrIV probe. The negative results confirm the absence of gtrIV within these Type IV negative 
strains. 
In order to investigate the genetic arrangement of the type 4 chromosomal DNA upstream 
and downstream of gtrIV, a set of SphI restriction digests were carried out as well. From Figure 6.2, 
it can be seen that within the gtrIV glucosylation cassette, there is only one SphI site which lies in 
the middle of gtrIV. Thus, digesting the genomic DNA with SphI would cut gtrIV in half. Since 
there is no available sequence information about the type 4 strains apart from the gtr cassette, 
carrying out this Southern would allow us to visualise if the genes upstream and downstream of this 
cassette in all the wildtype serotype 4 strains are arranged in a similar manner. At the same time, if 
one of the strains displayed a banding pattern that· was larger than the rest, it might indicate the 
presence of the phage SflV and that strain would be a prime candidate for phage induction. The SphI 
digests and the subsequent Southern blots however, were inconclusive due to incomplete genomic 
DNA digestion (results not shown). The experiment was repeated once again but due to time 
constraints, the process could not be optimised. 
6.5 Discussion 
The work of Adams et al (2001) in characterising the 3.8 kb glucosylation cassette ofNCTC 
8296 (wildtype serotype 4a) has paved the way for the elucidation of GtrIV topology and also, for 
the identification of critical segments within this protein. The emergence of new S. flexneri 
serotypes, as well as the current serotype diversity witnessed in S. flexneri could mean that the 
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Figure 6.5: Repeat of BamHI digests of genomic DNA and the subsequent Southern blot 
analysis. a) Genomic DNA from the strains that gave a negative result during the first round of 
Southern blots were digested with BamHI in preparation for Southern hybridization. The 4a 
control SFL1253 leaked out of the well during loading of the samples and as a result, not much 
DNA was left. b) Southern hybridization with DIG-labelled gtrIV probe was carried out on the 
digests. This time, all strains that exhi~ited agglutination against type N antisera displayed 3.8 
kb bands while all strains negative for type IV agglutination did not display any banding, thus 
confirming the absence of gtrIV within those strains. As expected, no band was seen for the 4a 
control while the 4b control exhibited a ,.._,10 kb band. c) The genomic DNA for SFL1305 was 
digested again with BamHI and the Southern was repeated, yielding a 3.8 kb band. 
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naturally occurring serotype 4 strains may have originally been of a different serotype and 
eventually became serotype 4a. 
Twenty-eight wildtype strains that were originally typed as serotype 4 were isolated from 
Bangladesh, Japan and Vietnam. To confirm their Type IV 0-antigen modification, they were 
subjected to slide agglutination assays against Type IV antisera. Twenty one strains were positive 
for agglutination while 8 strains were found to be negative. Of the 21 strains that carried the Type 
IV 0-antigen modification, 10 strains (4 from Bangladesh, 4 from Vietnam and 2 from Japan) did 
not display agglutination against Group 3, 4 antisera, uncharacteristic of typical serotype 4a strains. 
As seen in Figure 6.6, the serotype 4a 0-antigen consists of a single glucosyl residue attached to the 
N-acetylglucosamine of the 0-antigen repeat unit via an a 1, 6 linkage. It is this modification that is 
recognised by the Type IV antisera. The remaining sugars that make up the rest of the repeating 
tetrasaccharide unit, · rhamnose I, II and III, are unmodified. Thus, allowing the 0-antigen to be 
recognised by the serotype Y (unmodified 0-antigen) specific Group 3, 4 antisera. The absence of 
agglutination against Group 3, 4 antis era may be indicative of the presence of further 0-antigen 
modification caused by additional glucosyltransferases (GtrI, GtrII, GtrV or GtrX) that have 
glucosylated the 0-antigen in conjunction with GtrIV. By carrying out the slide agglutination assays 
against the other.available antisera (type I, type II, type V, Group 7,8), the 10 strains were tested for 
the potential presence of any additional Gtr(type), making them novel serotypes. Recently in China, a 
study was carried out that described a S. flexneri isolate from China agglutinating with anti-IV type 
antiserum and anti-7, 8 Group antisera, indicating that this isolate possibly contained gtrIV and gtr X 
(Ye et al., 2009). However, using monoclonal antibodies, the serotype also agglutinated with group 
antigen-specific monoclonal antibody MASF IV-1 but not with serotype 4 type-specific antibody 
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MASF IV-2 while sequencing data revealed that only gtr X was present in the genome (Ye et al., 
2009). This serotype X variant was dubbed SFxv and was claimed to be a new serotype 
Although agglutination against one of the serotype-specific antisera would have immediately 
confirmed the presence of the Gtr(type) responsible, the lack of agglutination does not mean that no 
other Gtr(type) or any other unknown modification factor is present. This is because the additional O-
antigen modification, in addition to Type IV modification, would have rendered the O-antigen to be 
undetectable by the respective serotype specific antisera. Unlike the agglutination patterns witnessed 
by SFxv, in the past, an uncommon serotype of S. flexneri type 4 was detected within Dhaka 
(Bangladesh) that showed a conflicting agglutination pattern by only reacting with serotype 4 
specific antiserum and not with any other type- and group- specific antisera (Talukder et al., 2001; 
Talukder et al., 2002). Recently, in Korea, 3 isolates were found to have displayed a reaction with 
only Type IV antisera and did not bind with any of the grouping sera (Hong et al., 2010). Both these 
cases mirror the agglutination patterns of the 10 test strains and could indicate they may in fact be a · 
new subserotype of S. flexneri. Qiu et al. ·(2011) have also reported the presence of a S. jlexneri 
isolate that displayed atypical agglutination patterns. This isolate was dubbed "serotype 4s" as it 
reacted strongly only with monovalent anti-MASF IV-type antisera but not with any group-specific 
antisera. Thus, indicating that it was a new· subserotype of S. jlexneri 4 (Qiu et al., 2011). Based on 
our slide agglutination results, there is a possibility that one or alt of the 10 wild type strains isolated 
from Bangladesh, Japan and Vietnam may in fact be the same subserotypes of S. flexneri type 4. 
Further tests should be carried on these strains to gain confirmation. Serotyping via slide 
agglutination in the lab was performed using commercial S. jlexneri antiserum (Denka Seiken, 
Tokyo, Japan). It would .. be ideal to carry out the slide agglutination assays using a panel of 
monoclonal antibodies against S. flexneri specific to all S. jlexneri type and group antigens. Another 
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set of interesting results seen from Table 6.1 was the fact that 2 strains, SFL2234 and SFL2265 were 
not reactive to all the test antisera. They were subject agglutination against Poly B antisera to 
confirm that they were indeed S. flexneri strains. Since these strains were grown on plain LB agar 
plates without any antibiotic selection markers, there is a distinct possibility that a contaminant 
colony could have been picked out and preserved. SFL2234 tested positive for Poly B agglutination 
while SFL2265 was negative (results not shown). This meant that while SFL2234 was indeed a S. 
flexneri strain, SFL2265 was not. SFL2234 was also seen to be negative against Type I agglutination 
meaning that there was a possibility that this was a new serotype. Alternatively, SFL2234 may be a 
rough strain. To confirm this, LPS analysis will be required. 
Apart from the crude slide agglutination experiments, the presence of gtrIV was confirmed 
by colony PCR and the resulting sequences obtained from the amplified DNA did not vary too much 
from the gtrIV nucleotide sequence obtained from the control wildtype serotype 4a strain (NCTC 
8296). gtrIV sequence data obtained from the Type lV negative strains would have been beneficial 
in helping us identify critical mutations within gtrIV. The lack of a PCR product for the strains that 
did not display agglutination against Type IV antisera suggested that gtrIV may not have been 
present within these stains in the first place. This was confirmed through the Southern blots. The 
gtrIV sequences 9btained from the rest of the wildtype strains were found to contain several point 
mutations when aligned with the GFenbank gtrIV sequence (Table 6.2). A total of 9 mutations were 
discovered among the strains. When mapped collectively, these mutations occur mainly within the 
re-entrant loop and loop No. 6. It is worth noting that all the mutations, except that of SFLl 523 and 
SFL2187, were found to occur in at least two strains. These strains all shared the same nucleotide 
point mutations that altered the resulting amino acid sequence. In all cases, the strains that shared 
the same mutation did not originate from the same country. The mutations D 146~ E 146 and 
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N231 ~ Y231 were observed in 8 strains and 7 strains, respectively. D 146 is located on the 
periplasmic face of the re-entrant loop of GtrIV while N231 occurs at the start of GtrIV loop No. 6. 
From the sequence data obtained, the two mutations that generated some interest were that of 
E254~K and E283~K. Both these mutations involved a negatively charged amino acid within loop 
No. 6 of GtrIV. In both cases, the strains bearing the respective mutations displayed agglutination 
against Type IV antisera, indicative of a functional GtrIV. This result reinforced the site directed 
mutagenesis results from chapter 5 which showed that when mutated individually, negatively 
charged amino acids within GtrIV loop No. 6 do not affect the function of GtrIV. 
SFL2187 was found to have three mutations that occurred within the re-entrant . loop of 
GtrIV. As mentioned in section 6.3, these mutations were initially thought to be critical mutations 
because of the strain' s failure to display agglutination against Type IV antisera despite the fact that 
colony PCR was successful in amplifying gtrIV within SFL2187. However, when the amplified 
gtrIV from SFL2187 was sub-cloned into pBCSK and transformed into SFL1616 (which contains 
gtrA and gtrB in a separate plasmid), agglutination against Type IV antisera was restored. As such, 
this strongly suggests that the mutations carried by SFL2187 are not critical for GtrIV function and 
that this strains ~arries a defective gtrA and/or gtrB, thus underline the important role played by gtrA 
and gtrB in serotype conversion. 
The Southern blot results showed that the strains negative for agglutination against Type IV 
antisera, apart from SFL2187, were not carrying gtrIV and thus, may have been mistakenly typed as 
serotype 4 strains or they may have lost the SflV prophage during laboratory culture. Of the 
remaining 22 strains, two qifferent band sizes were seen when the genomic DNA was digested with 
BamHI. A 3 .8kb band was witnessed in 19 of the serotype 4 strains. This band size matched up with 
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the expected 3.8kb fragment containing the gtr cassette that is flanked by BamHI restriction sites. 
SFL1314 (Japan), SFL1522 and SFL1526 (both Bangladesh) exhibited single bands of ,__,l0kb in size 
similar to the serotype 4b control (SFL1255). This suggests that these three strains could possibly be 
of serotype 4b origin and through time, lost the ability to O-acetylate the O-antigen. From figure 6.6, 
it can be seen that serotypes 4a and 4b differ by the addition of an O-acetyl group to the rhamnose 
III sugar of the O-antigen. This modification is mediated by O-acetyltransferase (Oac) which is 
encoded by the gene oac. O-acetylation occurs independently and does not require a glucosylation 
cassette, unlike GtrIV. Hence, the Southern hybridization experiments suggest that through the loss 
of gene function ( oac ), the serotype 4b strains have become serotype 4a. Several experiments can be 
carried out to confirm the presence of oac. One can attempt to amplify this gene through PCR and 
any amplification witnessed would be proof of oac presence. The loss of oac function could be 
attributed to deletions and pseudogenes, which are effective mechanisms that contribute to loss of 
function (Yang et al. / 2005). Such gene decay or reductive evolution is noted to be an important 
evolutionary mechanism for obligate intracellular pathogens such as Mycobacterium leprae (Cole et 
al., 2001). The loss of gene functions for adaptations and convergent evolution has also been 
documented within Shigella. The inactivation of ompT (encodes for the surface protease OmpT) and 
cadA (gene encoding lysine decarboxylase) genes have increased the pathogenicity of Shigella 
(Nakata et al., 1993; Sakellaris et al., 2000; Lan and Reeves, 2002). In the case of opmT, a gene 
present in E. coli K-12, the presence of the surface protease OmpT, was found to attenuate the 
virulence Shigella by degrading the IcsA (VirG) protein (Nakata et al., 1993; Sakellaris et al., 
2000). IcsA (VirG) is required for actin-based movement within infected cells (Goldberg et al., 
1993; Goldberg & Theriot, 1995). 
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The Southern hybridization experiments were carried out in order to visualise the 3 .8 kb 
glucosylation cassette present within wild type serotype 4a. Therefore, in theory, seeing as oac is 
independent of this cassette, the same sized band should have been picked up from all the strains 
regardless of serotype. The oac gene coding for the O-acetylation factor is carried by the temperate 
bacteriophage Sf6 of S. flexneri (Thanweer et al., 2008). As such, this may account for the 
difference in size of the bands witnessed as the insertion could have occurred in the region that of 
the genomic DNA that contains the Bamm restriction site. Alternatively, as allelic variations in 
bacteria arise from random mutations, point mutations would have occurred in the genome such that 
one of the BamHl restriction sites may have been destroyed. This occurrence is termed as single 
nucleotide polymorphisms (SNPs). SNPs are a DNA sequence variation occurring when a single 
nucleotide in the genome ( or other shared sequence) differs between members of a species (Barreiro 
et al., 2008). By this virtue, it is plausible to speculate that the same random mutations could have 
caused another BamHl site to be generated much further upstream/ downstream of the gtrIV 
cassette, giving rise to a much larger band. Similarly, without further confirmation for the presence 
of oac, it may also be that the three strains are actually serotype 4s strains carry mutations on their 
BamHl sites and as a result, generated larger Ba,nHl digest fragments. 
By subjecting the genomic DNA of the wildtype strains to Sphl digests, with the help of 
Southern hybridization, it would enable visualisation the sort of genetic arrangement present 
upstream and downstream of the gtrIV cassette. By comparing the various arrangements, I might 
have been able to determine the strain that still may have had the cryptic bacteriophage SflV 
embedded within its chromosomal DNA. Therefore, had the Sphl Southerns been successful, 
comparisons could have byen made among the strains. Another way to carry out such comparisons 
is through genome sequencing and is described in more detail in the discussion (Section 7.3). 
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6.6 Conclusion 
Twenty eight wildtype strains isolated from Japan, Bangladesh and Vietnam that were typed 
as serotype 4a, 4b or just 4 were subjected to a series of slide agglutination experiments to confirm 
their serotype. A number of strains had atypical agglutination patterns and thus highlighted the 
possibility that they are potentially new serotypes or subserotypes. Colony PCR was also carried out 
and the amplified DNA from the PCR reactions were sequenced and aligned to the control wildtype 
4a strain SFLl 253 (NCTC 8296). The sequences obtained revealed the presence of point mutations 
within several strains, although I was not able to identify mutations that were detrimental to the 
function of Gtrry. Southern blots carried out using DIG-labelled gtrIV revealed that two different 
serotype 4a strains, with the possibility of one of them being originally a 4b strain, have been 
circulating within these populations. A further attempt to elucidate the genetic arrangement of these 
-. 
strains proved to be unfruitful. Taken together, this preliminary study has highlighted the possibility 
of 2 serotype 4a strains currently circulating in Vietnam, Bangladesh and Japan. This study has 
provided valuable information for further investigation into the evolution of one of the most 
important human pathogens. 
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The LPS of S. jlexneri is an important virulence factor required for protection against host 
defences (Oaks et al., 1985; Hong & Payne, 1997; Schroeder & Hilbi, 2008). It is therefore 
paramount that the development of a multi-valent live attenuated vaccine is dependent on the 
creation of a single S. jlexneri strain with a LPS that elicits immunogenic responses for more than 
one serotype. To achieve this, the mechanism of O-antigen (LPS component) modification, which 
results in serotype conversion, must be clearly understood. O-antigen modification is mediated by 
glucosyltransferase genes (gtr) encoded by temperate serotype-converting bacteriophages. GtrIV, an 
integral membrane protein, is responsible . for attaching a glucosyl residue to the N-
acetylglucosamine of the O-antigen repeat unit via an al, 6 linkage, thus mediating the conversion 
of serotype Y to serotype 4a. 
7.1 Topological studies on GtrIV 
By using a dual reporter system consisting of PhoA/LacZ we were able to solve the 
secondary structure of GtrIV by creating C-terminal GtrIV-PhoA/LacZ deletion fusions and GtrIV-
PhoA/LacZ-GtrIV sandwich fusions. GtrIV was found to contain 8 transmembrane helices, 
cytoplasmic N- and C- termini, a large periplasmic N-terminal loop (loop No. 2) and large 
periplasmic C-terminal loop (loop No. 6) (see figure 3.2)(Nair et al., 2011). The existence of a 
unique re-entrant loop was also shown to occur between transmembrane. helices III and IV. Of all 
the known Gtrs, this unique topology resembles that of Gtrlc the most (Ramiscal et al. , 2010). 
Though both proteins possess the large periplasmic N- and C- terminal loops, the configuration of 
their re-entrant loops sets them apart. This study has highlighted the fact that the re-entrant loop of 
GtrIV starts on the periplasmic face of transmembrane helix 3, traverses across the lipid bilayer 
down to the cytoplasm, before making its way back to the periplasm. In contrast, the re-entrant loop 
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of Gtrlc starts at the cytoplasmic face of transmembrane helix IV forms a double intramembrane 
dipping structure and joins the cytoplasmic face of transmembrane helix V (Ramiscal et al., 2010). 
As mentioned in Chapter 3, the existence of a re-entrant loop has previously been reported in 
eukaryotic glutamate transporters and bacterial potassium channel KcsA and also in glycerol and 
water channels (Sonders & Amara, 1996; Seal et al., 2000; Grunewald et al., 2002; Brocke et al., 
2002). In the latter two cases, the two loops depicted in these channels play a major role in 
permeation (Sonders & Amara, 1996; Seal et al., 2000). In contrast to the pore loops of KcsA and 
the aquaporins, these re-entrant loops are not fixed and have been shown to undergo conformational 
changes in the presence of sodium (MacKinnon R, 1995; DeFelice & Blakely, 1996; Sonders & 
Amara, 1996). 
The use of the PhoA/LacZ dual reporter system has been highly successful in determining 
the topology of several other membrane proteins in Shigella flexneri (Korres & Verma, 2004; Korres 
et al., 2005; Lehane et al., 2005; Thanweer et al., 2008; Ramiscal et al., 2010). This system is 
however, not without its limitations. Though it has allowed us to determine the orientation of the 
various loops and the transmembrane regions, it does not allow us to know the transmembrane 
boundaries and proximities between the transmembrane helices and connective hydrophilic loops. 
Therefore, one cc1n continue this topological analysis with the help of cysteine scanning mutagenesis 
(SCAM) (Bogdanov et al., 2005; Lehrer et al., 2007) and thiol cross-linking (Kwaw et al., 2000; 
Wolin & Kaback, 2000). SCAM is a method which can be used to investigate structural alterations 
in different functional states of membrane proteins as well as determine the size of catalytic sites 
and any residues within (Liapakis et al., 2001). This system involves mutating all cysteine residues 
of the GtrIV to serine, thus creating a cysteine-less mutant (Bogdanov et al., 2005). In order for this 
technique to be successful, this mutant must be functional, after which specific cysteine residues can 
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be introduced in place of residues that span the hydrophilic loops and transmembrane regions. This 
would create a library of clones that have single cysteines introduced to different positions along the 
hydrophilic loops and corresponding transmembrane helices of GtrIV. Depending on the reaction of 
the introduced cysteine residues to a combination of reagents such as [2-(trimethylammonium)ethyl] 
methanethiosulfonate bromide (MTSET) and Na-(3-maleimidylpropionyl) biocytin (biotin 
maleimide) under different conditions (such as membrane permeability), the orientation and 
organisation of each transmembrane segment in its native membrane can be determined (Bogdanov 
et al., 2005). This will allow us to determine the length of transmembrane helices and the distance 
between each helix. A key drawback to this system, however, is the fact that the cysteine-less (Cys-
less) GtrIV mutant must be functional. The knocking out all 6 cysteine residues within GtrIV 
individually might not pose a problem but the cumulative burden of all cysteines being knocked 
simultaneously may prove to be too much to bear for GtrIV. Recently, researchers in our lab have 
successfully created a functional GtrV protein devoid of all 6 of its cysteine residues. This means 
that there is a chance that a Cys-less GtrIV mutant might also be functional. 
Thiol-cross linking can also be used to investigate transmembrane helix proximity as well as 
hydrophilic loop proximities by introducing cysteines at specific sites along the GtrIV protein. This 
technique has been successfully employed· in the past to determine the proximity of cytoplasmic 
loops and transmembrane domains of lactose permease in E. coli (Kwaw et al., 2000; Wolin & 
Kaback, 2000). It also requires a functional GtrIV cysteine-less mutant. By introducing a protease 
Xa site to the middle of the protein, it can be cleaved into two separate fragments. Specific tag such 
as FLAG or ·c-myc can be used for detection of the protein on western immunoblots. Upon 
introduction of the protease Xa site and confirmation of GtrIV function, cysteines can be introduced 
to specific loops of GtrIV, for example if the proximities of loop No. 2 with loop No. 10 need to be 
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investigated, one cysteine will be introduced in loop No 2 and another in loop No 10. The membrane 
extracts can then be treated with different chemical cross-linking reagents that form different bonds 
(rigid or flexible bonds) at varying lengths (ranging from 6A to 16A) such as N,N'-o-
phenylenedimaleimide (o-PDM) and 1,6-bis(maleimido)hexane (BMH) before being cleaved with 
factor Xa protease (Kwaw et al., 2000; Wolin & Kaback, 2000). If there is a potential cross-link 
between the introduced cysteines with the above mentioned reagents then the protein will not be 
separated in two separate fragments and thus a reconstituted protein will be detected on the 
immunoblots with incubation using the antibody specific to the tag introduced. If a cross-link is not 
present then only the half of the protein which has the specific tag attached will be detectable on the 
immunoblots. Cross-linked samples can be confirmed by subjecting them to a reducing agent such 
as Dithiothreitol (DTT) which would disrupt the bond between the two cysteines and revert the 
detection to only the fragment of the protein which has the specific tag attached to it. As such, 
additional residues 01t the target loops will also be tested to confirm or establish potential cross-links 
and proximity results. 
7.2 Functional analysis of GtrIV 
As glucosylation is thought to occur in the periplasm, the large periplasmic loops No. 2 and 
No. 6 of GtrIV were prime candidates for functional studies. A series of deletion experiments were 
aimed at the periplasmic loops No. 2 and No. 6, as well as cytoplasmic loop No. 3. Because if its 
large size, loop No. 6 was then deleted in smaller segments. All three segments were chosen such 
that they each encompassed the paired acidic residues DE261, ED283 and ED326 as well the 
negatively charged residues that flank them. From the resulting partial deletions and with the help of 
membrane protein westem blots, one of the non-functional deletion proteins, GtrIV loop No. 6 
partial deletion 3, was found to be localised within the bacterial membrane in amounts similar to that 
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of the intact GtrIV. This was in stark contrast to the other deletion proteins which had little to no 
protein localised in the bacterial membrane (Nair et al., 2011). As mentioned in chapter 4, the lack 
of protein assembly in the membrane could be attributed to a number of factors such as disruption of 
van der Waals forces that have affected the hydrophobicity of the deletion proteins or disruption of 
inter-helical interactions that are essential for stability of the tertiary protein structure (Harrington & 
Ben-Tal, 2009; Fiedler et al., 2010). In both cases, the result would have been an unstable, 
misfolded protein which would have been unable to localise within the cellular membrane, thus 
resulting in its degradation within the cytosol. This led to the belief that the missing 19 amino acid 
segment of loop No.6 partial deletion 3 could contain residues that may be part of a catalytic site 
present in the large periplasmic loop No. 6. Further deletions were carried out and narrowed the 
potentially critical region to 9 amino acids (see chapter 4). From these 9 amino acids, site-directed 
mutagenesis revealed that only when residues D261, E262 and D267 were knocked out in tandem, 
did GtrIV lose its function. Confirmation of this was done through LPS and membrane protein 
western blots which showed that the triple mutant was non-functional yet still assembled in the 
cellular membrane. The strategy of sequentially deleting segments and following up with site-
directed mutagenesis may prove to be a more efficient way to uncover critical residues within 
GtrIV. This is because of the fact that although critical acidic residues have been located within 
loops No. 2 of the other Gtrs, they still reniain elusive within GtrIV. Therefore, it would be a good 
idea to sequentially delete loop No. 2 of GtrIV and carry out functional analysis similar to what was 
undertaken with loop No. 6. In addition, one should also knock out the acidic residues within GtrIV 
loop No. 2 in tandem as like those of loop No. 6, these negatively charged residues (5 in total) may 
either be working in tandem with each other or may be compensating for the loss of any of the other 
acidic residues within the loop. 
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LPS and membrane protein western blotting were also employed for chimera studies 
between Gtrlc and GtrIV. Swapping of a single large periplasmic loop between Gtrlc and GtrIV 
effectively created four chimeras. Functional analysis showed that all four chimeras were non-
functional. Membrane protein westerns showed that apart from the Gtrlc-GtrIVlpNo.2-Gtrlc 
chimera, all other chimeras were present in the membrane. This result led to the assumption that 
interaction of both periplasmic loops are required for Gtr(type) proteins to function. However, double 
loop chimeras between Gtrlc and GtrIV whereby both loops No. 2 and No. 6 of GtrIV were replaced 
by loops No. 2 and No. 10 of Gtrlc and vice versa, were created and the resulting hybrids neither 
regained their native function nor gained their substitute function (Wang A, Honours Thesis 2011). 
Although all the deletion proteins, chimeric proteins and mutant proteins used in this study 
were successfully constructed and the LPS western blots provided definitive and consistent results, 
one main drawback With regards to the membrane protein western blot remains the fact that the 
results cannot be quantified with a high degree of accuracy. As such, intense bands may not be a 
direct result of good protein expression instead, they n1ay also be due to overexposure to the labelled 
antibody. To get around this issue, different western blotting systems such· as near-infrared 
fluorescence (NIF) for western detection are now available (Weldon et al., 2008; Mathews et al., 
2009). This metl).od involves using fluorophores · which are directly conjugated to the antibody 
probes used in western blotting (Weldon et al., 2008). With the help of a new laser-based imaging 
system by LI-COR biosciences, the resulting fluorescence can then detected (Mathews et al., 2009). 
Boasting sensitivity superior to chemiluminescence, NIF is also able to quantify relative protein 
expression in different samples (Weldon et al., 2008). This would have allowed for a more thorough 
analysis of all the differen~ modified proteins created. For instance, the GtrIV loop No. 6 deletion 
and partial deletion proteins all made their way to the membrane. However, they were present in 
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small quantities as compared to the intact GtrIV. As such, with the use of this system, one can 
quantify all the mutant/deletion proteins from future experiments and compare them to the intact 
GtrIV. 
7 .3 Genetic diversity of wildtype serotype 4 strains 
A preliminary study was carried out to gain an insight into the genetic diversity of wildtype 
serotype 4a strains. Of the 28 strains isolated from Japan, Bangladesh and Vietnam, 10 strains 
displayed atypical slide agglutination patterns, suggesting that they might potentially be new 
serotypes or subserotypes. Up till now, the slide agglutination method against specific type and 
group factors has been the only means to routinely identify the serotypes of S. flexneri. However, as 
mentioned in previous chapters, an incorrect reading can occur as a result of visual assessment of the 
agglutination reactions leads to conflicting agglutination results being re-examined through LPS 
western blotting. As f br molecular serotyping, up to 10 separate agglutination tests using antis era for 
type antigens I, II, III, IV, V, and VI and for group antigens 3;4, 7;8, and 6 and the monoclonal 
antibody MASFlc for serotype le are required (Talukder et al., 2003; Stagg et al., 2008; Ye et al., 
2010). This coupled with the high cost of antiserum kits limit its application in the laboratories of 
developing countries. Recently, Sun et al (2011) have developed a multiplex PCR assay especially 
for molecular serotyping of S. flexneri that targets the O-antigen synthesis gene wzx and the O-
antigen modification genes gtrl, gtrIC, gtrII, oac, gtrIV, gtrV, and gtrX. This assay contained eight 
sets of specific PCRs in a single tube and can identify 14 of the 15 serotypes (the exception being 
serotype Xv) of S. flexneri in a single reaction. This method would be ideal for identifying potential 
new subserotypes especially with the Bangladeshi and Vietnamese strains that agglutinated against 
Type IV antisera but not against Group 3, 4 antis era. Other advantages to this method include the 
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fact that it can be utilised for high-throughput serotype identification with results being obtained in 3 
to 4 hours (Sun et al., 2011 ). Following this, the results can then be confirmed through serotyping. 
Sequencing of the wildtype strains revealed the presence of point mutations within several 
strains, while Southern blots carried out using DIG-labelled gtrIV revealed two different bands for 
the serotype 4a strains. Although one of the bands is similar to that the serotype 4b strains, before 
one can confirm that these strains are indeed serotype 4b strains that lost the function of oac, 
attempts must be made to try and amplify the oac gene from these strains. Also, Southern blotting 
(with DIG-labelled oac as the probe) can be carried out on these strains. A better understanding of 
the intra-species diversity of Shigella requires the availability of whole genome sequences. Given 
that only a 3 .8kb region of the whole serotype 4a genome has been sequenced, it would be useful to 
gather sequence information on the flanking regions of the gtrIV cassette. Obtaining the whole 
genome sequence of'serotype 4a would allow us to make comparisons with the other S. flexneri 
genomes to identify any differences within them. In the past, the complete genome sequence of S. 
flexneri Sb (Sf8401) and a comparison with most of the S. flexneri 2a (Sf301) genome revealed 
differences in the pathogenicity islands and chromosomal rearrangements between different 
serotypes of this species (Nie et al., 2006). In the same study, the authors showed that there was ,..., 15 
kb of bacteriophqge SfV sequence remnants in Sf8401, though far less bacteriophage SflI sequence 
has remained in Sf301. This may suggest that Sf8401 arose later than Sf301. In this vein, by 
obtaining the whole genome sequence of serotype 4-a, similar comparisons can be made to help 
facilitate understanding of the common biological processes required for infection and identify 
unique properties that may differentiate between them in respect of epidemiology and pathogenicity, 
even if the virulence plasmid is closely similar. Moreover, the comparison will provide some insight 
into how these pathogens have evolved. 
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7 .4 GtrIV, a distinctly different glucosyltrasferase 
This study has highlighted that GtrIV has a unique topology compared to the other Gtrs. Its 
closest structural homologue, Gtrlc, is 526 amino acids long compared to the 437 amino acids of 
GtrIV. Bioinformatics comparisons between the two proteins revealed that although they are 
structurally similar, both proteins sequences only shared 4.6% identity and 8.7% similarity. 
Ramiscal et al., (2010) stated that the distinct topological differences between Gtrlc and the other 
Gtrs can be attributed to the fact that it catalyses a novel glucosyl to glucosyl linkage on the O-
antigen that is not present in any other serotypes. In the case of GtrIV, it has a strikingly different 
topology to the other Gtrs even though, like the other Gtrs, it catalyses a glucosyl group directly 
onto one of the sugar residues that make up the O-antigen. In terms of O-antigen modification, Gtrl 
is closest to GtrIV as it attaches a glucosyl residue to the N-acetylglucosamine of the O-antigen 
repeat unit via an al, 4 linkage. Their topologies though, differ quite significantly as Gtrl has a 
periplasmic C-terminal tail which is thought to attach the glucosyl group to the O-antigen in a site 
and linkage specific manner. Another unique GtrIV trait is the high number of acidic residues 
(aspartic acid and glutamic acid) present within loops No. 2 and No. 6, resulting in neither of the 
residues being critical on their own. 
The relatipnship' between GtrIV and the other glycosyltransferases that use sugar-nucleotide 
donors (GT) is insignificant. The GT-A superfamily is characterized by the presence of a DxD motif 
and depends on metal ions for activity (Unligil & Rini, 2000; Bourne & Henrissat, 2001). This motif 
is seen in loop No. 2 of GtrIV but not critical for its function. There is also no known association 
between GtrIV and any metal ions. On the other hand, another superfamily GT-B does not require 
metal ions for enzymatic activity but shows weak similarity to GtrIV (Hu et al., 2003). This further 
underlines the enzyme's unique function and mode of action. By comparison, the enzymes from 
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both GT-A and B superfamilies are quite diverse from the multi-transmembrane O-antigen 
modifying glucosyltransferases of S. flexneri. Since GtrIV uses a lipid-linked donor such as UndP-
f3-glucose, it can be compared to such other proteins from a range of organisms (Hu et al., 2003). 
For example, glycosyltransferases that use Dol-P-linked monosaccharides (Dol-P-Mannose, and 
Dol-P-Glucose) as the donor substrate show similar topological arrangements. Apart from the fact 
that these glycosyltransferases consist of at least 6-12 transmembrane segments, they all share a 
highly conserved N-terminal loop after a transmembrane segment, similar to loop No. 2 of GtrIV 
(which is after transemembrane helix !)(Oriol et al., 2002; Baulard et al., 2003). 
The results obtained throughout the course of this project have pointed to the fact that GtrIV 
may have a mechanism of action that different from the rest of its Gtr counterparts. From the models 
proposed for the mechanisms of action of GtrII, GtrV and Gtrlc, it is generally believed that the 
periplasmic loop No. 2 of the Gtrs binds with glucose-precursor and periplasmic loop No. 10 (Gtrlc) 
or the periplasmic C-terminal tail (GtrII and GtrV) are believed to stabilise the O-antigen by 
interacting with the specific sugar residue · that is going to be glucosylated (Lehane et al., 2005; 
Korres & Verma, 2006; Ramiscal et al., 2010). The re-entrant loops confer flexibility to these 
enzymes by allowing them to bend such that both the periplasmic domains can come into close 
contact to transfer and attach the glucosyl group to the O-antigen. This mode of action, however, 
cannot be used to describe GtrIV for a number of reasons. First of all, it is believed the DIE x DIE 
motif in loop No. 2 is required to deprotonate the hydroxyl group on the sugar residue of the O-
antigen so that a glucosyl group can be attached (Ramiscal et al., 2010). This hypothesis is 
underpinned by the fact that D40 (Gtrlc ), E40 (GtrII), E42 and D43 (both GtrV) are critical for the 
function of their respective Gtrs. The periplasmic loop No. 2 of GtrIV contains this motif and both 
acidic residues D31 and D33 within this motif were found to be non-critical (Nair A, Honours 
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Thesis 2006) while all the other acidic residues within this loop were also non-critical. This finding, 
coupled with the discovery of three critical residues (when knocked out in tandem) in GtrIV loop 
No. 6 brings out two possible but highly speculative modes of action. 
Over time, evolution could have rendered the presence of periplasmic loop No. 2 of GtrIV to 
be purely structural. As such, all the glucosylation work is carried out within loop No. 6 itself. In 
which case, D261, E262 and D267 would obtain the glucosyl group from the bactoprenol-glucosyl 
complex and assist in deprotonating the nucleophilic hydroxyl group of the acceptor sugar (N-
acetylglucosamine) while a combination of the other acidic residues, in tandem with the paired 
residues ED283 or ED326, stabilise the O-antigen so that the glucosyl residue can come in contact 
with the N-acetylglucosamine. The UndP carrier is then flipped to the cytoplasmic leaflet of the 
inner membrane to be used again. This model takes into account the fact that no acidic residue was 
found to be critical within GtrIV loop No. 2. Alternatively, the acquisition of a glucosyl group and 
the subsequent deprotonation of the hydroxyl group of the acceptor sugar residue could be carried 
out by anyone of the 5 acidic residues within loop No. 2. In this scenario, anyone of the 5 acidic 
residues may carry out this role and therefore, act to compensate for the loss of the other acidic 
residues or they may be acting in combination of each other. D261, E262 and D267 from loop No. 6 
would then bind , to the O-antigen. The re-·entrant loop then acts as a 'hinge' to bend the protein 
allowing the O-antigen to be stabilised and presented in a manner that allows the glucosyl group to 
be attached via an al, 6 linkage. The UndP carrier is then flipped back into the cytoplasm. 
In order to prove or disprove these hypothetical models, one must knock-out all the acidic 
residues in GtrIV loop No_. 2 in combination. In addition, further deletion experiments should be 
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carried out on the other loop No. 6 partial deletions (1 and 2). This would help generate more data to 
help clarify the mode of action of this unique Gtr. 
7.5 Moving forward: Future work on GtrlV 
Apart from topological and functional studies on GtrIV, not much else is known of this 
integral membrane protein. It is still unknown whether GtrIV interacts in vivo with other host 
factors. By utilising the membrane yeast two-hybrid (MYTH) assay, one can study whether GtrIV 
interacts with GtrA, GtrB and/or other host proteins. MYTH adapts the principle of split ubiquitin 
for use as a potent in vivo sensor of protein-protein interactions, allowing large scale screening for 
interactors of full-length membrane proteins, from a range of organisms, using Saccharomyces 
cerevisiae as a host (Snider et al., 2010). It offers two major advantages over the conventional yeast 
two-hybrid system. Firstly, the interaction is detected in situ at the cellular membrane instead of the 
nucleus. Secondly, whole membrane proteins can be assayed. In this system, the bait membrane 
protein (GtrIV) is fused to the C-terminal half of ubiquitin and an artificial transcription factor. The 
mutated N-terminal moiety of ubiquitin is fused to the prey protein. Upon interaction of bait and 
prey proteins, ubiquitin is reconstituted and further recognized by ubiquitin-specific proteases, 
which subsequently cleave off the transcription factor, thus resulting in reporter gene activation 
(Snider et al., 4010; Petschnigg et al., 2012)(Figure 7.1). The reporter genes used are two 
auxotrophic growth markers (HIS3 and ADE2), whose activation enables the yeast to grow on 
defined minimal medium lacking histidine or adenine, and lacZ, encoding the enzyme ~ -
galactosidase for colour development (Snider et al., 201 0; Petschnigg et al., 2012). Thus, potential 
interaction between the two proteins at the membrane of the yeast will be translated into a 
transcriptional readout, res\llting in growth of yeast on selective medium and colour development in 
a ~-galactosidase assay. 
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Figure 7.1: The membrane yeast two-hybrid assay (MYTH). In the MYTH system, interactions between 
two membrane proteins are monitored by an indirect transcriptional output. The auxotrophic growth 
markers are HIS3(red) and ADE2 (purple), whose activation enables the yeast to grow on defined minimal 
medium lacking histidine or adenine, and lacZ, encoding the enzyme ~-galactosidase for colour 
development in the presence of its substrate X-gal. (I) The bait, a membrane protein of interest (shown in 
red) is fused to Cub followed by the artificial transcription factor LexA-VP16 (TF). The prey, another 
membrane protein (shown in purple) is fused to the NubG domain. If the bait and the prey membrane 
proteins which are fused to NubG and Cub respectively do not interact, then the TF is never cleaved from 
Cub and remains associated with the membrane. This results the genes HIS3, ADE2 and lacZ remaining 
silent. This renders cells unable to grow on medium lacking histidine and adenine and they are colourless 
when exposed to X-gal. (II) Interaction between bait and prey proteins allows NubG and Cub to associate 
and form a pseudoubiquitin molecule, which can then be recognized by cytosolic deubiquitinating 
enzymes (DUBs). DUB cleavage (scissors) after the C -terminus of the Cub tag releases the TF. (III) The 
TF can then enter the nucleus and activate the reporter system. This turns on the expression of HIS3, 
ADE2 and lacZ resulting in cells which are able to grow· on medium lacking histidine and adenine and also 
tum blue in the presence of X-gal. (Adapted from Snider et al, 2010). NubG, N-terminal fragment of 
ubiquitin with its isoleucine residue replaced to glycine. Cub, C-terminal fragment of ubiquitin. 
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In order to identify other host factors that may interact with GtrIV (bait), prey libraries can 
be made by either using S. flexneri genomic DNA or generating S. flexneri cDNA libraries. For 
genomic libraries, the S. flexneri genomic DNA is randomly cut, size-selected, and the resulting 
fragments ligated into one or more two-hybrid prey vector(s). Only colonies which display robust 
growth and a blue colour are selected for further analysis (Rajagopala & Detz, 2011; Petschnigg et 
al., 2012). Plasmid DNA can be isolated from these colonies after they have been grown overnight 
in SD-Tryptophan media only, to select for retention of prey and not bait plasmids (Raj agopala & 
Detz, 2011; Petschnigg et al., 2012). The isolated plasmid can then be transformed, minipreped and 
sequenced using a primer complementary to sequence within the NubG. From this data, a 
preliminary list of proteins that interact with GtrIV can be generated. 
Another way to investigate protein-protein interactions is through the fluorescence resonance 
energy transfer (FRET) assay. FRET is a physical process in which energy is transferred non-
radioactively from an excited fluorophore, serving as a donor, to another chromophore (acceptor) 
(Masi et al., 2010). Among the techniques · related to fluorescence microscopy, FRET is unique in 
providing signals sensitive to intra- and intermolecular distances in the 1-10 nm range (Masi et al., 
201 O; Fernandez-Duenas et al., 2012). This assay is based on using fluorescence lifetime imaging 
(FLIM) to measD;re FRET between two fluorophores (Lleres et al., 2007; Fernandez-Duenas et al., 
2012). FRET occurs when the fluorescence emission spectrum of a donor fluorophore overlaps the 
absorption spectrum of an acceptor fluorophore and their dipoles align (Barber et al., 2009). A 
schematic of the FRET assay is shown in Figure 7 .2. In order to perform this assay, fluorescent 
protein (FP) tags must be fused to the two proteins believed to interact. In this case, GtrIV and either 
GtrA or GtrB. These FP.,tags must be able to function as a FRET pair with one of the pair 
functioning as a donor and the other as an acceptor. Interaction of the proteins of interest brings the 
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Figure 7.2: Schematic representation of the basic FRET principle applied to the study of plasma 
membrane proteins: The proteins of interest (A and B) are fused to the donor and acceptor fluorophores, 
CFP and YFP, respectively. If A and B do not interact, the donor is excited at 433nm and emits at 475nm. 
However, if A and B do interact, then the donor and acceptor fluorophores might be in close proximity 
(¾10 nm) and energy transfer between the two fluorophores can occur after donor excitation at 433 nm 
(which emits at 475 nrri) and acceptor emission at 527 nm. Adapted from Fernandez-Duenas et al., (2012). 
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two FP tags into close proximity allowing FRET to occur. FRET can then be detected and measured 
using FLIM. When performing FRET experiments, care must be also taken to the method chosen for 
labelling interacting proteins. Two principal tools can be applied: ( 1) fluorophore tagged antibodies; 
(2) recombinant fluorescent fusion proteins (Masi et al., 2010; Fernandez-Duenas et al., 2012). The 
latter method essentially takes advantage of the discovery and use of spontaneously fluorescent 
proteins, like the green fluorescent protein (GFP). Because of its potency, FRET has been widely 
used to analyze the structural characteristics of several proteins, including integrins and ion 
channels. More recently, this method has been applied to clarify the interaction dynamics of these 
classes of membrane proteins with cytosolic signalling proteins (Barber et al., 2009; Masi et al., 
2010). 
Obtaining high resolution structural information is a crucial step in elucidating the molecular 
basis for the function -of GtrIV. To help achieve this, one could employ solid-state NMR, which is 
an extremely versatile and powerful method for _determining membrane proteins structures. It is also 
capable of characterizing the dynamics of these membrane proteins in lipid environments that 
closely mimic the cell membrane. The other major advantage of using solid-state NMR is that no 
crystal is required for structure determination (Baldus, M 2007; Etzkorn et al., 2007). The GtrIV 
protein has to b~ overexpressed, labeled and purified. Following this, proteoliposomes containing 
labeled GtrIV can be prepared according to the protocols required for solid-state NMR experiments 
as described by Andronesi et al (2005). The samples can then be subjected to NMR experiments 
employing MAS (magic-angle-spinning) NMR. The spectra obtained from the MAS-based NMR 
can be utilized to construct a structural model of GtrIV protein in lipid bilayers. 
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Alternatively, high resolution structural information can also be achieved by X-ray 
crystallography (Yaffe MB, 2005; Geerlof et al., 2006). This technique involves the overexpression 
and subsequent purification and crystallisation of the protein of interest, in this case GtrIV (Geerlof 
et al., 2006). Following this, X-ray beams are passed through the purified crystal. Due to the 
intensity and angles of the diffracted beams, a 3-D electron density map can be generated (Hickman 
& Davies, 2001). This map will help in identifying the residues and catalytic sites involved in 0-
antigen modification. This would be greatly beneficial in understanding the function of GtrIV. As 
the natural abundance of membrane proteins is too low for convenient isolation of enough material 
for structural and functional studies, optimising the overexpression of GtrIV would be an important 
first step (Andronesi et al., 2005; Wagner et al., 2006; Wagner et al., 2008). Most membrane protein 
overexpression leads to the production of more protein than the Sec translocon can process. As the 
Sec translocon is responsible for mediating the translocation of secretory proteins across and the 
integration of membrane proteins into the cytoplasmic membrane, its saturation makes it impossible 
for most overexpressed membrane proteins to insert into the membrane (Wagner et al. , 2008). 
Membrane proteins that cannot insert into the membrane end up in the cytoplasm and may 
aggregate, resulting in hampered translocation of secretory proteins. This adds further stress onto the 
cell (Wagner et al., 2006; Wagner et al., 2008). In the commonly used E. coli strain for expression 
studies, BL21(DE3), the bacteriophage T7 RNA polymerase (T7RNAP) usually drives recombinant 
protein production and is controlled by the strong promoter lacUV5 (Andronesi et al. , 2005). 
Wagner et al., (2006) reported that key mutations in this promoter led to improved protein 
expression. This discovery led to Wagner et al., (2008) engineering a derivative strain of E. coli 
BL2l(DE3), termed Lemo21(DE3), in which the activity of the T7 RNA polymerase can be 
precisely controlled by its_ natural inhibitor T7 lysozyme (T7Lys). By placing T7Lys under the 
control of an L-rhamnose-inducible marker, the authors showed that adding different amounts of L-
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rhamnose into the cultures resulted in different and scalable concentrations of overexpressed protein 
YidC. As such, this strain may prove useful in overexpressing large quantities of GtrIV for X-ray 
crystallography. 
7 .6 Vaccine development 
One of the major considerations in using cocktails of live attenuated vaccine strains is to be 
able to establish O-modification resulting in all possible serotypes. It has been mooted that the 
creation of a single plasmid that carries the genes of all the Gtrs allowing their expression from the 
chromosome was a possible solution to the creation of such a multi-valent vaccine. One major 
drawback in this approach is the potential stability of all the Gtrs expressed in the inner membrane 
and their competition with one another. Based on the site-directed mutagenesis results for GtrIV 
loop No. 2, failure to find any critical acidic residues has hinted that loop No. 2 of GtrIV may not 
play the same consented role in interacting with the UDP-Glucose as is hypothesised with the other 
Gtrs. These results coupled by the failure of the GtrIV-Gtrlc loop swap chimeras suggests to us that 
creating chimeric proteins for vaccine work may not be the best way forward at this time. Instead, 
the best way forward would be to obtain the 3-D structure of GtrIV first. This will -allow us to better 
understand the protein. Then, by identifying the important regions of the protein through its 3-D 
model one can create functioning chimeric proteins with the other Gtrs, enabling us to create a 
cocktail of chimeric proteins that express all the various serotypes by ensuring that each chimera 
consists of two or more closely related Gtrs (GtrI & dtrII, GtrV &GtrX). 
7.7 Conclusion 
This study has detepnined the topology of GtrIV to contain 8 transmembrane helices, a large 
N-terminal periplasmic loop No. 2, a large C-terminal 'periplasmic loop No. 6, a short cytoplasmic 
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C-terminal end and a re-entrant loop located after transmembrane helix 3. Through a combination of 
loop deletion studies and site-directed mutagenesis, the acidic residues D261, E262 and D267 
(located in loop No. 6) were critical for GtrIV function when knocked out together. Membrane 
protein western blotting has revealed that this triple mutant, although non-functional, is able to 
assemble in the plasma membrane in quantities comparable to that of the unmodified GtrIV. The 
failure to find any critical acidic residues within GtrIV loop No. 2 indicates that there is a possibility 
that the acidic residues residing there may also work in combination of one another. Loop swap 
chimeras were created between GtrIV and its closest structural homologue, Gtrlc, to determine if 
loops No. 2 of both Gtrs play a similar role in glucosylation while their C-terminal periplasmic loops 
are involved in the conferring serotype specificity. The resulting hybrids lost their native function 
and were unable to substitute function to the other protein. This signifies the importance of both 
loops in GtrIV function. 
A total of 28 wild type strains isolated from Japan, Bangladesh and Vietnam that were typed 
as serotype 4a, 4b or just 4 were subjected to a series of slide agglutination experiments to confirm 
their serotype. A number of strains had atypical agglutination habits and thus highlighted the 
possibility that they are potentially new serotypes or subserotypes. Sequencing results revealed the 
presence of point mutations within several strains, although we were not able to identify mutations 
that were detrimental to the function of GtrIV. Southern blotting revealed the possibility of two 
different serotype 4a strains ( one of them being possibly derived from a serotype 4b background) 
circulating within Bangladesh and Japan. Further investigations based on the data provided from this 
study can lead to better understanding on how Gtr(type) proteins modify the O-antigen in S. flexneri, 
thus advancing our knowle,dge on this prevalent human pathogen and leads to the development of a 
' multi-valent vaccine against multiple S. flexneri serotypes. 
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APPENDICES 
Appendix A 
Buffers, Solutions and Media 
All solutions were made up to volume with sterile MilliQ water and stored at room temperature 
unless otherwise stated. 
Bacterial Growth Media 
LB Broth 
4g Tryptone 
2 g Yeast Extract 
2g NaCl 
Make up to 400 mL in MilliQ water an4 sterilize by autoclaving 
LB Agar 
As for LB broth, adding 15 g/L agar before autoclaving 
IPTG I X-Gal Plates 
Add 20µL each of X-Gal and IPTG solutions (20 mg/mL) and spread on plate 
143 
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Plasmid DNA Isolation by Alkaline Lysis 
Solution I 
50 mM Glucose 
25 mM Tris.HCl pH 8.0 
10mMEDTApH8.0 
Sterilised by autoclaving. Stored at 4 °C 
Solution II 
0.2MNaOH 
1% SDS 
APPENDICES 
Freshly prepared from sterile stock solutions (10% SDS, 3M NaOH) before use 
Solution III 
60 mL 5 M CH3COOK 
11.5 mL Glacial acetic acid 
28.5 mL Water 
Prepared from sterile stock solutions and stored at 4°C 
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Agarose Gel Electrophoresis 
5X TBE Buffer 
54 g Tris Base 
27 .5 g Boric acid 
20 mL 0.5 M EDTA pH 8.0 
Make up to 1 L with water 
Blue Loading Buffer 
1 mg/mL Bromophenol blue 
20% Glycerol 
Dual Indicator Plates 
Supplement LB agar with: 
80 µg/ml X-phos 
100 µg/mL Red Gal 
1 mMIPTG 
80mMK2HPO4 
( antibiotics for selection added to above mixture just before pouring plates) 
.. 
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B-Galactosidase Assay 
Z buffer 
0.06 M Na2HPO4.7H2O 
0.04 M NaH2PO4.H2O 
0.01 MKCl 
0.001 M MgSO4 
0.27% (v/v) 2-mercaptoethanol 
pH7.0 
(store at 4°C, make fresh) 
Phosphate Buffer 
0.06 M Na2HPO4.7H2O 
0.04 M NaH2PO4.H2O 
pH7.0 
SOS-PAGE 
2x Sample Loading Buffer 
10% (w/v) SDS 
20% (v/v) glycerol 
0.1 % (w/v) bromophenol blue 
0.5 M Tris-HCl (pH 6.8) 
5% (v/v) 2-mercaptoethanol (add fresh before boiling) 
" 
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JOx SDS-PAGE Running Buffer 
0.029 g/mL Tris Base 
0.144 g/mL glycine 
0.01 % (w/v) SDS 
12% Resolving gel solution 
3 .2 mL MilliQ Water 
2.1 mL Bis Acrylamide 
1.9 mL Tris HCl (1.5M pH8.8) 
75 µL 10% SDS (w/v) 
75 µL Ammonium Persulfate 
3 µL Tetramethylethylenediamine 
4% Stacking Gel 
1.6 mL MilliQ Water 
250 µL Bis Acrylamide 
625 µL Tris HCl (0.5M pH6.8) 
25 µL 10% SDS (w/v) 
12.5 µL Ammonium Persulfate 
2.5 µL Tetramethylethylenediamine 
-----___ _ : 'b 
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Silver Staining 
Fixing Solution (100ml) 
7. 5 mL Glacial Acetic Acid 
25 mL Propan-2-ol 
Made up to 100 mL with MilliQ Water 
Oxidizing Solution (1 00mL) 
0. 7 g Periodic Acid 
7. 5 mL Glacial Acetic Acid 
Made up to 100 mL with MilliQ Water 
Silver Staining Solution (1 00mL) 
187 ~LL Sodium Hydroxide (1 OM) 
1.3 mL Ammonium Hydroxide 
0.67 g Silver Nitrate 
Made up to 100 mL with MilliQ Water 
Developer Solution (1 00mL 
22.2 ~LL Formaldehyde 
5 mg Citric Acid 
Made up to 100 mL with MilliQ Water 
"' 
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Coomassie Staining 
Coomassie Staining Solution (IL) 
0.25 g Comassie Brilliant Blue 
7 5 mL Acetic Acid 
500 mL Methanol 
Made up to 1 L with MilliQ Water 
Destaining Solution (IL) 
400 mL Methanol 
100 mL Acetic Acid 
Made up to 1 L with MilliQ Water 
Western Immunoblotting 
I x PBS (500 mL) 
4 gNaCl 
0.1 g KCl 
0.72 g Na2HPO4 
0.12 g KH2PO4 
Made up to 500 mL with MilliQ Water 
--~ .. ~--· .......... 1) 
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1 x PBS + 0. 05% Tween20 (1 L) 
8 gNaCl 
0.2 g KCl 
1.44 g N a2HP04 
0.24 g KH2P04 
0.5 mL Tween 20 
Made up to 1 L with MilliQ water 
Blocking Solution (50 mL) 
2.5 g Skim Milk 
50 mL 1 x PBS 
Transfer Buffer ( 1 L) 
6.05 g Tris base 
28.82 g Glycine 
1 g SDS 
200 mL methanol 
Made up to· 1 L with MilliQ water 
-- ... ~"--,- · ........ . ~ 
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Southern Hybridization 
20 x SSC(JL) 
175.31 g NaCl ( ➔3M) 
88.23 g tri-Na citrate (➔0.3M) 
pH to 7 
Make up to 1 L with MilliQ water and sterilize by autoclaving 
Denaturing Solution (500 mL) 
1.5 MNaCl 
0.5MNaOH 
Make up to 500 mL with MilliQ water and sterilize by autoclaving __ 
Neutralising solution (500 mL) 
1.5 M NaCl (43.83g) 
0.5 M Tris-HCl (pH= 7.2) (39.40g) 
1 mM EDTA (0.146g) 
Make up to 500 mL with MilliQ water and sterilize by autoclaving 
0.25M HCl (400 mL) 
10 mL of 10 M HCl stock 
390 mL MilliQ water 
---~-e-----···· .. ~·~, 1::1 
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1 Ox Maleic acid buffer (5 00 m L) 
0.1 M Maleic Acid (116.08 g / L) 
0.15 M NaCl (87.66 g / L) 
Adjust to pH 7,5 with 5 M NaOH 
Make up to 500 mL with MilliQ water and sterilize by autoclaving 
DIG detection buffer 
0.lMNaCl 
0.1 M Tris-HCl (pH 9.5) 
DIG-Washing buffer 
0.3 % (v/v) Tween-20 in DIG Maleic acid buffer 
~ 
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Appendix B 
NCTC GtrIV alignments of wildtype serotype 4 strains against NCTC 8296 
SFL1758 
SFL1768 
SFL1714 
SFL1305 
SFL1526 
SFL2178 
SFL1314 
SFL2241 
SFL1522 
SFL1769 
SFL1524 
NO'I'C GtrIV 
' ,,,·. 
SFL1523 
SFL2187 
SFL1758 
SFL1768 
SFL1714 
SFL1305 
SFL1526 
SFL2178 
SFL1314 
SFL2241 
SFL1522 
SFL1769 
SFL1524 
., ~-, ~··· -r\ 
NCTe. GtrIV 
'-.,; - . .,, 
SFL1523 
SFL2187 
SFL1758 
SFL1768 
SFL1714 
SFL1305 
SFL1526 
SFL2178 
SFL1314 
SFL2241 
SFL1522 
·. SFLl 769 
SFL1524 
wc'i'·a .,·c;-frrv . 
:,,,, ' •• 1.. ',,.:.,,c • 
SFL1523 
SFL2187 
--·•-e-- --: .... ~.~ - t) 
MAERIRYVFLAIFCALLCKESIDIWMMNNGDFDRAITPFMNGIRQFSHDGTLLYTLKENF 60 
MAERIRYVFLAIFCALLCKESIDIWMMNNGDFDRAITPFMNGIRQFSHDGTLLYTLKENF 60 
MAERIRYVFLAIFCALLCKESIDIWMMNNGDFDRAITPFMNGIRQFSHDGTLLYTLKENF 60 
MAERIRYVFLAIFCALLCKESIDIWMMNNGDFDRAITPFMNGIRQFSHDGTLLYTLKENF 60 
MAERIRYVFLAIFCALLCKESIDIWMMNNGDFDRAITPFMNGIRQFSHDGTLLYTLKENF 60 
MAERIRYVFLAIFCALLCKESIDIWMMNNGDFDRAITPFMNGIRQFSHDGTLLYTLKENF 60 
MAERIRYVFLAIFCALLCKESIDIWMMNNGDFDRAITPFMNGIRQFSHDGTLLYTLKENF 60 
MAERIRYVFLAIFCALLCKESIDIWMMNNGDFDRAITPFMNGIRQFSHDGTLLYTLKENF 60 
MAERIRYVFLAIFCALLCKESIDIWMMNNGDFDRAITPFMNGIRQFSHDGTLLYTLKENF 60 
MAERIRYVFLAIFCALLCKESIDIWMMNNGDFDRAITPFMNGIRQFSHDGTLLYTLKENF 60 
MAERIRYVFLAIFCALLCKESIDIWMMNNGDFDRAITPFMNGIRQFSHDGTLLYTLKENF 60 
..• ,a,· ··:WMAERii{xvF:i::1r1]fc~:~'c ;iE,S"'(R'~~MNN.GJ)FDRA;IT'P¥MNGTiiQ·Fstfi3G-TLLYTLKENF 60 
MAERIRYVFLAIFCALLCKESIDIWMMNNGDFDRAITPFMNGIRQFSHDGTLLYTLKENF 60 
MAERIRYVFLAIFCALLCKESIDIWMMNNGDFDRAITPFMNGIRQFSHDGTLLYTLKENF 60 
************************************************************ 
SSIVNYEYKSSFSYILYLYAYVISIFTHTFDLRLWSSLSKIVYICALYKLFVEINNKKYS 120 
SSIVNYEYKSSFSYILYLYAYVISIFTHTFDLRLWSSLSKIVYICALYKLFVEINNKKYS 120 
SSIVNYEYKSSFSYILYLYAYVISIFTHTFDLRLWSSLSKIVYICALYKLFVEINNKKYS 120 
SSIVNYEYKSSFSYILYLYAYVISIFTHTFD~ RLWSSLSKIVYkCALYKLFVEINNKKYS 120 
SSIVNYEYKSSFSYILYLYAYVISIFTHTFD~ RLWSSLSKIVYICALYKLFVEINNKKYS 120 
SSIVNYEYKSSFSYILYLYAYVISIFTHTFDLRLWSSLSKIVYICALYKLFVEINNKKYS 120 
SSIVNYEYKSSFSYILYLYAYVISIFTHTFDLRLWSSLSKIVYICALYKLFVEINNKKYS 120 
SSIVNYEYKSSFSYILYLYAYVISIFTHTFDLRLWSSLSKIVYICALYKLFVEINNKKYS 120 
SSIVNYEYKSSFSYILYLYAYVISIFTHTFDLRLWSSLSKIVYICALYKLFVEINNKKYS 120 
SSIVNYEYKSSFSYILYLYAYVISIFTHTFDLRLWSSLSKIVYICALYKLFVEINNKKYS 120 
SSIVNYEYKSSFSYILYLYAYVISIFTHTFDLRLWSSLSKIVYICALYKLFVEINNKKYS 120 
SSIVNYEYKSSFSYILYLYAYVISIFTHTFDLRLWSS.LSKI.VYICALYKLFVEINNKKYS 120 . '". - . '· . - - .:. . ..,, __ . -.:, . .. . 
.· ~ ' ~ . 
SSIVNYEYKSSFSYILYLYAYVISIFTHTFDLRLWSSLSKIVYICALYKLFVEINNKKYS 120 
SSIVNYEYKSSFSYILYLYAYVISIFTHTFDLRLWSSLSKIVYICALYKLFVEINNKKYS 120 
*******************************·**************************** 
YLLFPVSALLLFTPSILSQFTAFYQ~EQIVITLLPVITYIILKKEISRFDKVLLVACAALI 180 
YLLFPVSALLLFTPSILSQFTAFYQ~ QIVITLLPVITYIILKKEISRFDKVLLVACAALI 180 
YLLFPVSALLLFTPSILSQFTAFYQEQIVITLLPVITYIILKKEISRFDKVLLVACAALI 180 
· YLLFPVSALLLFTPSILSQFTAFYQEIQIVITLLPVITYIILKKEISRFDKVLLVACAALI 180 
YLLFPVSALLLFTPSILSQFTAFYQEQIVITLLPVITYIILKKEISRFDKVLLVACAALI 180 
YLLFPVSALLLFTPSILSQFTAFYQEQIVITLLPVITYIILKKEISRFDKVLLVACAALI 180 
YLLFPVSALLLFTPSILSQFTAFYQEQIVITLLPVITYIILKKEISRFDKVLLVACAALI 180 
YLLFPVSALLLFTPSILSQFTAFYQ§ QIVITLLPVITYIILKKEISRFDKVLLVACAALI 180 
YLLFPVSALLLFTPSILSQFTAFY,QDQIVITLLPVITYIILKKEISRFDKVLLVACAALI 180 
YLLFPVSALLLFTPSILSQFTAFYQDQIVITLLPVITYIILKKEISRFDKVLLVACAALI 180 
YLLFPVSALLLFTPSILSQFTAFYQDQIVITLLPVITYIILKKEISRFDKVLLVACAALI 180 
YL½.PPV};ALLI.±1)FTP·s :;i;,isQF<TAFYQ[)QIVITLLPV,ITYIIL:KKEISRFDKVLLVACAALr' 18 0 
YLLFPVSALLLFTPSILSQFTAFYQDQIVITLLPVITYIILKKEISRFDKVLLVACAALI 180 
YLLFPVSALLLFTPSILSQFTAFYQDQIVITLLPGITYVILKKEISRFDRVLLVACAALI 180 
*************************·******** ***·********** ********** 
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SFL1768 
SFL1714 
SFL1305 
SFL1526 
SFL2178 
SFL1314 
SFL2241 
SFL1522 
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SFL1523 
SFL2187 
SFL1758 
SFL1768 
SFL1714 
SFL1305 
SFL1526 
SFL2178 
SFL1314 
SFL2241 
SFL1522 
SFL1769 
SFL1524 
McT:c ··crtrrv 
SFL1523 
SFL2187 
SFL1758 
SFL1768 
SFL1714 
SFL1305 
SFL1526 
SFL2178 
SFL1314 
SFL2241 
SFL1522 
SFL1769 
SFL1524 
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ATSKSQFFYIPILISLISIIFIDIRDKKFHLAMVIATIIALSFSFFSPSATKNNSYHSLY 240 
ATSKSQFFYIPILISLISIIFIDIRDKKFHLAMVIATIIALSFSFFSPSATKNNSYHSLY 240 
ATSKSQFFYIPILISLISIIFIDIRDKKFHLAMVIATIIALSFSFFSPSATKNNSYHSLY 240 
ATSKSQFFYIPILISLISIIFIDIRDKKFHLAMVIATIIALSFSFFSPSATKYNSYHSLY 240 
ATSKSQFFYIPILISLISIIFIDIRDKKFHLAMVIATIIALSFSFFSPSATKYNSYHSLY 240 
ATSKSQFFYIPILISLISIIFIDIRDKKFHLAMVIATIIALSFSFFSPSATKYNSYHSLY 240 
ATSKSQFFYIPILISLISIIFIDIRDKKFHLAMVIATIIALSFSFFSPSATKl NSYHSLY 240 
ATSKSQFFYIPILISLISIIFIDIRDKKFHLAMVIATIIALSFSFFSPSATKNNSYHSLY 240 
ATSKSQFFYIPILISLISIIFIDIRDKKFHLAMVIATIIALSFSFFSPSATKYNSYHSLY 240 
ATSKSQFFYIPILISLISIIFIDIRDKKFHLAMVIATIIALSFSFFSPSATKr NSYHSLY 240 
ATSKSQFFYIPILISLISIIFIDIRDKKFHLAMVIATIIALSFSFFSPSATK~NSYHSLY 240 
·ATSKSQf:fy{f'.IiiisEiii:iF:i'brRDKKFH1AM'i!i ATiiA1s'FSiFSPSATKNNSYHSLY 2 4 0 ...... .,;, .,. . ' ,.-:,· . ',,, . .,,. •, -~';;' ,--.•. ; . -·-. ·'"' ·_,,_, ',: . . ,·. ' . /..·) .. ' ' . ,._ •.'. . . . ·. •, .· ' :::. 
_; __ ,. . .. 
ATSKSQFFYIPILISLISIIFIDIRDKKFHLAMVIATIIALSFSFFSPSATKNNSYHSLY 240 
ATSKSQFFYIPILISLISIIFIDIRDKKFHLAMVIATIIALSFSFFSPSATKNNSYHSLY 240 
**************************************************** ******* 
FGTLLYNKSNGKENPSWAVDECIGVDAWGNKFDLDKGAVTTEDAGACFAKNKERGLKDSL 300 
FGTLLYNKSNGKENPSWAVDECIGVDAWGNKFDLDKGAVTTEDAGACFAKNKERGLKDSL 300 
FGTLLYNKSNGKENPSWAVDECIGVDAWGNKFDLDKGAVTTEDAGACFAKNKERGLKDSL 300 
FGTLLYNKSNGKENPSWAVDECIGVDAWGNKFDLDKGAVTTEDAGACFAKNKERGLKDSL 300 
FGTLLYNKSNGKENPSWAVDECIGVDAWGNKFDLDKGAVTTEDAGACFAKNKERGLKDSL 300 
FGTLLYNKSNGKENPSWAVDECIGVDAWGNKFDLDKGAVTTEDAGACFAKNKERGLKDSL 300 
FGTLLYNKSNGKKINPSWAVDECIGVDAWGNKFDLDKGAVTTEDAGACFAKNKERGLKDSL 300 
FGTLLYNKSNGKKNPSWAVDECIGVDAWGNKFDLDKGAVTTEDAGACFAKNKERGLKDSL 300 
FGTLLYNKSNGKENPSWAVDECIGVDAWGNKFDLDKGAVTTKIDAGACFAKNKERGLKDSL 3 0 0 
FGTLLYNKSNGKENPSWAVDECIGVDAWGNKFDLDKGAVTTKDAGACFAKNKERGLKDSL 300 
FGTLLYNKSNGKENPSWAVDECIGVDAWGNKFDLDKGAVTTEDAGACFAKNKERGLKDSL 300 
FGTLLYNKSNGKENP~FWAVDE:C :{GVD.A.WGNKFDLDKGAVTTEDAGACFAKNKERG LKD SL 3 0 0 . ' . - '· . . ' ·:. \ . . ' -_·-. . ·,. - . . . 
FGTLLYNKSNGKENPSWAVDECIGVDAWGNKFDLDKGAVTTEDAGACFAKNKERGLKDSL 300 
FGTLLYNKSNGKENPSWAVDECIGVDAWGNKFDLDKGAVTTEDAGACFAKNKERGLKDSL 300 
************·****************************·****************** . . 
LLMLKQPSMFLLLPFDSGVRTQLTEDYFHVFKENKLIISKSVFLNEVQKIKDSALSTVRI 360 
LLMLKQPSMFLLLPFDSGVRTQLTEDYFHVFKENKLIISKSVFLNEVQKIKDSALSTVRI 360 
LLMLKQPSMFLLLPFDSGVRTQLTEDYFHVFKENKLIISKSVFLNEVQKIKDSALSTVRI 360 
LLMLKQPSMFLLLPFDSGVRTQLTEDYFHVFKENKLIISKSVFLNEVQKIKDSALSTVRI 360 
LLMLKQPSMFLLLPFDSGVRTQLTEDYFHVFKENKLIISKSVFLNEVQKIKDSALSTVRI 360 
LLMLKQPSMFLLLPFDSGVRTQLTEDYFHVFKENKLIISKSVFLNEVQKIKDSALSTVRI 360 
LLMLKQPSMFLLLPFDSGVRTQLTEDYFHVFKENKLIISKSVFLNEVQKIKDSALSTVRI 360 
. LLMLKQPSMFLLLPFDSGVRTQLTEDYFHVFKENKLIISKSVFLNEVQKIKDSALSTVRI 360 
LLMLKQPSMFLLLPFDSGVRTQLTEDYFHVFKENKLIISKSVFLNEVQKIKDSALSTVRI 360 
LLMLKQPSMFLLLPFDSGVRTQLTEDYFHVFKENKLIISKSVFLNEVQKIKDSALSTVRI 360 
LLMLKQPSMFLLLPFDSGVRTQLTEDYFHVFKENKLIISKSVFLNEVQKIKDSALSTVRI 360 
. · LLMLKQPSMFLLLPFDSGVRTQLTEDYFHVFKENKLlisi<:svFLNEVQKIKDSALSTVRI 3 6 o 
LLMLKQPSMFLLLPFDSGVRTQLTEDYFHVFKENKLIISKSVFLNEVQKIKDSALSTVRI 360 
LLMLKQPSMFLLLPFDSGVRTQLTEDYFHVFKENKLIISKSVFLNEVQKIKDSALSTVRI 360 
************************************************************ 
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SFL1523 
SFL2187 
APPENDICES 
PVAFIAMIASLIFIRKKYSVAIFTLSAFSISQFYISFIGEGYRDLDKHLFAMNFSFDLMI 420 
PVAFIAMIASLIFIRKKYSVAIFTLSAFSISQFYISFIGEGYRDLDKHLFAMNFSFDLMI 420 
PVAFIAMIASLIFIRKKYSVAIFTLSAFSISQFYISFIGEGYRDLDKHLFAMNFSFDLMI 420 
PVAFIAMIASLIFIRKKYSVAIFTLSAFSISQFYISFIGEGYRDLDKHLFAMNFSFDLMI 420 
PVAFIAMIASLIFIRKKYSVAIFTLSAFSISQFYISFIGEGYRDLDKHLFAMNFSFDLMI 420 
PVAFIAMIASLIFIRKKYSVAIFTLSAFSISQFYISFIGEGYRDLDKHLFAMNFSFDLMI 420 
PVAFIAMIASLIFIRKKYSVAIFTLSAFSISQFYISFIGEGYRDLDKHLFAMNFSFDLMI 420 
PVAFIAMIASLIFIRKKYSVAIFTLSAFSISQFYISFIGEGYRDLDKHLFAMNFSFDLMI 420 
PVAFIAMIASLIFIRKKYSVAIFTLSAFSISQFYISFIGEGYRDLDKHLFAMNFSFDLMI 420 
PVAFIAMIASLIFIRKKYSVAIFTLSAFSISQFYISFIGEGYRDLDKHLFAMNFSFDLMI 420 
PVAFIAMIASLIFIRKKYSVAIFTLSAFSISQFYISFIGEGYRDLDKHLFAMNFSFDLMI 420 
PVAF iAMiASL](F J:RKKYSV~I FTLSA#Ei:i:'SQF-Yi SF IGE;GYRDLDKHL-FAMNF s F6LMl 4 2 0 
PVAFIAMIASLIFIRKKYSVAIFTLSAFSISQFYISFIGEGYRDLDKHLFAMNFSFDLMI 420 
PVAFIAMIASLIFIRKKYSVAIFTLSAFSISQFYISFIGEGYRDLDKHLFAMNFSFDLMI 420 
************************************************************ 
FIVLSIILDKVASGIYK 437 
FIVLSIILDKVASGIYK 437 
FIVLSIILDKVASGIYK 437 
FIVLSIILDKVASGIYK 437 
FIVLSIILDKVASGIYK 437 
FIVLSIILDKVASGIYK 437 
FIVLSIILDKVASGIYK 437 
FIVLSIILDKVASGIYK 437 
FIVLSIILDKVASGIYK 437 
FIVLSIILDKVASGIYK 437 
FIVLSIILDKVASGIYK 437 
. 1r:i:vis I I.LDKVASGI Y'I(. 4 3 7 
FIVLSIILDKVASWIYK 437 
FIVLSIILDKVASGIYK 437 
************* *** 
The NCTC GtrIV sequence is highlighted in grey. All mutations are highlighted in yellow. 
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